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Characterisation of the anti-Gal response to Leishmania infection for the diagnosis 
of cutaneous leishmaniasis 
By Victoria M. Austin 
 
Abstract 
The most abundant natural IgG antibody in healthy humans is known as anti-Gal. 
These antibodies are continually generated in response to antigenic Galactosyl 
residues expressed by gastrointestinal microbiota. However, during the course of 
several parasitic infections, including leishmaniasis, the levels of serum anti-Gal are 
greatly increased mainly due to the expression of αGalactosylated glycoconjugates 
by these parasites.  
 
The surface glycocalyx of Leishmania parasites consists of a complex mix of 
glycoconjugates, with varied roles in cell invasion and protection from host immune 
responses. Most abundant amongst these is a family of glycoinositolphospholipids 
(GIPLs), the glycan components of which vary between Leishmania species. Type-II 
GIPLs are abundantly expressed by L. major parasites and contain terminal  
αGalactosyl residues that are recognised by serum from infected patients. Since the 
oligosaccharidic portion of the main L. major GIPLs terminate with the linear 
sequences Galα(1,3)Galfβ(1,4)-R (GIPL-2) or Galα(1,6)Galα(1,3)Galfβ(1,4)-R (GIPL-3), 
which differs to the main epitope (Galα(1,3)Galβ(1,4)GlcNAcβ1-R) recognised by 
normal anti-Gal antibodies, I hypothesised that the specificity of the anti-Gal 
produced during a course of a Leishmania infection will be different to that of normal 
anti-Gal. 
 
In this thesis, I set out to characterise the human anti-Gal response that is triggered 
during Leishmania infection, aiming to exploit this knowledge for the development 
of a novel diagnostic test. The utility of native GIPLs extracted from both L. major and 
L. tropica cells as diagnostic antigens was assessed first through a combination of Thin 
Layer Chromatography (TLC) immuno- and lectin-staining, mass spectrometry 
analysis, and chemiluminescent ELISA (CL-ELISA). GIPLs extracted from L. major 
promastigotes were strongly recognised by sera from L. major-positive patients, but 
not from L. tropica-positive patients, or that from healthy controls. In addition, it was 
confirmed that L. tropica does not express αGalactosylated GIPLs, suggesting that this 
residue must be decorating an uncharacterised glycoconjugate. 
 
To determine the specificity of the Leishmania spp. anti-Gal, a bespoke panel of 
neoglycoproteins (NGPs) was used to investigate anti-Gal produced in response to 
leishmaniasis infection in three patient cohorts. These sample collections 
encompassed the spectrum of the leishmaniases, from systemic visceral disease to 
localised cutaneous lesions. Antibody detection in Leishmania patients has potential 
in screening of suspect cases, but also in monitoring response to treatment. NGPs 
with Galα(1,3)Galfβ-R and Galα(1,6)Galα(1,3)Galfβ-R terminating glycans were the 
best discriminators of L. major infections and also showed potential in the diagnosis 
iii 
 
of American cutaneous leishmaniasis caused by L. braziliensis. In addition, the 
presence of a terminal β-galactofuranose residue in these NGPs dramatically 
improved their recognition in CL-ELISA, and their value in the diagnosis of Old World 
CL. Combining these two glycotopes maximises antibody detection, through capture 
of two anti-Gal populations. 
  
Fluorescent microscopy analysis confirmed L. major cells express αGalactosylated 
epitopes throughout the parasite lifecycle, whilst in L. tropica the same epitope was 
only detected in promastigote cells. While the nature of this epitope remains 
unknown, future work should focus on the analysis of L. tropica glycoconjugates.  
 
Results in this thesis are discussed in relation to the variability of αGalactosyl epitopes 
recognised by sera from patients with different Leishmania infections, and their 
possible exploitation in the development of novel disease biomarkers. 
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1.1 Leishmaniasis 
The leishmaniases are a diverse group of diseases caused by the parasitic protozoa 
Leishmania. Leishmania infection in humans have a long history; reports in Syria 
date back to the 17th century, and L. donovani DNA has been identified in 
mummified Egyptian remains dating to between 1500-2500 BCE 1,2. 
 
 
Figure 1.1. Co-endemicities of human pathogenic Leishmania species globally. Colours 
indicate the number of species endemic within each country, from pale yellow (complete 
absence of Leishmania spp.) to dark red (eight species of Leishmania). Grey regions indicate 
the absence of data. Dots represent countries where leishmaniasis has been eradicated. 
Abbreviations for species name are as follows: A: L. aethiopica; Am: L. amazonensis; B: L. 
braziliensis; C: L. colombiensis; D: L. donovani; G: L. guyanensis; Gh: 'Ghana strain'; I: L. 
infantum; La: L. lainsoni; L: L. lindenbergi; M: L. major; Ma: L. martiniquensis; Mx: L. mexicana; 
N: L. naiffi; Pa: L. panamensis; P: L. peruviana; S: L. 'siamensis'; Sh: L. shawi; T: L. tropica; V: 
L. venezuelensis and W: L. waltoni. The species with question marks need to be confirmed by 
further genotyping. Taken from Akhoundi et al. (2017). 
 
Leishmaniasis has wide distribution across the Americas, Europe, North Africa and 
the Middle East, with the majority of disease focused disproportionately on the 
poorest in society (Figure 1.1) 4,5. Like many neglected tropical diseases (NTDs) the 
burden of leishmaniasis is difficult to estimate; despite many advances in diagnosis 
and reporting, new cases are chronically under reported. Studies put the number of 
new infections each year between 0.9 and 1.6 million although this figure likely 
misses a considerable proportion of cases 6. The disease has spread dramatically in 
the last 20 years due to a complex interplay of environmental and human factors, 
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including deforestation, urbanisation and conflict 7–9. Changes in human behaviour 
that bring naive populations into contact with the disease can cause resurgence of 
infections or new areas of endemicity, as seen with CL in Syria since 1998, and the 
repeated outbreaks of VL in Sudan 10–14.  
 
 
Figure 1.2. Taxonomy of Leishmania species, both Old World (blue text) and New World 
(red text). * and + indicate synonymous species, and names in bold are human pathogens. 
Underlined species have no final classification. Taken from Akhoundi et al. (2017). 
 
There are 20 Leishmania species and species complexes that cause disease in 
humans (Figure 1.1,3,15). The parasite has a digenetic lifecycle (detailed in Figure 
1.2), alternating between the intracellular amastigote form in the mammalian host 
and extracellular, flagellated promastigote forms in female phlebotomine sandflies, 
the insect vector. Within the sandfly there are several developmental stages before 
the transmissible metacyclic promastigotes are produced 16. Historically, the 
human-infecting Leishmania spp. were divided into two subgenera based on the 
location of parasite development within the sandfly, with parasites in the subgenera 
Viannia developing in the hindgut initially before migrating to the fore- and midgut, 
and those in the Leishmania subgenera developing entirely in the fore- and midgut 
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(Figure 1.2, Figure 1.3) 17. Molecular classification groups a further three species, 
capable of infecting humans, into the Mundinia subgenera 3,18,19. 
 
 
Figure 1.3. Life cycle of Leishmania parasites within the human and sandfly hosts. The 
human host becomes infected through the injection of motile promastigotes into the skin by 
an infected sandfly. The intracellular amastigote forms multiply within human cells and are 
ingested by a sandfly as it feeds. The parasites flagellate and multiply extracellularly within 
the sandfly, passing through several distinct forms. The metacyclics are injected with saliva 
as the sandfly feeds on a mammalian host. BM1 = the first bloodmeal. Circular arrows at 
procyclic and leptomonad indicate multiplicative stages of development. Adapted from 
Serafim et al. (2018). 20 
 
1.2 Leishmania Transmission 
The vast majority of Leishmania transmission for all species is through the bite of an 
infected female sandfly (Figure 1.3) 21. There are an estimated 400 sandfly species, 
although less than 50 are medically important 22. The leishmaniases can be 
categorised based on the type of transmission; zoonotic or anthroponotic (Figure 
1.4). Zoonotic transmission generally involves a single reservoir species but may 
incorporate multiple minor or incidental hosts depending on local geography and 
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biodiversity 23. Anthroponotic transmission requires no reservoir hosts to maintain 
transmission. 
 
Figure 1.4. Vector-borne Leishmania transmission cycles. Human leishmaniasis transmitted 
through insect bite can be the result of either zoonotic infection, involving many types of 
mammalian hosts (rodents and dogs in particular), or anthroponotic, independent of animal 
reservoirs. Sandflies bite infected hosts and take up amastigotes in the bloodmeal, which 
develop into transmissible promastigotes within the gut. (Human figure from Servier Medical 
Art). 
 
1.3 Leishmaniasis Disease Types 
Leishmania infection is classified according to the clinical presentation of disease, 
which is determined by a number of factors including the parasite species or strain 
24, sandfly factors 25–28 and the host immune response 29–31.  
 
1.3.1 Visceral leishmaniasis 
The most severe form of the disease is visceral leishmaniasis (VL), which affects the 
internal organs including the liver, spleen and pancreas 32,33. Infection with 
viscerotropic Leishmania species frequently results in asymptomatic infection 
(estimated 10 asymptomatic cases for each symptomatic), and the complex 
determinants of visceralisation are not well understood 34. In those that do develop 
overt disease, mortality approaches 100% without treatment 35,36. VL is 
predominately caused by the L. donovani-L. infantum complex although there are 
some instances of VL resulting from L. tropica in the Middle East and L. amazonensis 
in the Americas 37,38. While VL has historically affected predominantly children, in 
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some regions the disease focus has shifted to adults, associated with an increase in 
HIV infection and immunosuppressant therapy used in organ transplantation 15. VL 
outbreaks can be extremely dangerous, particularly in vulnerable and unstable 
populations. Epidemics in South Sudan have resulted in tens of thousands of cases, 
and are linked with the continued civil unrest and associated human migration 39.  
 
1.3.2 Tegumentary leishmaniasis 
In 2017, 87 of the 200 countries and territories reporting to the WHO were endemic 
for CL, with 95% of new cases reported in Iraq, Afghanistan, Algeria, Brazil, 
Colombia, the Syrian Arab Republic and Iran 40. Tegumentary leishmaniasis can take 
several clinical forms (Figure 1.5). 
 
Figure 1.5. Diversity of tegumentary leishmaniasis disease. Uncomplicated cutaneous 
lesions (A) typically form at the infectious insect bite. Disease can progress to severe and 
disfiguring mucocutaneous leishmaniasis (B and C). All images taken in Bolivia 41. 
Typically characterised by localised ulceration at the site of infection, cutaneous 
leishmaniasis (CL) can take several months to manifest symptoms (Figure 1.5A) 42,43. 
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Symptoms are usually limited to the skin, although parasites can migrate to the 
lymph nodes 44. CL lesion appearance depends on a complex interplay between 
various factors, including host immune response 45,46, parasite species 37,47–49 and 
the presence of other infections, such as HIV 50–52. Most lesions are localised to 
areas of the body that are uncovered, such as hands and feet, or the face i.e. where 
a sandfly can bite 42,53,54. In some species, typically limited to the Americas, the 
disease can progress into severe disfiguration of mucosal membranes, termed 
mucocutaneous leishmaniasis (MCL; Figure 1.5B+C) 55,56. MCL never self-heals and 
tissue damage occurs as the disease advances, which can require reconstructive 
surgery once the infection has been treated. In the Middle East and Africa, MCL can 
occur, although it is much rarer than in the New World and is associated with 
immune suppression and HIV co-infection 55,57–59. 
 
Uncomplicated CL lesions are frequently painless, although discomfort can occur 
when lesions become secondarily infected with bacterial or fungal pathogens 60. 
The effect of secondary infections on healing is unclear; some reports link infection 
to reduced healing and increased scarring, while others see no effect 60,61. Typically 
CL is a sporadic disease in areas of endemicity, although epidemics are noted in 
groups of naïve people, such as during military deployment, or settlement by 
refugees and/or internally displaced people 13,62–66 
 
While usually not fatal, both CL and MCL can have a significant negative impact on a 
patient’s mental health due to the highly visible and sometimes extensive nature of 
the tissue damage, and resulting scars (Figure 1.6) 67–69. The negative impact on an 
individual correlates with size/visibility of the lesion 70,71. Children are often kept out 
of school and isolated from others during active infection, and adults report 
ostracisation from the community 69,72. Young women in particular seem to report 
fears of lowered marriage prospects; a significant concern in patriarchal societies 
that equate female beauty with human worth 67,72–74. Much of the stigma is linked 
with a lack of education surrounding the mode of transmission, with people 
avoiding patients through fear of contracting the illness. Educational schemes 
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designed to alleviate the fear and stigmatisation focus on changing attitudes in 
school age children, as well as wider cultural change 75. 
 
 
Figure 1.6. Examples of the scars left by cutaneous leishmaniasis, likely caused by L. major 
infection. Images taken of healed patients in 2017, at the Al-Ahsa leishmaniasis clinic, Saudi 
Arabia. Credit: Dr L. Haines.  
 
1.4 Leishmaniasis in the Old World 
CL is widespread throughout the Middle East, Asia and northern Africa, with four 
main etiological species; L. major, L. tropica, L. aethopica and L. infantum (Figure 
1.7B) 3,6. VL has a more restricted distribution, with the vast majority of cases 
limited to Bangladesh, China, Ethiopia, India, Kenya, Nepal, Somalia, South Sudan 
and Sudan, and outbreaks in East Africa are frequent and deadly (Figure 1.7D) 6,14. 
 
1.4.1 Leishmaniasis in the Kingdom of Saudi Arabia 
While VL outbreaks are low level, sporadic and restricted to a single district (Jazan), 
CL is a significant public health problem in the Kingdom of Saudi Arabia (KSA) 54,76,77. 
Zoonotic CL is caused by L. major and transmitted by Ph. papatasi, with several 
reservoir rodent species including Psammomys obesus and Meriones libycus 78,79. L. 
tropica, which has a more limited distribution within KSA, causes anthroponotic CL 
and is transmitted by Ph. sergenti 76,78–80. There is variation in lesion number, 
treatment requirements and duration of infection between parasite species. L. 
major infections are frequently self-curing (>50%), with multiple, painless lesions 
that resolve without treatment 49. In contrast, L. tropica infections are associated 
with fewer lesions which can persist for many years and result in extensive scarring 
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42,75,76,81. 17 countries, including the Kingdom of Saudi Arabia, are co-endemic for 
both L. major and L. tropica 5.  
 
Figure 1.7. Global Distribution of the Leishmaniases. Blue points indicate occurrence points 
or centroids of occurrences. Colour indicates the evidence consensus for presence of disease 
within each country, from green (100% consensus of absence) to purple (100% consensus of 
presence). Left Panels (A + C) show New World and Right Panels (B + D) show Old World 
countries. Top Panels (A + B) depict CL incidence, and Bottom Panels (C + D) VL incidence. 
(Adapted from Pigott et al. (2014)). 
 
Visceralisation of typically dermatropic species, which is sometimes observed in L. 
tropica infection, is not reported in KSA 81. L. tropica and L. major lesions are 
typically categorised as wet and dry respectively, however there is sufficient 
variation in appearance that presentation alone is not diagnostic 82,83. Within KSA 
there is a reliance on clinical presentation and patient history for diagnosis, despite 
the low specificity of this approach 76. Anti-leishmanial drug treatment is performed 
in two steps: the first one consists of the topical application of fusidic acid in 
combination with oral azoles to reduce secondary infections. This resolves the 
infection in 30% of L. major infections 84. If re-epithelization is not achieved, 
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patients undergo 1-2 courses of intralesional antimonial injections (Pentostam™). 
Interestingly, a recent report suggests that the presence and type of secondary 
infections tend to modulate the treatment outcome in patients infected with L. 
major, but not with L. tropica 84. In this study, 60% of L. tropica infections were 
unresponsive to two injections of SSG. National programmes in KSA have been 
successful in reducing numbers of CL cases, although the zoonotic nature of L. 
major transmission requires continued monitoring and control 85–87. 
 
1.4.2 Leishmaniasis in Spain 
The zoonotic species L. infantum is hypoendemic in Spain, with domestic dogs as 
the main reservoir host 88. VL is the most common disease type, and, in adults, is 
associated with HIV coinfection, although non-HIV infected patients are also at risk 
51,89–92. An outbreak of leishmaniasis in Madrid, between 2009-12 was, unusually, 
linked to hares as a reservoir host, and decreases in human cases was in part due to 
rabbit and hare culls 93–96. 
 
1.5 Leishmaniasis in the New World 
Leishmania infection in the Americas reaches from Texas in North America to 
Argentina in South America, covering at least 18 countries (Figure 1.7A+C) 97. 
Tegumentary leishmaniasis is caused by several species of both the Viannia and 
Leishmania subgenera 3,98. In 2017, 3.9% of all cases were MCL, of which 90% were 
reported in Bolivia, Brazil, Colombia, Paraguay and Peru 97. Zoonotic VL, caused by L. 
infantum (syn. L. chagasi), results in several thousand cases reported annually, 
although this is certainly an underestimate 6,36. Where living standards improve, 
cases of VL have fallen, however the changing epidemiology of VL, from rural to 
urban settings, indicates that VL transmission in cities may become more of a 
concern 6,99. Response to treatment of leishmaniasis in New World countries differs 
between both species and strain of infecting parasites 100.  
 
1.5.1 Leishmaniasis in Bolivia 
In 2017, four tegumentary-causing species were reported in Bolivia; L. amazonensis, 
L. braziliensis, L. guyanensis, and L. lainsoni. Of the over 2000 reported cases of 
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tegumentary leishmaniasis in 2017, 10% were MCL, which is the highest ratio of 
CL:MCL cases in Latin America, and is attributed to prevalence of L. braziliensis in 
the country 41,101. Bolivia has one of the highest incidences of CL in the Americas, 
due in part to the large percentage of forest (70% of the country) and the 
associated sylvatic transmission risk 102. VL is comparatively much less common and 
is caused by L. infantum. Leishmania spp. have been detected in several animal 
species including rodents, domestic dogs, skunks and porcupines, but incrimination 
as reservoirs requires further study 41. 
 
1.6 Leishmaniasis Control  
Zoonotic outbreaks can occur when human activity encroaches on animal reservoir 
populations, with human infection incidental alongside the established transmission 
cycle 35. Where the primary host species is known, trapping of animals, and 
destruction of burrows and food sources can be effective methods of reducing 
overlap between human and animal habitats 103. However, this can be costly and 
requires repeated intervention to maintain control. Often the relationship between 
vector and reservoir host is unknown, preventing adequate removal of either 23,104. 
Canine reservoirs are a major risk factor for L. infantum infection, and interruption 
of contact between dogs and sandfly bites can reduce incidence of associated 
human VL, although efficacy of canine culls is debated 33,104–106. Reports of reduced 
incidence following treatment of seropositive dogs is tempered by noted 
resurgence of disease following treatment in endemic areas 104,107. 
 
Reduction of contact between humans and vector species is effective at preventing 
infection, but not practical for many at-risk populations, such as agricultural 
workers who work outside with exposed skin. Indoor residual spraying (IRS), such as 
national programmes with DDT in India or pyrethroids in Nepal to control P. 
argentipes, can have some impact on indoor biting sandflies, although resistance 
and poor quality control limits efficacy 108–111. When sandflies bite out of doors, IRS 
is less effective than when employed against endophagic species, requiring a good 
understanding of the transmission setting for each locality 23. Focused spraying and 
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distribution of barriers (i.e. insecticide treated bed nets) to transmission “hot spots” 
may have an impact on transmission, particularly in anthroponotic cycles, and in the 
control of VL 112–114. Truly effective control strategies are unclear, with most 
randomly controlled trials too small to give strong evidence for or against 
intervention 115. 
 
Leishmanization (vaccination with live Leishmania) is one of the oldest known 
methods of leishmaniasis control that is still in use today 116. Historically, the 
deliberate exposure of infants' skin to biting sandflies resulted in an infection early 
in life, and protects against subsequent lesions. It was typically the buttocks that 
were exposed, leading to a scar that was hidden from view. Modern attempts to 
use a live Leishmania vaccine have variable levels of protection 116–118. The 
importance of sandfly saliva in transmission success is possibly one reason for the 
reduced efficacy of artificial inoculation, although the age and virulence of the 
culture used is also likely a major determinant 117. There is currently no available 
vaccine against human leishmaniasis, despite many varied approaches which have 
been extensively reviewed 118–121. Recent advances include a partially protective 
vaccine against L. major infection, based on antigenic Leishmania glycans (discussed 
in further detail in section 1.11.4) 122.  
 
Effective control of leishmaniasis is most probably through a combined approach; 
case detection, treatment and educational programmes in at-risk human 
populations, control/treatment of reservoirs and reduction of vector numbers 
33,75,104,112,123. 
 
1.7 Treatment of leishmaniasis 
While mortality from VL infection approaches 100% without intervention, it is not 
always necessary to treat CL; a decision is made based on lesion number and 
location, as well as the parasite species 68,98. Response to treatment varies between 
Leishmania species, although trial data is conflicting and reflects the complex nature 
of leishmaniasis 98,124–126.  
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Pentavalent antimonials have been the front line drug of choice since the 1940s, 
and are still used where resistance is not reported, mostly outside of the Indian sub-
continent 127,128. Intralesional injection of antimonials have cure rates of over 75%, 
although cure requires multiple injections over several weeks and adverse reactions 
are frequent 129. Intramuscular injection is recommended as a second line 
treatment for Old World CL, when lesions are present in high numbers or in 
particularly problematic places, for example, joints 130. However, systemic 
antimonials are almost always required in the treatment of New World CL, due to 
the risk of mucosal involvement. Pentamidine is used in the treatment of L. 
guyanensis, for which antimonials are ineffective 131. The antifungal Amphotericin B 
has been in use for decades, and typically a single dose of the liposomal 
amphotericin B (AmBisome, Gilead, USA) can cure VL, although the cost can be 
prohibitive 132–134. Oral drugs are preferable to parenteral methods, but again, 
options are limited. Miltefosine is effective in the treatment of VL, although has 
associated gastrointestinal adverse effects, and is not always superior to standard 
antimonials, as is the case in American CL caused by L. braziliensis 135,136. Further 
restrictions apply to its use in childbearing women due to the teratogenic risks 137. 
However, utility in treating unresponsive MCL can justify recommendation as a 
second line treatment in the Americas 138. Oral treatment with azole drugs can also 
be effective across the spectrum of tegumentary leishmania, although there is 
considerable heterogeneity between trials and clinical settings 98. Topical 
paromomycin for L. major and L. tropica has demonstrated high cure rates alone 
and in combination with gentamicin, but has limited availability currently and some 
trials report no improvement vs placebo controls after several weeks 125,126,139,140. In 
spite of WHO guidelines for treatment, drug concentrations and duration of 
treatment can vary between heath care providers, giving an inconsistent approach 
to chemotherapy across regions 141. 
 
Non-chemical treatments may also be efficacious in treatment of lesions, and avoid 
the complication of resistance faced by chemotherapeutic methods 128. Cryotherapy 
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can be useful in treating uncomplicated lesions, even in species with reduced drug 
sensitivity, such as L. tropica, and has only mild reported side effects 142,143. While 
cryosurgery by liquid nitrogen can be very expensive and therefore unsuited to low-
resource countries, the cheaper alternative of carbon dioxide slush has been used 
with some success in Yemen, however it must be noted there was no control 
comparison group in this study so true benefit is unclear 144. Photodynamic therapy 
is another alternative to chemotherapy, although one that is unlikely to find 
widespread use in low resource settings 145. Thermotherapy is more widely used. A 
single application of localised heat (50°C) was demonstrably effective in the 
treatment of CL, in several settings including L. tropica in Afghanistan 146 and L. 
donovani CL in Sri Lanka 147. Adverse effects are relatively low when compared to 
systemic treatments such as pentavalent antimonials, and so thermotherapy is 
typically tolerated, although it may not be a suitable treatment in areas where the 
risk of mucosal involvement is high 148. Self-treatment with non-biomedical 
chemicals and traditional methods is sometimes used, and these can vary from 
battery acid and bleach to veterinary products and insecticides 149–151.  
 
1.8 Current status of Leishmania diagnostics 
CL diagnosis is typically based on epidemiology, clinical features, and laboratory 
tests, but can be difficult due to the lack of specificity in clinical symptoms, as CL 
lesions can resemble many other skin conditions 100,152–156. Further complications 
arise due to the diversity in lesion appearance, which can vary widely depending on 
duration of infection, presence of secondary infections and host responses (Figure 
1.8) 157. For both VL and CL local procedures vary, depending on available 
infrastructure and expertise, but fall into three main categories: parasitological, 
molecular and serological.  
 
Parasitological diagnosis depends on either in vitro culture from patient samples or 
direct staining of tissues to visualise amastigotes. It is considered the gold standard 
due to high specificity, although sensitivity is low (50-70%), particularly when 
amastigotes are scanty, such as in chronic cutaneous leishmaniasis 158. A high level 
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of histopathological expertise is required, and, as all Leishmania species are 
morphologically very similar, species cannot be determined. Establishment of 
parasite culture from lesions aspirates is limited by the need to control 
bacterial/fungal contaminants, a heavy dependence on lab infrastructure, and the 
lengthy period required for cell growth (>10 days) 158. Both methods also depend on 
tissue collection, which can be invasive, painful, and even fatal if performed 
inexpertly, particularly for VL (bone marrow or splenic aspirates) 32,159. 
 
 
Figure 1.8. Diversity in the appearance of cutaneous lesions caused by L. major infection. 
Each image is of a different patient and was taken at the Al-Ahsa leishmaniasis clinic, Saudi 
Arabia in 2017. Credit: Dr L. Haines 
 
Molecular detection of parasite DNA has many advantages over parasitological 
methods, including the ability to differentiate between Leishmania species and 
higher sensitivity, especially for chronic CL or cases with similarly low parasitaemia 
83,160–162. The method of sample collection for PCR can be invasive, although in CL, 
punch biopsies can be replaced with lesion scrapings, which have equal diagnostic 
value 163. However, as with parasite culture, high quality DNA detection usually 
depends on appropriate laboratory facilities, and consumables and equipment are 
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expensive, limiting applications in low-resource settings. The development of a 
loop-mediated isothermal amplification (LAMP) assay for the detection of multiple 
Leishmania species, Loopamp™ Leishmania Detection Kit (Loopamp™), has 
considerable advantages over traditional molecular methods, in that it requires no 
cold chain (reagents are dried), a single temperature (no thermocycling), and 
samples can be collected through swabs rather than invasive methods 164. As a 
novel protocol, Loopamp™, requires validation in more endemic regions, but is 
potentially an important tool in the diagnosis of both VL and CL 165,166. An 
alternative method, direct-boil LAMP, further simplifies the protocol and shows 
encouraging results, however, it has a much lower detection limit than conventional 
LAMP, and remains unvalidated in clinical settings 167,168. 
 
Serological diagnostic approaches have been highly successful in the diagnosis of 
VL, particularly with the recombinant leishmanial antigen K39 or a direct 
agglutination test (DAT) 169–172. Antibody detection is less widely used for CL 
diagnosis, due in part to lower humoral response and associated low sensitivity. 
However, several ELISA methods have shown promise in antibody detection, for 
both New World 173,174 and Old World CL 175,176. Recently, an immunochromatic 
point of care test has become available; the CL Detect™ Rapid Test (InBios 
International Inc., USA), which detects amastigote peroxidoxin antigen, shed by 
amastigotes of Leishmania. This RDT has mixed performance, with low sensitivity in 
cohorts from Suriname, Sri Lanka and Afghanistan 177–180, but reportedly high 
sensitivity in Tunisia (de Silva et al. 2017 cites conference communications by Ben 
Salah et al., ASTMH 2012 Atlanta/2014 New Orleans). Vink et al. (2018) show that 
combining Loopamp™ and CL Detect™ to screen patients in Afghanistan maximised 
the potential of both tests, and minimised false negative cases.  
  
1.9 The case for improved leishmaniasis diagnostics 
Under-reporting of Leishmania infection is rife, in large part because the burden of 
disease falls on the poorest and most isolated communities, and the stigma 
associated with infection further hinders access to healthcare 4,43. A rapid diagnostic 
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test (RDT) that could be used in rural communities could increase uptake of 
diagnostic tests by bringing the test to the patient, rather than requiring long 
distance travel to specialist health centres 181. RDTs are simple medical devices 
(often cassettes or dipsticks) that require minimal training, allowing preliminary 
screening of suspected cases at community level. A cost effectiveness study 
comparing combinations of a CL RDT (CL Detect™), a molecular testing kit 
(Loopamp™) and the gold standard microscopy determined that initial screen with 
the RDT in a rural clinic, followed by LAMP/microscopy of negative suspects at the 
central reference clinic, was a cost-effective and robust diagnostic protocol 181. 
Further benefits to a low-tech RDT would be during intense human displacement, as 
seen in recent decades 182. Human migration and resulting imported cases are 
becoming increasingly important for the control and monitoring of CL in the Middle 
East and North Africa 13,78. Vast numbers of displaced Syrian refugees are linked to 
changing patterns of Leishmania incidence, in Lebanon 62,183, Jordan 184, Iran 185, 
Turkey 186–188, and Northern Europe 189,190. While diagnosis to species level is not 
always necessary when the local disease dynamics are known, imported and newly 
emerging infections demand a more in-depth screening process. Active case 
surveillance is essential in the changing climate of leishmaniasis burden globally, but 
requires accurate, cheap diagnostic tests that can be used in low-resource settings 
76. Health care for economically deprived people requires minimal investment in 
infrastructure and human expertise. This rules out most molecular and 
parasitological diagnostic methods, and requires something more akin to the RDT 
format used in malaria detection 62,67. 
 
1.10 Glycan Diversity 
Monosaccharides, the building blocks of more complex glycans, are carbohydrates 
that cannot be hydrolysed into simpler forms, and, when attached to each other 
through glycosidic linkages are typically found in ring form. The pyranose form 
(denoted p as in Galp for galactopyranose) has a six-ring structure, whereas the 
furanose form gives a five-ring structure (Galf). This work is primarily concerned 
with hexoses (sugars with six carbons), although hexosamines (hexoses with an 
18 
 
amino group at the 2-position, such as GlcNAc) are incorporated into several of the 
structures discussed (Figure 1.9).  
 
Figure 1.9. Common monosaccharides found in vertebrates. Monosaccharides found in 
Leishmania spp. GIPLs include Galactose, Mannose and N-Acetylglucosamine. Adapted from 
Essentials of Glycobiology, 2nd Ed. 
 
The carbons in a hexose are numbered 1-6, so a glycosidic bond described as 
Gal(1,4)Man, indicates a bond between C-1 of the galactose and C-4 of the 
mannose. The configuration of the hydroxyl group at C-1 determines if the glycan is 
α or β (Figure 1.10). This determines the biological and structural function of the 
glycan, neatly demonstrated by the human immunogenic αGalp and the non-
immunogenic βGalp, which are otherwise identical in structure.  
 
 
Figure 1.10. α and β configurations of galactopyranose monosaccharides. Immunogenicity 
of galactopyranose is determined by its α or β configuration. If the hydroxyl group on C-1 is 
axial (α), the residue is immunogenic. If the hydroxyl group is equatorial (β), then the 
galactose is not immunogenic.  
1.11 Human anti-αGalactosyl antibodies (anti-Gal)  
Anti-Gal is a natural human antibody (i.e. produced continually without inducement 
by a vaccine) that constitutes 1-5% of circulating IgG in healthy adults, with lower 
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levels in young children 191–193. The high titre of natural anti-Gal in healthy humans 
is likely due to continual antigenic stimulation by gut microbiota, as it has been 
shown to bind to several bacterial species, including E. coli and Klebsiella, which are 
commonly found in the human gut, and clearance of gram negative bacteria in 
baboons has a corresponding reduction in circulating anti-Gal IgG 194,195. 
Interestingly, individuals on a meat-free diet have lower anti-Gal titres than those 
who are not vegetarian 196. Natural anti-Gal specifically binds the trisaccharide 
Galα(1,3)Galβ(1,4)GlcNAcβ-R. Binding of anti-Gal is determined largely by the 
terminal, non-reducing αGalactosyl (αGal) residue, however, overall specificity is 
driven by the subsequent glycans in the chain 197–199. The Galβ(1,4)GlcNAc linkage is 
an important feature, likely due to the relative rigidity of the linkage, as compared 
to the more flexible Galα(1,3)Gal portion, allowing a consistent antibody 
recognition 200. This αGal epitope is present on cells of New World primates and 
other mammals, but not human or Old World primates, because the glycosylation 
enzyme required (α1,3galactosyl-transferase, α1,3GT) was lost in these latter 
groups through a mutation >20 million years ago 201–203. Individuals synthesising 
αGal epitopes would be unable to produce anti-Gal antibodies without generating 
an autoimmune response. The loss of the enzyme and subsequent synthesis of the 
polyclonal anti-Gal is likely to have given a significant evolutionary advantage 203. 
Galili (2018) hypothesises that a hyperepidemic may have eliminated ancient 
primate species that had functional α1,3GT.  
 
The relationship between anti-Gal and blood type has been described in detail 204–
206. B antigens (Galα1-3[Fucα1-2]Galβ1-4GlcNAc-R) have a similar structure to αGal 
(Galα(1,3)Galβ(1,4)GlcNAc-R), and are recognised by anti-Gal from sera of A- and O-
Type patients. B Type-Individuals produce less anti-Gal than other blood types, and 
the frequency of this blood type correlates positively with the incidence of certain 
αGalactosylated pathogens, while a non-αGal-containing virus, Dengue, had no 
relationship 207. αGal epitopes are a major barrier to xenotransplantation, for 
instance in the use of porcine organs in humans. Hyperacute rejection of grafts can 
occur within hours due to the presence of αGal epitopes on porcine cells 208. 
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Rejection can be overcome temporarily through depletion of anti-Gal from sera, or 
the use of organs from α1,3GT-KO pigs 209,210.  
 
Due to its ubiquity in humans, anti-Gal has been the focus of many studies for 
exploitation in a variety of clinical settings. A recent study showed the conjugation 
of αGal to a therapeutic antibody increased immune response against cancer cells, 
through recruitment of anti-Gal 211. Anti-Gal can also be exploited in improving 
immunogenicity of influenza vaccines, and against HIV glycoproteins in α1,3GT-KO 
mice 212,213. Cancer immunotherapy using intratumoral injection of αGalactosylated 
glycolipids to generate a protective anti-tumour response in humans may have 
promise, following a Phase I Clinical Trial demonstrating safety 214–216. Whalen et al. 
(2012) suggest utility in this approach as a vaccine against recurrence of tumours, 
following resection of tissue. Injection of αGal lipids into a tumour, 3-4 weeks prior 
to surgical removal, could induce continued protection against tumour antigens 214. 
 
1.11.1 Anti-Gal during a leishmaniasis infection 
It has been known for more than three decades that the titres of antibodies 
recognising αGal terminating residues are increased, compared to healthy controls, 
in both CL and VL infections 217–220. Inoculation of α1,3GT-KO mice with L. major 
promastigotes results in high titres of IgG anti-Gal 221. During VL infection, levels 
increase throughout the initial course of disease, with high values seen in over 70% 
of patients at 0.5 months after onset of symptoms 218. These antibodies, the main 
subject of this thesis, present a viable candidate for a biomarker of Leishmania, if a 
specific capture antigen can be identified (discussed in the Chapters 4 and 5). 
 
1.11.2 αGal epitopes in Leishmania parasites 
The surface of Leishmania parasites is covered in a vast number of glycoconjugates. 
This glycocalyx is made up mainly of glycosylphosphatidylinositol (GPI)-linked 
proteins, proetophosphoglycans (PPG), lipophosphoglycan (LPG) and 
glycoinositolphopholipids (GIPLs) (Figure 1.11) 222–225. The nature of this surface 
coat changes throughout the parasite lifecycle, becoming thinner during the 
amastigote stage due to a down-regulation in LPG expression 226. Furthermore, the  
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exact composition is species-specific. LPG expression varies, in both the length and 
composition of glycan side chains as well as copy number per cell 222,227,228. GIPLs 
are the most abundant glycoconjugates present (an estimated 107 copies per cell), 
with likely important roles in mediating parasite:host interactions 229–232. These low 
molecular weight glycolipids are categorised according to the structure of their 
glycan and lipid components (Type-I, Type-II or Hybrid). While the number of GIPLs 
 
 
Figure 1.11. Details of the promastigote Leishmania surface glycocalyx. Major 
glycoconjugate components of Leishmania promastigote surface. GPI anchored (LPG, 
lipophosphoglycan; GIPLs, glycoinositolphospholipids, and proteins e.g. gp63), and secreted 
(proteins e.g. sAP, secreted phosphoglycan; PPG, proteophosphoglycan). There is variation 
in glycan core between GIPLs, LPG and GPI-anchored proteins, and in the PI anchor 233. 
Downregulation of LPG expression in amastigotes exposes low molecular weight GIPLs, which 
are invariant throughout the life cycle 226. Adapted from Cabezas et al. (2015). 234  
 
is invariant throughout the Leishmania lifecycle, the presence of each type depends 
on the parasite species (Figure 1.12) 230,235,236.  
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The majority of the GIPLs present in L. mexicana, L. major and L. braziliensis 
parasites are Type-II, and contain a terminal galactose residue 230,231,237. Anti-Gal 
recognises the major GIPLs found on the surface of L. major which contain the 
immunogenic αGal residues, but the epitope on L. tropica remains unknown 
230,238,239. Despite this apparent lack of αGal, anti-Gal antibodies are raised during 
 
 
Figure 1.12. Structure of the three major classes of GIPL found on the surface of Leishmania 
parasites. The Type-II GIPL series contain the immunogenic terminal αGal residues. This type 
contains an R-Manα1- substitution on the 3rd carbon of the proximal mannose ring. Type-I 
GIPLs are mannosylated and are characterised by the R-Manα1-addition at the 6th carbon of 
the proximal mannose ring. Hybrid GIPLs contain features of both Type-I and Type-II GIPLs, 
with R-Manα1- substitutions on both the 3rd and the 6th carbons of the mannose ring. 
Adapted from Assis et al. (2012). 231.  
 
infection with L. tropica, as with L. major 217. Other Leishmania species, including L. 
infantum and L. tropica, have structurally different GIPLs; largely Type-I GIPLs. Assis 
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et al. (2012) discusses the mannose-rich glycans detected in GIPL extract from L. 
infantum promastigotes, with 82% of the glycan composition derived from mannose 
residues, compared to around 30% in L. braziliensis.  
 
1.11.3 Anti-Gal antibodies in Chagas disease and malaria 
Over 5 million people are estimated to be infected with Trypanosoma cruzi, the 
aetiological agent of Chagas disease 240. The majority of transmission is through the 
insect vector, triatomine bugs, although transfusion of infected blood 241,242, 
transplacental transmission from mother to child 243,244 and ingestion of 
contaminated food contribute to the burden of disease globally 245. Chagas disease 
has two stages beginning with the acute phase with generally mild or no symptoms 
that lasts up to two months 246. Between 30-40% of infected individuals will 
subsequently develop the chronic phase, which has much higher morbidity and 
mortality due to heart and digestive complications 247.  
 
T. cruzi parasites have a dense glycocalyx, largely made up of GPI anchored mucin-
like glycoproteins (Figure 1.13A) 248. These mucins coat the entire surface of the 
bloodstream trypomastigote stage, including the flagellum, with around 2 x 106 
copies per cell. Each mucin can be heavily O-glycosylated with glycans that have a 
terminal αGal residue at the non-reducing end (Figure 1.13B) 222,248–250. High anti-
Gal titres, recognising these immunogenic mucins, have been reported in patients 
infected with several Trypanosoma species, including T. cruzi and T. rangeli 229,251–
253. Chagasic anti-Gal are likely to be an important immunological method of 
protection against T. cruzi, with these antibodies directly lysing parasites, and 
inducing complement-mediated clearance 253–257. The high levels of anti-Gal are 
seen in the acute and chronic phase of Chagas, returning to normal once the patient 
is cured; this trait has been exploited as a marker for effective cure following 
chemotherapeutic treatment 253,258,259. Natural anti-Gal recognises T. cruzi mucins, 
but to a lesser degree than anti-Gal from patients with chronic Chagas infection 
254,260. Chagasic anti-Gal has broad affinity for αGal-terminating structures 
(Galα(1,2/3/6)Gal and Galα(1,3)Galf), whereas natural anti-Gal has a much more 
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limited range of recognition, driven by its higher specificity for the subterminal units 
as well as the terminal, non-reducing αGal residue 200. 
 
 
Figure 1.13. The main components of the surface glycocalyx of T. cruzi parasites. A. Major 
GPI components of T. cruzi trypomastigote surface; mucins number 2 x 106 copies/cell, while 
the much smaller GIPLs are the most abundant. Red components are protein, blue are 
saccharides and yellow ovals denote sialic residues. Adapted from Ferguson et al. (1999).222 
B. Detailed structure of T. cruzi trypomastigotes mucins. Left panel: The heavily O-
galactosylated protein core. Right. The glycan side chains have abundant αGal terminal 
residues that are recognised by Chagasic anti-Gal. Adapted from Ortega-Rodriguez et al. 
(2019). 261. 
 
Anti-Gal titres are also increased in patients with P. falciparum, and individuals 
living in P. falciparum-endemic regions 262. IgM anti-Gal is linked to protection from 
clinical malaria in children 263. A study of serum from 112 P. vivax-infected people 
found titres of anti-Gal were significantly higher than in non-malarial controls but to 
date no study has investigated the presence of αGal in P. vivax cells 263. αGal has 
been identified on P. falciparum cells, both in asexual and sporozoite stages, by 
indirect methods 264,265. Curiously, no α1,3GT orthologue gene has been yet 
identified in P. falciparum, leading to the hypothesis that the detected αGal may be 
vector-derived 266,267. Natural anti-Gal, produced through antigenic stimulation by 
gut microbiota, has been linked to protection from P. falciparum infection 265. 
Theoretically, this could be exploited in the generation of an anti-malaria probiotic 
to induce anti-Gal and therefore protect against Plasmodium infection 268.  
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1.11.4 Anti-Gal vaccines against parasitic infection 
The presence of αGal on Plasmodium, Leishmania and T. cruzi cells alludes to the 
possibility of anti-Gal based vaccines for these pathogens 269,270. Yilmaz et al. (2014) 
demonstrate that α1,3GT-KO mice are protected from P. berghei and P. yoelii 
infection after inoculation with a synthetic αGalactosyl-terminating glycan, 
conjugated to bovine serum albumin (αGal-BSA). This protective effect was largely 
driven by IgM antibodies and was limited to the dermis; immunisation had no 
impact on sporozoites injected intravenously, rather than intradermally or through 
mosquito bite. Additionally, for immunised mice that did get infected, disease was 
just as severe as in the controls. As fluorescent labelling of sporozoites confirmed 
the presence of αGal in P. falciparum, as well as P. berghei and P. yoelii, there are 
potential application in the human malaria species.  
 
No therapeutic or prophylactic vaccine exists for Chagas disease, but Portillo et al. 
(2019) demonstrate promising results in mice, exploiting the immunogenic T. cruzi 
mucin glycans. α1,3GT-KO mice immunised with a synthetic 
Galα(1,3)Galβ(1,4)GlcNAc conjugated to human serum albumin were protected 
from a lethal T. cruzi challenge for up to 31 days (the experimental end point). 
Parasite load was reduced >90% in all tissues/organs tested, and weight loss 
reduced and then reversed in the immunised groups, compared to the non-
immunised control mice. Antibodies from the immunised mice lysed a higher 
proportion of T. cruzi trypomastigotes than naïve mouse sera in in vitro assays 271.  
 
A similar approach was used to evaluate the protective potential of three synthetic 
disaccharides, Galα(1,3)Galα-BSA, Galα(1,4)Galβ-BSA, and Galα(1,6)Galβ-BSA, 
against L. major infection in the same mouse model 122. Immunisation with 
Galα(1,6)Galβ-BSA (with and without an adjuvant) resulted in significantly smaller 
lesions, alongside weight gain following challenge, an indicator of general health 
(the non-immunised mice consistently lose weight after L. major challenge). As with 
Chagas anti-Gal, anti-Gal from the immunised mice lyse L. major metacyclics in 
26 
 
vitro. Both Yilmaz et al. (2014) and Iniguez et al. (2017) observe a high titre of IgG1 
and IgG3 in response to immunisation with the synthetic αGal. 
Taken together, these three studies demonstrate both the importance of αGal 
epitopes in generating an immune response, and the protective potential of anti-
Gal against parasitic infection. 
 
1.12 Objectives of this work 
Diagnostic tools for cutaneous leishmaniasis are currently limited to methods 
requiring expertise and laboratory infrastructure, which is antithetical to the rising 
burden of CL in refugee and migrant communities who lack access to healthcare. 
Therefore, the overall objective of this thesis was to assess whether human anti-gal 
antibodies developed during a leishmaniasis infection can be exploited as 
biomarkers in the diagnosis of CL.  
 
1.13 Aims 
1. Assess the utility of parasite glycolipids in diagnostic development, through TLC 
and ELISAs (Chapter Three). 
2. Determine the anti-Gal specificities in patient sera with Old and New World 
leishmaniasis, using synthetic neoglycoproteins (NGPs) (Chapter Four). 
3. Identify anti-Gal epitopes on L. tropica and L. major cells throughout life stages 
(Chapter Five). 
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Chapter Two 
Methods 
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2.1 Cell Culture Methods 
2.1.1 Leishmania Cell Culture 
L. major (Friedlin strain; MHOM/IL/81/Friedlin) and L. tropica (LV357 strain; 
MHOM/IR/60/LV357) were cultured in Medium 199 (M199) with Hanks' Balanced 
Salts (Gibco, 22350029), supplemented with Penicillin-Streptomycin (Life 
Technologies, 15140-122), 1.5% BME vitamins (Sigma, B6891) and 10% heat-
inactivated Foetal Bovine Serum (Hyclone, SV30160). Flasks were seeded at low 
density and passaged at 48-72 hours as needed. Cultures were maintained at 27°C 
in non-filter flasks and discarded after 15 passages.  
 
2.1.2 Large scale Leishmania spp. cell culture 
L. major and L. tropica promastigote cultures were grown to log phase (density ~1 x 107 
cells/mL) in large volumes (>500 mL). The culture was harvested in volumes of around 
200 mL, and washed twice with ice cold, sterile PBS, counted using a Neubauer 
haemocytometer and pelleted at maximum speed to remove the supernatant. A final 
high-speed centrifugation step ensured maximal liquid removal. Parasite pellets were 
stored at -80°C until used. The cells were collected in batches to minimise the length of 
time each step took and therefore reduce the risk of degradation during the collection. 
Counts were performed after two washes to give as accurate an estimate of the 
number of cells collected as possible, as a percentage of cells are lost with each wash. A 
sample of each batch was kept at this point and stored for PCR confirmation of species 
purity (Section 2.1.3). The final wash was performed at maximum speed, and ensures 
minimal loss of cells, but damages the cells to such a degree that counts at this stage 
are impossible. There is a degree of inaccuracy in this way of counting cells, so although 
counts were done on 100-200 cells, and in duplicate, cell equivalents are estimates 
only, and should be considered as such. 
 
2.1.3 Identification of Leishmania spp. by PCR of parasite ITS1 region 
Confirmation of Leishmania species in culture was performed on each batch of 
parasite cells, prior to extraction of glycolipids or use in other assays. A PCR method 
based on that developed by Schonian et al. (2003) exploits the polymorphisms in 
fragment length of the ribosomal internal transcribed spacer locus (ITS1), after 
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treatment of extracted parasite DNA with HaeIII restriction enzyme. Genomic DNA 
was extracted using DNeasy Blood & Tissue Kit (Qiagen, 69504). PCR reactions 
contained 5 µL 10x PCR buffer, 1 µL genomic DNA, 1.5 µL each forward and reverse 
primers, 1 µL dNTPs, 1 µL Taq DNA Polymerase and 39 µL nuclease free water. PCR 
conditions were one cycle at 95°C for 40 seconds, 35 cycles of 95°C for 40 seconds, 
53°C for 40 seconds and 72°C for 50 seconds, followed by cooling to 4°C for storage. 
Restriction digests were performed according to the manufacturers protocol for 
HaeIII digestion (New England Biolabs, R0108S). 43 µL of PCR product was incubated 
with 5 µL NEB Buffer 2 and 2 µL HaeIII for 2 hours at 37°C. Digests were then run on 
2% agarose gels with SYBR Safe DNA Gel Stain and the species confirmed based on 
banding pattern (compared to 272). 
 
2.1.4 Human monocyte THP-1 cell culture 
THP-1 monocytes (kindly donated by H. Price, Keele; original source 273), were 
cultured at low density in RPMI (ThermoFisher, 21875), supplemented with 10% HI-
FBS (Hyclone, SV30160) and 100 U/mL Penicillin-Streptomycin (Life Technologies, 
15140-122). When cultures approached a density of 1 x 106 cells/mL, cells were 
washed and resuspended in fresh media to a density of 2-5 x 105 cells/mL. Cultures 
were discarded every four weeks and fresh aliquots thawed. 
 
2.1.5 Infection of THP-1 cells with Leishmania spp. 
THP-1 cells were differentiated at densities between 2.5-3 x 105 cells/mL. Phorbol 
12-myristate 13-acetate (PMA; Merck, P8139), stock solution dissolved in DMSO, 
was added to a final concentration of 25 ng/mL and incubated at 37°C for 48 hours. 
Non-adherent cells were removed, by gentle washing with serum-free RPMI pre-
warmed to 37°C, three times. The adherent cells were supplied with complete RPMI 
with 10% HI-FBS were rested overnight at 37°C. 
 
Leishmania procyclic promastigote cultures were collected in late log phase, washed 
and resuspended in RPMI media before counting. Parasites were incubated with 
THP-1 cells at a ratio of 10 parasites per THP-1 cell, for 4 hours at 37°C. Non-
internalised parasites were removed with gentle washing with pre-warmed 
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incomplete RPMI, and the infected THP-1 cells incubated for 72 hours at 37°C, with 
daily media changes. After 72 hours (peak of amastigote yields and minimal loss of 
THP-1 cells) the cells were processed for other applications i.e. immunostaining. 
 
2.1.6 Amastigote extraction from infected THP-1 cells 
THP-1 cells were differentiated into 6 well plates, and infected (as described Section 
2.1.5). Each parasite species was added to wells in triplicate. After 72 hours the 
infection was confirmed through Giemsa stain. One well for each species (L. major 
or L. tropica) was washed gently with PBS twice, and fixed with methanol for 10 
minutes on ice. The methanol was removed, and Giemsa solution added for ten 
minutes at room temperature. The stain was rinsed off with distilled H2O and wells 
allowed to dry. Parasites were counted using an eye-piece objective, as 1) a 
percentage of infected THP-1 cells, and 2) number of parasites per cell. The 
remaining unstained wells were then harvested; adherent THP-1 were treated with 
0.25% trypsin for 3 minutes at 37°C and collected in 15 mL Falcon tubes. The cells 
were pelleted at 100 x g for 5 minutes and washed once with incomplete RPMI. The 
pellet was resuspended in a small volume of incomplete media supplemented with 
0.05% SDS and gently agitated by hand for 30 seconds to release amastigotes. A 
large volume (10X the current volume) of incomplete media was added, and the 
cells pelleted at 3000 x g for 5 minutes. The supernatant was collected and 
transferred to a plate, and the pellet washed a further time. The pellet was 
resuspended in incomplete media and transferred to a plate and rested at 37°C for 
1 hour to allow cells to settle and viability confirmed (intact cell bodies, normal 
morphology). The amastigotes were then gently aspirated from the plate, spun at 
low speed to pellet and transferred to slides for staining, as described below. 
 
2.1.7 Immunostaining of fixed Leishmania promastigote cells using 
IB4-AF488 lectin 
Leishmania procyclic promastigotes were cultured to stationary phase (days 5-7) i.e. 
until metacyclic promastigotes were visualised. 2-3 mL culture (~2 x 107 cells/mL) 
was washed and resuspended in serum-free M199 and returned to the incubator 
for 2 hours. 1 mL culture was washed 3 times with ice cold TBS (1900 x g for 5 mins, 
31 
 
4°C). On the final wash, the supernatant was removed, and the pellet resuspended 
in a small volume. 50 µL of the suspension was transferred to a poly-L-lysine slides 
and allowed to settle for 30-60 minutes in a humidity chamber. The remaining liquid 
was removed after this time and the slides transferred to 100% ice-cold methanol 
and incubated on ice for 10 minutes. The slides were then washed twice in TBS 
before blocking overnight in 0.22 µM-filtered 2% BSA-TBS-S (TBS supplemented 
with salts – CaCl2, MgCl2, MnCl2, each at 1 mM). Staining with IB4 lectin was done 
for 2 hours at room temperature, in the dark. The lectin solution was resuspended 
in TBS-S, and for inhibition experiments, 0.5 M galactose was added and the 
solution preincubated for one hour at RT, prior to application to the slide. Slides 
were washed in TBS three times for five minutes each, to remove excess lectin. 200 
µL DAPI at 200 ng/mL was added to each slide for 3 minutes at room temperature, 
in the dark, before washing as before. Slides were mounted in VectaShield™ and 
coverslip edges sealed with clear nail varnish. Slides were stored at 4°C in the dark 
until imaged using a Zeiss Confocal LSM 880/Axio Observer Z1 microscope. Confocal 
imaging facilities were funded by a Wellcome Trust Multi-User Equipment Grant 
(104936/Z/14/Z). 
 
2.2 Antibody Purification methods 
2.2.1 Purification of IgG from sera using a Protein G Column 
1 mL Pierce Protein G Chromatography Cartridge (ThermoFisher, 89926) was 
equilibrated with 10 column volumes (CV) Binding Buffer (50 mM sodium acetate, 
pH 5.0), flow rate of 1 mL/minute. Pooled L. major sera was diluted 1:1 in binding 
buffer (total volume 1 mL), centrifuged at 10,000 x g for 20 minutes, and applied to 
the column at a rate of 1 mL/minute. A sample of the diluted sera was kept for 
binding quantification. The column was incubated for 1 hour at room temperature, 
before washing with 10 CV binding buffer. 1 mL fractions of the washes were kept 
and assayed for absorbance. Elution of the bound antibody was only performed 
once absorbance of the fractions was zero. 5 CV elution buffer (0.1 M glycine, pH 
2.5) was applied to the column, and fractions collected in tubes containing 1 M Tris 
(pH 9) for immediate neutralisation. The purified IgG was then applied to a second 
column of NHS-activated Agarose conjugated to Dextra-BSA. 
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2.2.2 Elaboration of an αGalactosyl column for anti-Gal purification 
Activated agarose contains N-hydroxy succinimide (NHS) ester functional groups 
that form amide linkages with the primary amine groups on proteins, such as BSA. A 
quantity of Pierce NHS-Activated Agarose Dry Resin (ThermoFisher, 26196) was 
added to a spin column and incubated with 500 µg of the synthetic glycan 
Galα(1,3)Galβ(1,4)GlcNAcβ-BSA (Dextra Laboratories Ltd, NGP0334; hereafter called 
Dextra-BSA), diluted in 100 µL coupling/wash buffer (0.1 M sodium phosphate, 0.15 
NaCl, pH 7.2), to give a final volume of 250 µL hydrated resin. The resin was mixed 
end-over-end at room temperature for one hour. Flow through (FT) was collected 
and retained for analysis of binding efficiency. The column was washed with 2 CV of 
coupling/wash buffer, before addition of quenching buffer (1 M Tris, pH 7.4), to 
block remaining active sites. The column was mixed end-over-end for 20 minutes at 
room temperature, then washed with 5 CV of coupling/wash buffer, until 
absorbance approached zero.  
 
2.2.3 Affinity purification of anti-Gal antibodies by affinity 
chromatography 
IgG from L. major infected patient sera, acquired through Protein G 
chromatography (Section 2.2.1) was diluted 1:10 in PBS, and 500 µL applied to the 
column. The column was incubated overnight at 4°C with end-over-end mixing. The 
FT was collected for monitoring binding efficiency, and the column washed with 5 
CV of PBS. The bound antibody was eluted with 0.1 M glycine and immediately 
neutralised with 1 M Tris (pH 9). The final fractions were dialysed into PBS, 
concentrated and assayed from protein content. 
 
2.2.4 Anti-Gal purification using αGalactosyl coated nitrocellulose 
membrane 
50 µg Dextra-BSA was diluted in 100 µL in PBS and applied to a strip of 
nitrocellulose (7 mm x 30 mm). The strip was dried for approximately one hour at 
room temperature, before washing three times with PBS (1 mL each time). The strip 
was then incubated with 1% BSA-PBS for 1 hour at room temperature under gentle 
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agitation, gently washed three times with PBS, then incubated overnight at 4°C in 
pooled sera from L. major positive patients. The serum was diluted 1:10 in PBS, to a 
total volume of 1 mL (50 µL kept for protein quantification). Following the 
incubation, the unbound serum was collected and stored at -20°C for binding 
assessment. The membrane was washed well with PBS, before the bound antibody 
was eluted with 50 mM citric acid (pH 2.8). The elution was performed three times, 
each elution immediately neutralised with 1 M Tris (pH 9). The membrane was 
washed with PBS, and each wash kept for protein analysis to ensure no unbound 
antibody remained. The final elution was pooled, dialysed into PBS and assayed for 
protein content. The membrane strip was stored at 4°C, in PBS with 0.05% sodium 
azide for further use.  
 
2.2.5 Anti-Gal quantification after purification  
Protein quantification was done through BCA assay, according to the manufacturers 
protocol (Pierce BCA Protein Assay Kit; ThermoFisher, 23225). 25 µL of sample was 
pipetted into each well of a clear 96-well plate, and 200 µL of working reagent 
added. The plate was incubated at 37°C for 30 minutes, cooled to room 
temperature and the absorbance measured at 562 nm. Where necessary, the Pierce 
660nm Protein Assay (ThermoFisher Scientific, 22660) was used as an alternative, 
according to the manufacturer protocol. 10 µL of each sample was added to the 
wells of a clear 96-well plate, with 150 µL of Protein Assay Reagent. Following 
agitation for 60 seconds, the plate was incubated at room temperature for 5 
minutes and the absorbance at 660 nm read. The concentration was calculated 
from a standard curve generated from Bovine Gamma Globulin (ThermoFisher, 
23212) standards, ranging from 2 mg/mL to 20 µg/mL (the working range of the 
BCA assay is 20-2000 µg/mL, and 50-2000 µg/mL for the 660nm). 
 
2.2.6 SDS-PAGE and Western blotting analysis of purified anti-Gal 
fractions  
Membrane elution fractions of antibodies were fractionated by SDS-PAGE using two 
12.5% gels. The gels were run for 90 mins at 120V. One gel was then washed under 
distilled water three times for 15 minutes each and incubated overnight with 
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Coomassie protein stain. The proteins from the second gel were transferred to 
nitrocellulose membrane at 90V for 30 minutes, on ice in Tris-Glycine buffer 
containing 20% methanol. The membrane was incubated with Ponceau Red (Sigma, 
P7170) stain to reversibly visualise the transferred bands, then washed gently to 
remove the stain before incubation in 5% skim milk for 1 hour. The membrane was 
washed vigorously with PBS-0.05% Tween 20 (PBS-T) three times for 5 minutes, 
then incubated in goat anti-human IgG secondary antibody with HRP conjugation 
(Abcam, ab6858) at 1:50,000 overnight at 4°C. The membrane was washed several 
times and developed with SuperSignal™ West Dura Extended Duration Substrate 
(ThermoFisher, 34076) and exposed to Kodak Carestream® BioMax® light film 
(Merck, Z370371). Film was processed with AFP Imaging Corp X-Ray developer using 
RG X-Ray Developer and Fixer solutions. 
 
2.2.7 Coffee bean α-Galactosidase enzyme treatment of Dextra-BSA 
0.5 µg Dextra-BSA was incubated overnight at 27°C with either 0.1 U coffee bean α-
galactosidase (CBAG; New England BioLabs, P0747S) or the equivalent volume of 0.1 
M potassium phosphate buffer (pH 6.5). The digested product was fractionated on a 
12.5% SDS-PAGE gel and then transferred to nitrocellulose as described above. 
After transfer, the membrane was incubated with Ponceau Red, washed and 
incubated in 5% goat serum-TBS (Sigma, G9023) overnight, 4°C. The membrane was 
washed with TBS-T three times for 5 minutes, then sequentially incubated with 1) 
0.2 µg/mL eluted antibody (15 mL total volume) and 2) goat anti-human IgG-HRP 
(Abcam, ab6858) 1:100,000 (15 mL total volume). Each incubation was for 1 hour at 
room temperature and followed by three TBS-T washes. The membrane was 
developed with SuperSignal™ West Dura Extended Duration Substrate 
(ThermoFisher, 34076) and exposed to Kodak Carestream® BioMax® light film 
(Merck, Z370371). Film was processed with AFP Imaging Corp X-Ray developer using 
RG X-Ray Developer and Fixer solutions. 
 
2.2.8 Dot blot with enzyme treated Dextra-BSA and eluted antibody  
0.1 µg Dextra-BSA was incubated overnight at 27°C with either 0.1 U CBAG (treated) 
or equivalent volume of 0.1 M potassium phosphate buffer (pH 6.5) (mock-treated). 
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Treated and mock-treated Dextra-BSA was dotted on a small nitrocellulose strip, 
alongside 0.1 µg of BSA. The strip was dried, washed gently in PBS then sequentially 
incubated with 1) 1% BSA-PBS, 2) 1 ug/mL eluted antibody (1 mL total volume) and 
3) goat anti-human IgG-HRP (Abcam, ab6858) 1:50000 (1mL total volume). Each 
incubation was for 1 hour at room temperature and followed by three PBS washes. 
The membrane was developed with SuperSignal™ West Pico PLUS 
Chemiluminescent Substrate (ThermoFisher, 34579), 100 µL total volume, and 
exposed to Kodak Carestream® BioMax® light film (Merck, Z370371) for 90 seconds. 
Film was processed with AFP Imaging Corp X-Ray developer using RG X-Ray 
Developer and Fixer solutions. 
 
2.3 Glycolipid Analysis Methods 
2.3.1 Extraction of Leishmania spp. GIPLs 
Glycolipids were extracted from L. major and L. tropica parasite pellets (as collected in 
Section 2.1.2) under sonication, through sequential treatment of the parasite pellet 
with chloroform:methanol (1:1, by volume) to remove phospholipids and 
chloroform:methanol:water (10:10:3, by volume) to extract the polar glycolipids. The 
C:M:H2O fraction was dried under N2 and partitioned with equal volumes n-butanol and 
H2O. The lower phase was washed with water-saturated butanol twice, and both 
phases dried under N2 and resuspended in chloroform:methanol:water (10:10:3, by 
volume). 
 
2.3.2 High Performance Thin Layer Chromatography (HPTLC) 
separation of Leishmania lipids 
The fractions were applied to aluminium-backed silica HPTLC plates in volumes 
equivalent to 2 x 108 cells. The fractions are dotted onto marked lanes of 7 mm width 
and dried. Plates were developed sequentially in two separate solvent systems; A) 
chloroform:methanol:0.2% KCl-H2O (5:5:1.5, by volume) and B) butanol:pyridine:0.2% 
KCl-H2O (9:6:4, by volume), and dried overnight. To ensure solvent evaporation plates 
were additionally gently dried with a hairdryer or in an oven at 30°C. Samples are 
duplicated on each plate, allowing one half to be chemically stained, and the remaining 
half processed for lectin/immunostaining. 
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2.3.3 Orcinol staining of L. major and L. tropica glycolipids fractionated 
on HPTLC 
The plate was clipped to a glass support and sprayed with the orcinol/H2SO4 (180 mg 
orcinol in 83% ethanol, 11% H2SO4, 6% H2O) solution using a fine aerosoliser. Porcine 
ganglioside mixture (Avanti Polar Lipids, 860053) was used as a standard for band 
migration (applied in a lane adjacent to the Leishmania extracts prior to HPTLC 
separation). The plate and glass were heated to 120°C in an oven for 5 minutes, until 
the bands were visible. Longer heating results in darker stain; the optimal resolution is 
achieved when the stain is pink in colour. The plate was cooled and any excess stain 
was removed by sandwiching the plate between pieces of filter paper.  
 
2.3.4 Immunostaining of glycolipids from Leishmania spp. 
Chromatographed TLC plates were dipped in 100% hexane for 30 seconds and 
transferred immediately to a solution of 0.2% poly(isobutylmethacrylate) (Merck, 
181544) in hexane for 90 seconds, and air dried. PIBMA-fixed plates were blocked with 
of 5% BSA-PBS-T for 30 minutes at room temperature. The plate was gently washed in 
PBS-T before serial incubation in 1) human sera (1:500), 2) goat anti-Human IgG 
(1:1000; Sigma, I2136), 3) donkey anti-Goat biotin (1:2000; ThermoFisher, PA128663) 
and 4) streptavidin-HRP conjugate (1:2000; Invitrogen, SNN4004), between washes 
with PBS-T. Binding was visualised through incubation with SuperSignal™ West Pico 
PLUS Chemiluminescent Substrate (ThermoFisher) (1 ml solution per 5 cm2 plate) and 
the plate exposed to Kodak Carestream® BioMax® light film (Merck, Z370371). Film was 
processed with AFP Imaging Corp X-Ray developer using RG X-Ray Developer and Fixer 
solutions.  
 
2.3.5 Lectin staining of αGalactosylated lipids from Leishmania spp. 
As in section 2.3.4, TLC plates were fixed with 0.2% PIBMA in hexane. The fixed plate 
was incubated in Carbo-Free block buffer (Vector Labs), washed gently in PBS-T and 
incubated overnight with 20 µg IB4-HRP in 50 mL PBS with 0.1 mM salts (MgCl2, MnCl2, 
CaCl2) at 4°C, under very gentle agitation. The plate was gently washed three times 
with PBS-T. Bands were visualised through incubation with SuperSignal™ West Pico 
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PLUS Chemiluminescent Substrate (ThermoFisher) (1 ml solution per 5 cm2 plate, 
applied to a glass support and the TLC plate inverted into the solution). The plate was 
then exposed to Kodak Carestream® BioMax® light film (Merck, Z370371). Film was 
processed with AFP Imaging Corp X-Ray developer using RG X-Ray Developer and Fixer 
solutions.  
 
2.3.6 Octyl-Sepharose purification of L. major and L. tropica GIPLs 
1.4 x 109 cell equivalents (CE) of the butanol phases of glycolipid extracts were dried 
under N2 and resuspended in 100 µL 0.1 mM ammonium acetate, through repeated 
vortexing and sonication. This was applied to a 0.5 mL Octyl-Sepharose column 
(Sigma Aldrich, O0511). The vial was washed with a further 100 µL 0.1 M 
ammonium acetate buffer, and this was again applied to the column. The 200 µL 
buffer was allowed to enter the resin bed, before the column was capped at both 
ends and incubated at room temperature for one hour. FT was collected, and the 
column washed with 1 mL 5% 1-propanol-0.1 M ammonium acetate. Fractions were 
collected in volumes of 250 µL. The bound glycolipids were eluted from the column 
with increasing concentrations of 1-propanol in 0.1 M ammonium acetate (10, 20, 
30 and 40%). Fractions were collected as before. The column was washed and 
regenerated with 10 CV of 0.1 M ammonium acetate buffer. Fractions were checked 
for glycan contents through spotting on TLC plates and staining with orcinol/H2SO4 
as described above (Section 2.3.3). Small aliquots of positive fractions are applied to 
TLC plates and chromatographed as above (Section 2.3.2), to confirm presence and 
migration of GIPL species. 
 
2.3.7 Extraction of glycolipids from silica and identification by orcinol 
staining 
Two controls were included on each plate; 10 µg of porcine ganglioside mixture (Avanti 
Polar Lipids, 860053), as a standard for the migration from the point of origin to the 
solvent front, and a duplicate of each sample, to allow marking an extraction of the 
location of each band of interest. Control lanes were placed on one side of the plate 
with a gap of 2 cm between the controls and the samples. After the plates were 
chromatographed (Section 2.3.2) and air dried to remove all solvents, the plate was 
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placed in a tank saturated with iodine vapour. Iodine (reversibly) stains many lipid 
compounds and gave visual confirmation that the plate has run consistently; i.e. bands 
are at the same height in all lanes.  
 
After the iodine dissolved off the plate, the section of the plate containing the controls 
was cut off using a razor blade. This portion of the TLC plate is stained using 
orcinol/H2SO4 (Section 2.3.3). The bands of interest were identified from the orcinol 
stained controls and the distance of migration was measured. Using a pencil, the band 
location was marked in the unstained plate, and a clean scalpel was used to scrape the 
silica containing the band into a vial. This silica was then treated with three washes of 
chloroform:methanol:H2O (10:10:3, by volume) to extract the glycolipids from the 
silica, with sonication and high-speed centrifugation between each wash. The solvent 
was dried under N2 to dryness, before the extract was resuspended in a small volume 
of chloroform:methanol:H2O (10:10:3, by volume). A small volume of this sample 
(equivalent of 1-2 x 108) was applied to a new plate, alongside the original sample, 
chromatographed as described above (Section 2.3.3) and stained with orcinol to detect 
glycolipids migration. 
 
2.3.8 Electrospray ionisation mass spectrometry (ESI-MS) and ESI-
MS/MS analysis of L. major and L. tropica glycolipids 
Glycolipid extract and individual bands were dried under nitrogen flow with gentle 
heat and resuspended in 70% 1-propanol 5 mM ammonium acetate, followed by 
high speed centrifugation for 15 minutes to ensure supernatant was clear of 
precipitate. Samples were run on LTQ Orbitrap XL MS in positive and negative 
mode, by Dougie Lamont at the University of Dundee.  
 
2.3.9 CL-ELISA detection of reactivity of serum samples against native 
Leishmania spp. glycolipid samples  
A sample of glycolipid extract (Section 2.3.1) in chloroform:methanol:water (10:10:3, 
by volume) was dried under N2 and resuspended, through sonication and vortexing, in 
PBS. White lipid-binding 96-well plates (ThermoFisher, 9502887) were coated with 
glycolipid extract (concentration determined through titration experiments) in 50 mM 
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carbonate:bicarbonate buffer (pH 9.6), 75 µL/well, and allowed to dry overnight at 
37°C. Plates were blocked with 200 µL/well 1% BSA-PBS, followed by serial incubation 
with primary antibody (concentration determined through titration) and goat anti-
human IgG HRP conjugate antibody (1:8000; Abcam, ab6858). The signal was 
developed with SuperSignal™ ELISA Pico Chemiluminescent Substrate (ThermoFisher, 
37070). All volumes (except the blocking step) were in 50 μL, and plates were shaken 
for 1 minute at a gentle speed to ensure complete coating of the base of the well with 
each step. Each plate contained two Leishmania-negative controls - pooled sera from 
North America and Saudi Arabia, and a primary antibody negative control i.e. incubated 
with diluting buffer only in place of the primary antibody. All samples were run in 
triplicate. Luminescence were read at excitation 425nm using a FLUOstar OMEGA plate 
reader. 
 
To determine glycan specificity, after antigen fixation and drying overnight, CBAG 
(Sigma, G8507) was added to wells in 0.1 M potassium phosphate buffer (pH 6.5), 
and plates were covered and incubated overnight at 27°C. Enzyme (mock) controls 
were treated with potassium phosphate buffer without enzyme under identical 
conditions. The plates were then washed prior to blocking and the ELISA then 
continued as described above. 
 
2.4 Neoglycoprotein ELISA methods 
2.4.1 Neoglycoprotein (NGP) Synthesis for use in CL-ELISA 
The synthesis of all non-commercial NGPs used in this study was performed in the 
lab of Dr Katja Michael (University of Texas at El Paso, UTEP). The general method is 
described in detail by Ashmus et al. (2013) but briefly, chemically synthesised 
glycans were conjugated to maleimide-activated BSA through a thioether linkage. 
BSA was chosen for its ease of use in immobilising on microtiter plates for CL-ELISA 
analysis, low or no recognition by human serum, the multiple binding sites per BSA 
molecule and its high solubility in aqueous solutions 260,274. 
 
The first set of NGPs (KM1-KM17) were synthesised in 2013, with a second panel 
synthesised in 2015 (new KM3, KM24), and a third (KM27-KM30, BME), to give a 
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total of 15 structures (Table 2.1, Figure 2.14). Due to minor variation in conjugation 
efficiency, the average number of glycans per BSA molecule ranges from 20-25. 
Lyophilised NGPs were reconstituted in distilled H2O by gentle pipette mixing, with 
no vortex or sonication. After protein concentration quantification by BCA (Pierce 
BCA Protein Assay Kit, Thermo Scientific, 23225; protocol according to 
manufacturer’s instructions), samples were adjusted to a standard concentration, 
aliquoted into small volumes and frozen at -80°C.  
 
 
Figure 2.1. Structures of non-commercial NGPs synthesised in Dr K Michael’s laboratory. 
Linear structure detailed in Table 2.1. Chemically synthesised glycans were conjugated to 
maleimide-activated bovine serum albumin (BSA) through a thioether linkage. 
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Table 2.1. Non-commercial neoglycoproteins (NGPs) used to assess levels of anti-Gal in 
human serum samples. ID refers to the code used to refer to each structure throughout 
this thesis. The glycan portion varies for each structure. R corresponds to the linker-BSA. All 
NGPs have at least one terminal αGal residue, except two controls KM15 (cysteine) and 
BME (β-mercaptoethanol). The NGPs were synthesised in batches; KM1-17 in Panel 1, 
KM24 in Panel 2, and KM27-BME in Panel 3.  
Panel ID Structure of Terminal Glycan 
1 
KM1 Galα(1,3)Galβ(1,4)Glcβ-R 
KM3 Galα-R 
KM5 Galα(1,6)Galβ-R 
KM8 Galα(1,2)Galβ-R 
KM9 Galα(1,3)Galβ-R 
KM11 Galα(1,6)[Galα(1,2)]Galβ-R 
KM12 Galα(1,4)Galβ-R 
KM17 Galα(1,3)Galα-R 
KM15 Cysteine-R 
2* KM24 Galα(1,3)Galβ(1,4)GlcNAcα-R 
3 
KM27 Galα(1,3)Galβ-R 
KM28 Galα(1,6)Galα(1,3)Galβ-R 
KM30 Galα(1,3)Galβ(1,3)Manα-R 
BME 2-ME-R 
* Panel 2 also included KM3 
 
2.4.2 CL-ELISA assays to determine with αGal-NGPs  
Levels of Leishmania anti-Gal IgG antibodies in human sera was determined as 
previously described 217,275. The antibodies and concentrations varied between 
assays (see Table 2.2 for details) but the overall steps remained the same. Briefly, 
white 96-well plates (Nunc) were coated with the appropriate NGP in 0.2 M 
carbonate:bicarbonate buffer (pH 9.6) at 4°C, overnight, at concentrations 
determined through titration experiments. The plates were blocked with 200 
µL/well 1% BSA-PBS (PBS-B), and serially incubated with antibodies; all incubations 
were performed at 37°C for one hour. Plates were washed between incubations, 
three times with PBS-T. The luminescence was developed with SuperSignal™ ELISA 
Pico Chemiluminescent Substrate (ThermoFisher, 37070) diluted 1:1:8 in 0.2 M 
carbonate-bicarbonate buffer. Controls for each NGP/sera pool combination were 
included in duplicate on each plate; Antigen Negative, Primary Negative, Secondary 
Negative, and HRP Negative. The average RLU was taken for these controls and 
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subtracted from the average of the unknown sample replicates to control for non-
specific/background signal from the reagents.  
 
To determine if a single, polyclonal antibody was responsible for binding to the 
αGal-NGPs, wells were coated with pairs of NGPs at the same concentrations as in 
solo experiments. CL-ELISA protocol was followed as described above. 
 
Table 2.2. CL-ELISA Conditions for each NGP Panel as described in this thesis.  
 
 
2.4.3 Specificity of αGal-NGPs after CBAG treatment 
Optimisation of the appropriate conditions for the use of CBAG in the CL-ELISA was 
carried out for a single NGP (KM30), using a checker-board titration of enzyme vs 
serum concentration. Plates were coated with NGP as described previously at a 
concentration of 50 ng/well. After overnight incubation, wells were blocked with 
PBS-B. The required amount of CBAG (Sigma, 8507) was removed to a centrifuge 
tube and spun at 13000 x g for 10 mins, 4°C to discard the ammonium sulphate 
buffer. The pellet was then resuspended in 0.1 M potassium phosphate buffer (pH 
6.5) and applied to the plate in a serial dilution from 0.1 U/well to 0.013 U/well. 
Some wells had no enzyme and only buffer added. The ELISA was carried out as 
previously described (Section 2.4.2), using L. major positive pooled sera. The serum 
was diluted in PBS and titrated down the plate from 1:100 to 1:800. In a separate 
experiment, NGP was titrated against enzyme concentration. Plates were coated 
with NGP in a serial dilution from 50 ng/well to 12.5 ng/well, and the enzyme 
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titrated from 0.1-0.025 U/well, with the primary antibody constant at 1:800 in all 
wells. 
 
2.4.4 Glycan inhibition of purified anti-Gal antibodies 
CL-ELISA was conducted as described with one modification. Sera samples were pre-
incubated in PBS-T with 1% BSA (PBS-TB) buffer containing either 0.1 M or 0.5 M 
inhibitory sugars (detailed in legends for individual experiments), for one hour at 
37°C, before addition to the plate. Reduction in binding was calculated relative to 
controls, where the serum was incubated with PBS-TB alone, under the same 
conditions. Results were expressed as percentage of antibody titre bound, relative 
to control (the control is set at 100%) 
 
2.4.5 C-Reactive Protein (CRP) assay 
To assess any correlation between CRP concentration and infection status, a subset 
of samples was randomly selected for testing with the Eurolyser CRP test kit 
(Eurolyser, ST0102; machine and reagents were donated by Dr E. Adams). The 
protocol was carried out according to the manufacturer’s instructions. 5 µL serum 
were added to the supplied ERS cuvette, the cap replaced, and the cuvette inserted 
into the Eurolyser CUBE machine. The machine then initiates an automated 
protocol to detect the levels of CRP in the sample, giving values in µg/mL.  
 
2.5 Statistical Analysis 
All analysis was conducted using SPSS 24, and figures produced in GraphPad v5. 
 
2.5.1 One-Way ANOVA 
For CL-ELISA data, Log10 transformation corrected positive skew and the absence of 
outliers was assessed in boxplots. Normal distributions confirmed through plotting 
histograms and as assessed by Shapiro-Wilk's test (p > 0.05). For variables that did 
not violate the assumption of homogeneity of variance as assessed by Levene's test 
for equality of variances (p > 0.05), one-way ANOVA on the transformed values was 
followed with Tukey-Kramer post hoc tests to identify if any variables showed a 
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significant difference between groups. For the NGPs that did violate this assumption 
(p < 0.05), a Welch ANOVA followed by Games-Howell post hoc tests were used. 
 
2.5.2 Kruskal Wallis H Test 
For CL-ELISA data that could not be normalised through transformation, Kruskal 
Wallis H test was used to compare differences between group means. Normality 
was assessed through histograms and Shapiro Wilks normality score (normal if p = > 
0.05). Outliers were detected through boxplots, and extreme values that could not 
be justified for inclusion were removed (Table 2.3). Post-hoc comparisons were 
used to determine where differences lay, either by planned contracts using Mann 
Whitney non-parametric tests or all pairwise comparisons. Mean ranks were used 
when the distributions of groups were dissimilar, otherwise group medians were 
used.  
 
Table 2.3. Outliers from the KSA 2017 cohort that were removed from analysis. 
Outlier Analysis Reason 
H47 T0 Titres against 
KM30 
Replicates all lower than background for this 
antigen only 
A26 T0 All All replicates lower than background signal 
H71 T0 Titres against 
KM27 
Replicates all lower than background for this 
antigen only 
 
2.5.3 Repeated Measures ANOVA 
Histograms and Shapiro Wilk test of normality showed moderate non-normal 
distribution for all NGPs, which was corrected to approximately normal on Log10 
transformation. Mauchly's test of sphericity was used to confirm that the 
assumption of sphericity had not been violated (p > 0.05). Where the assumption 
was violated, the Greenhouse and Geisser (1959) correction was used. Planned 
contrasts were used for specific comparisons between groups, or all pairwise 
comparisons were conducted as needed. Bonferroni correction was used for 
multiple comparisons 277. 
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2.5.4 Correlation curves 
Variables were checked for linearity and normality, based on scatterplots and non-
significant Shapiro-Wilk scores (p > 0.05) and any variable that violated these 
assumptions were corrected through Log10 transformation. Data were plotted to 
confirm the absence of outliers.  
2.5.5 Binary Logistic Regression 
To ascertain diagnostic potential of the NGPs for the patient samples, binary logistic 
regression was performed, followed by ROC curve generation. Data were coded as 
either positive (1) or negative (0), to give a binary disease outcome. Linearity of the 
continuous variables with respect to the logit of the dependent variable was 
assessed via the Box-Tidwell (1962) procedure. A Bonferroni correction was applied 
to correct for multiple comparisons 277. Based on this assessment, all continuous 
independent variables were found to be linearly related to the logit of the 
dependent variable. The absence of outliers was confirmed based on standardized 
residuals (values accepted with a range of ±2.5 SD); no values were excluded from 
the model. 
 
2.5.6 Paired Sample T Test 
Paired Sample T Test was used for comparison of titres between active and cured 
samples from the same patient. After calculating the mean difference, one sample 
(LCC1, difference between active and cured titre = 293 RLU) was excluded as being 
an extreme outlier in the BME set. The differences between active and cured 
samples were all normally distributed as determined through Shapiro-Wilks test of 
normality (p > 0.05). No extreme outliers were detected in mean difference scores 
for VL patients, although KM27 showed a significant deviation from normality, as 
denoted by Shapiro-Wilk score of normality (p = 0.04). Paired sample T-test is fairly 
robust to deviations from normality, and the violation of normality was driven by a 
single value (LV3, difference between active and cured titre = -1787 RLU). The 
Paired Sample T-Test was performed both with and without this value and gave the 
same result, so the decision was made to perform the test without transformation 
or outlier removal. 
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2.6 Cohort Descriptions 
All patient samples were collected by collaborators. The Saudi Arabian samples 
were collected chiefly by Dr Waleed Al-Salem, Mr Yasser Al-Raey, and the Saudi 
Ministry of Health, in collaboration with other colleagues at LSTM. Molecular 
analysis of the samples was performed by Dr Waleed Al-Salem and Mr Yasser Al-
Raey. The Bolivian samples were collected by the laboratory team of Dr Albert 
Picado from ISGlobal, Barcelona. Molecular analysis was performed by this team. 
The Spanish samples were donated to LSTM by Dr Javier Moreno Javier Moreno of 
the Instituto de Salud Carlos III. Molecular analysis was also performed by this team. 
  
2.6.1 Characteristics of patient cohorts from Saudi Arabia 
This cohort of archived samples from 2013 was collected from 5 CL endemic regions 
in Al-Ahsa, KSA, and has been described in detail elsewhere (Table 2.4) 275. Three 
sample types were collected;  
1) Active L. major infection (n = 17) (confirmed through dermatological 
examination and microscopy) 
2) Cured infections (determined through re-epithelisation of the lesion) 
3) Heterologous controls – individuals with non-CL dermatological conditions, 
such as eczema (confirmed negative by ITS1-PCR RFLP). 
Leishmaniasis was treated as directed by KSA Ministry of Health guidelines. Serum 
and parasite isolates were collected from each patient. Gender, lesion number, 
nationality and age were recorded (blood type was not recorded). 
 
A second collection in 2017 was conducted at two sites, one in Al-Ahsa, and one in 
Asir (Table 2.5). Individuals with suspected CL were referred to the clinic and 
diagnosed by dermatological examination. Lesion aspirates were taken for culture 
and microscopy confirmation of parasites, as were swabs for ITS1-PCR RFLP 
identification of Leishmania species. Serum samples were also collected at the same 
time. Where possible, patient samples were collected before any treatment had 
commenced. Where secondary infection was present (fungal or bacterial), 
antibiotics or antifungals were prescribed first, before assignation of either 
intralesional or intramuscular sodium stibogluconate (Pentostam®). Where patients 
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returned to the clinic for subsequent treatment, additional samples were collected. 
Blood type, gender, lesion number, nationality and age were recorded.  
 
Table 2.4. Details of patient samples in the 2013 collection from KSA.
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Table 2.5. Details of patient samples in the 2017 collection from KSA. 
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2.6.2 Characteristics of patient cohorts from Bolivia 
Patient samples were collected by Dr Albert Picado (ISGlobal) and their detailed 
methods are described elsewhere (Table 2.6; Publication pending, 2019). Between 
September 2014 and November 2015, patients with suspected CL or ML/MCL 
infection in Cochabamba city were invited to participate in the study. Consent was 
obtained, demographic information collected, and clinical samples obtained 
(smears/lesion aspirates and blood samples). Diagnosis was confirmed via culture of 
lesion aspirates and microscopic examination of Giemsa-stained lesion smears. 
Patients were categorised based on lesion location i.e. cutaneous or mucosal (no 
molecular species ID was performed). 
 
Table 2.6. Details of patient samples in the collection from Bolivia.
 
2.6.3 Characteristics of patient cohorts from Spain 
Archived samples from an outbreak of leishmaniasis in Fuenlabrada, Madrid (2010-
2012) were kindly donated by Dr Javier Moreno (Table 2.7) 93. Diagnosis was based 
initially on clinical symptoms, with immunofluorescent antibody titre (IFAT), cellular 
assays (IL-2 and cell proliferation), and/or PCR confirmation. Cure was determined 
when parasite DNA was undetectable by qPCR. Control samples were collected 
from blood bank donations by healthy individuals from the endemic region, who 
were serologically negative and had no prior history of leishmaniasis. Individuals 
with prior exposure to leishmaniasis gave positive cellular assay results (IL-2 and cell 
proliferation), but negative serology and qPCR results, and were termed 
asymptomatic samples. Patients were treated according to local protocols. 
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Individuals provided informed consent under the ethics applications (APR 12-65 and 
APR 14-64), approved by the Human Research Ethics Committee of the Hospital 
Universitario de Fuenlabrada, which covers the blood bank and hospital samples. 
 
Table 2.7. Details of patient samples in the collection from Spain, L. infantum infection.
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Chapter Three 
Identification and characterisation of 
immunogenic glycolipids from Leishmania 
spp. 
 
  
52 
 
3.1 Introduction 
 
Antibodies against αGal epitopes have been implicated in protection from parasitic 
diseases, including malaria and Chagas 265,271. The surface glycoconjugates of T. cruzi 
parasites have important roles in the production of anti-Gal, which is highly specific 
for the O-linked glycans decorating the mucins that coat much of cell surface 254. 
Similarly, glycoconjugates of Leishmania species have demonstrable 
immunogenicity, and the highly abundant glycoinositolphospholipids (GIPLs) of L. 
major are strongly recognised by sera from individuals with leishmaniasis 219,279. The 
likely epitope on these glycolipids are the αGal-terminating oligosaccharides that 
are only found on certain GIPL types; GIPL-2 and GIPL-3 of the Type-II GIPL family, 
which are expressed in all stages of L. major cells 230,235,239,280. Unlike L. major, αGal 
residues have not been identified in GIPLs extracted from L. tropica; instead the 
only components so far characterised so far are the Type-I mannosylated GIPLs 230. 
However antibodies in serum from patients with L. tropica infection recognise an 
αGal epitope at comparable levels to L. major serum in CL-ELISA analysis, indicating 
that there must be an as yet-unknown αGalactosylated glycoconjugate expressed 
by this species 217. If the glycan structure of this epitope is significantly different 
from the αGal epitopes of L. major cells, this could be exploited in the development 
of biomarkers of infection for both species, based on the native glycolipid 
composition of each. The known antigenicity of L. major GIPLs suggests that 
revisiting the immunogenicity and structural features of the glycolipid components 
of L. tropica promastigotes are a sensible starting point for investigation. 
 
To evaluate the potential of glycolipids extracted from Leishmania parasites as 
diagnostic antigens, I have first purified antigenic material from cultured 
promastigote cells and confirmed their recognition by lectin and human serum. 
Mass spectrometry allowed confirmation of the expected glycolipid profiles for L. 
major and L. tropica, although the structural composition of the L. tropica extract 
was not possible to determine. Using ELISA, L. major extracts proved to be antigenic 
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against human sera and are discussed in the context of the potential development 
of a novel CL diagnostic. 
 
3.2 Results 
3.2.1 Recognition of Leishmania glycolipids by IB4 lectin 
In order to characterise GIPLs, total glycolipids from L. tropica and L. major 
promastigotes were purified using sequential extraction with organic solvents 
(according to methods detailed in 239) and then fractionated on HPTLC (as described 
in Section 2.3). The chromatographed glycolipid samples showed a pattern 
consistent with that previously published 239. The glycolipid families are separated 
by their relative polarities (depending on glycan composition) and hydrophobicity 
(fatty acid species) (Figure 3.1A). Thus, GIPLs containing the same glycan core tend 
to resolve on TLC plates as multiple bands due to the heterogeneity of their fatty 
acids and hydrophobicity of the solvent system used.  
 
IB4 lectin has broad specificity for glycans with terminal αGalactopyranose, but 
does not bind to βGal-terminating glycans 281–283. As expected, based on published 
structural work, IB4 did not recognised L. major GIPL-1 as its oligosaccharide core is 
capped by a βGalactofuranose residue 230,237. L. major GIPL-2 and -3, containing 
terminating glycans with Galα1-3Galƒ- and Galα1-6Galp-, respectively, were well 
recognised by lectin on HPTLC plates (Figure 3.1B). On the other hand, no bands 
were recognised in the L. tropica samples, supporting previous structural work 
showing that no αGal-containing GIPLs are made by procyclic promastigotes in this 
species (Figure 3.1B).  
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Figure 3.1. HPTLC analysis of Leishmania spp. glycolipids with IB4 lectin. Leishmania 
glycolipids were extracted with organic solvents as described in (Chapter 2, Section 2.3.1). 
Samples equivalent to ~2 x 108 (L. major) and ~4 x 108 (L. tropica) cells were fractioned on 
HPTLC plates using chloroform:methanol:0.2% KCl-H2O (10:10:3, by volume), and 
butanol:pyridine:0.2% KCl-H2O (9:6:4, by volume) organic solvent systems and either stained 
with orcinol-H2SO4 (A) or IB4-HRP (B). In (A) commercial porcine gangliosides (20 µg/lane) 
were used as positive control for orcinol staining. In (B) αGalactosylated Dextra-BSA (1 µg; 
upper right) and BSA alone (1 µg; not shown) were used as positive and negative controls, 
respectively.  
In order to corroborate the identity of the GIPLs species, parasite glycolipid extracts 
were analysed by positive ion ESI-MS and ESI-MS/MS (Chapter 2, Section 2.3.8). L. 
major GIPL-1-3 were easily detected as multiple [M+H+]+ species, with GIPL-2 being 
the most abundant of all with a m/z of 1663 (Figure 3.2B). This mass is consistent 
with a glycan core composed of Hex4-HexN-PI as indicated by the MS/MS 
fragmentation spectrum (Figure 3.2B) and in agreement with a previous work 284. 
However, this paper reports a main GIPL-2 species of m/z 1607 indicating that our 
detected species contains fatty acids bigger by four carbon units (56 Da). 
Unfortunately, it was not possible to corroborate the PI lipid structure in negative 
ion mode, which would have indicated the types and possible positions of the two 
fatty acid chains. Nevertheless, the masses are consisting with the reported GIPL-2 
structure Gal1-3)Galf1-3)Man1-6)Man1-4)GlcN1-alkyl-acyl-phosphatydil 
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inositol, with a great fatty acid heterogeneity as depicted in Figure 3.2C. 
Furthermore, consistent with this structure, less abundant species like GIPL-1 and 
GIPL-3 seem to contain the same lipid composition (Figure 3.2B and C), but differ in 
the glycan core with respect to GIPL-2; i.e. whilst GIPL-1 (of m/z 1501) is shorter by 
one hexose (one galactose residue of mass 162), GIPL-3 (of m/z 1825) contains a 
glycan core with an extra galactose residue (Figure 3.2C and E). Unfortunately, I was 
unable to identify by mass spectrometry the GIPL species extracted from L. tropica 
promastigote cells.  
 
Table 3.1. Predicted and experimental masses of L. major GIPLs, based on EIS-MS analysis 
(Figure 3.2B+C). Glycolipid extract from L. major promastigotes was analysed by positive ion 
ESI-MS. Experimental values reported in Figure 3.2. Predicted values and suggested glycan 
structures and fatty acid compositions calculated from 238. Hex = Hexose. HexN = 
Hexosamine.  
GIPL 
Species 
Predicted 
[M+H+]+ 
Experimental 
Value [M+H+]+ 
Suggested Glycan 
Structure 
Suggested Fatty Acid 
Composition (alkyl marked ' ) 
Unknown 
- 1319 
Unknown 
Unknown 
- 1343 Unknown 
- 1481 Unknown  
1 
1418 - 
Hex3-HexN 
18:0' 12:0 
1446 - 18:0' 14:0 
1502 1501 24:0' 12:0 
- 1529 Unknown 
2 
1580 - 
Hex4-HexN 
18:0' 12:0 
1608 1607 18:0' 14:0 
1636 1635 18:0' 16:0 or 22:0' 12:0 
- 1649 Unknown 
1664 1663 24:0' 12:0 
- 1677 Unknown 
1692 1691 24:0' 14:0 or 26:0' 12:0 
1720 1719 24:0' 16:0 or 26:0' 14:0 
3 
1798 1797 
Hex5-HexN 
18:0' 16:0 or 22:0' 12:0 
1826 1825 24:0' 12:0 
1854 1853 24:0' 14:0 or 26:0' 12:0 
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Figure 3.2. Positive ion EIS-MS and EIS-MS/MS analysis of glycolipid extracts from L. major 
promastigotes. L. major GIPLs were extracted with organic solvents and enriched after 
butanol/water partition (as described in Section 2.3.1). Whole butanol extracts were then 
processed for EIS-MS analysis in positive ion mode. GIPL species are summarised in Table 3.1. 
A. ESI-MS of a blank sample consisting only of organic solvents; no contaminating peaks were 
detected. B. EIS-MS of whole butanol extract. Δ28 indicates variation in fatty acid 
composition (the identity of m/z ions 1319, 1343 and 1481 was not determined, but they are 
likely to be related to GIPL-1). C. Analysis of GIPL-2 species showing a high variability in fatty 
acids composition. D. Positive mode EIS-MS/MS fragmentation spectrum of main GIPL-2 
species at m/z 1663. The spectrum revealed at least three types of fragmentation patterns: 
a series of abundant ions (at m/z 1501, 1339, 1177, 1015; indicated in purple) showed that 
the main fragmentation pattern occurred from the non-reducing end, as indicated by losses 
of one Hex (162 Da); the second most abundant series of fragments (m/z 1071, 909, and 747; 
indicated in green) showed a group of ions lacking both fatty acids from the glycerol moiety 
and reduced glycan cores; and the least abundant series (m/z 811 and 649; indicated in blue) 
corresponds to fragments of the glycan core (no lipid attached); glycan fragments are 
summarised in Table 3.2. E. Proposed GIPL structures based on the analyses done in this 
thesis and previous published work 284.  
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Table 3.2. Composition of fragments identified by EIS-MS/MS analysis of GIPL-2 (m/z 1663) 
(Figure 3.2D). Fragmentation of m/z 1663 resulted in three fragmentation patterns, indicated 
by Series A, B or C. Series A (blue text in Figure 3.2D) are fragments of the glycan core, with 
no attached lipid. Series B (green text in Figure 3.2D) show ions lacking fatty acid chains, with 
reduced glycan core. Series C (purple text in Figure 3.2D) are ions with the fatty acid 
components intact, with loss of hexoses from the non-reducing end. 
Peak Series Experimental Mass [M+H+]+ Suggested Composition 
1 A 649 Hex4 
2 A 811 Hex4-HexN 
3 B 747 Hex2-HexN-Ino-P-glyc 
4 B 909 Hex3-HexN-Ino-P-glyc 
5 B 1071 Hex4-HexN-Ino-P-glyc 
6 C 1015 HexN-PI 
7 C 1177 Hex-HexN-PI 
8 C 1339 Hex2-HexN-PI 
9 C 1501 Hex3-HexN-PI 
10 C 1663 Hex4-HexN-PI 
 
3.2.2 Leishmania spp. glycolipids recognition by human serum 
Having identified putative glycolipid species containing terminal αGal (Figure 3.1), I 
then tested the antigenicity of the same Leishmania glycolipids on HPTLC-
immunostaining. It was found that only a pool of sera from L. major patients 
reacted against all L. major GIPL species (Figures 3.3 and 3.4). GIPL-2 and GIPL-3 are 
Galpα-terminating, but GIPL-1 is Galfβ. The presence of all three bands confirms the 
immunogenic nature of both galactosyl configurations. This pattern is different to 
the one obtained with IB4, with only the two bands with αGal-terminal glycan 
recognised by the lectin (GIPL-2 and -3). Interestingly, L. major sera also recognises 
a single band in L. tropica glycolipid extract, which IB4 did not. This is therefore 
unlikely to be αGal-binding and is probably instead cross-reactivity against a shared 
structure. The identity of this glycolipid species remains to be determined.  
 
Both L. tropica sera and healthy sera pools showed no recognition of any glycolipid 
component from either parasite species (Figure 3.4). While this was expected for 
healthy sera (having no immune-priming against Leishmania antigens), it was 
surprising that serum from L. tropica did not recognise any of the L. major GIPLs, 
not even the αGalactosylated (GIPL-2 and -3). Neither increasing the sample 
amount nor changing conditions of the antibody incubations revealed any bands.  
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Figure 3.3. HPTLC immunostaining of Leishmania spp. glycolipid extract with pooled sera 
from L. major-infected individuals. Lipid extracts from either L. major (~2 x 108 cells) or L. 
tropica (~4 x 108 cells) were fractionated on HPTLC using chloroform:methanol:0.2% KCl-H2O 
(10:10:3, by volume), and butanol:pyridine:0.2% KCl-H2O (9:6:4, by volume) solvent systems 
and then either stained with orcinol-H2SO4 (A) or processed for immunostaining with a pool 
of sera from L. major (B and C). Arrows indicate glycolipids recognised by sera. In (A) 
commercial porcine gangliosides (20 µg/lane) were used as positive control for orcinol 
staining. In (B) and (C), α-galactosylated Dextra-BSA (1 µg; dots in upper and lower right) and 
BSA alone (1 µg; not shown) were used as positive and negative controls, respectively. 
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Figure 3.4. HPTLC immunostaining of Leishmania spp. glycolipid extract with pooled sera 
from L. tropica-infected individuals or healthy controls. Lipid extracts from either L. major 
(~2 x 108 cells) or L. tropica (~4 x 108 cells) were fractionated on HPTLC using 
chloroform:methanol:0.2% KCl-H2O (10:10:3, by volume), and butanol:pyridine:0.2% KCl-H2O 
(9:6:4, by volume) solvent systems and then either stained with orcinol-H2SO4 (A) or 
processed for immunostaining with a pool of sera from L. tropica (B) or sera from healthy 
individuals from KSA (C).In (A) commercial porcine gangliosides (20 µg/lane) were used as 
positive control for orcinol staining. In (B) and (C), α-galactosylated Dextra-BSA (1 µg; dots in 
upper and lower right) and BSA alone (1 µg; not shown) were used as positive and negative 
controls, respectively. 
 
3.2.4 CL-ELISA optimisation with L. major GIPL extract 
The results of the TLC immunostaining strongly indicated that the main L. major 
GIPLs were exclusively recognised by sera from L. major patients but not from those 
infected with L. tropica parasites (Figure 3.3). Therefore, I reasoned that an ELISA 
assay using fractions enriched with L. major GIPLs as antigens will be more 
informative in terms of specificity and could lead the way to develop this as a 
specific L. major diagnostic assay.  
 
The first step was to develop glycolipid CL-ELISA protocol, using L. major glycolipid 
extract. Optimisation of block steps, antigen immobilisation, wash steps, and 
buffers was conducted, and conditions selected were used for all subsequent assays 
(Section 2.3.9). Cross-titration of L. major glycolipid extract against pooled sera 
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allowed the selection of conditions that showed the differential levels of 
recognition between L. major infected sera and healthy KSA control sera (Figure 
3.5). All further assays were conducted with sera at 1:400 dilution, as this gave a 
clear distinction between control and patient sera. 
 
Figure 3.5. Recognition of L. major glycolipids by pooled serum samples from individuals 
with active L. major infection, or from healthy controls from the endemic region. L. major 
glycolipid extract was serially diluted in PBS 1:1 (starting from 5 x 106 CE/well). Serum pools 
are at 1:200 (A) or 1:400 (B) and detected with anti-IgG-HRP antibody at 1:5000. RLU = 
relative luminescence units. 
 
3.2.5 L. major glycolipids are only recognised by sera from L. major-
infected individuals 
Further optimisation with extract concentration showed a sigmoidal curve of L. 
major antibody binding with changing glycolipid concentration (Figure 3.6A). 
Healthy sera and L. tropica sera show slight decreases in binding with reduced 
concentration of L. major glycolipids, but there is no clear distinction between these 
two pools. From the 1:1600 dilution point (approximately 6.25 x 105 CE/well) the 
three pools, L. major, L. tropica and healthy KSA are indistinguishable from each 
other.  
 
Binding to L. tropica extract was reduced for all sera types, as compared to L. major 
extract, despite the coating concentration being approximately equivalent for both 
extracts (Figure 3.6B). It should be noted that the quantification method used to 
ascertain glycolipid amount, i.e. counting cells using a haemocytometer, is 
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inherently inaccurate and a second quantification method using mass spectrometry 
analysis is currently underway. These results are pending, but will inform my 
interpretation of the titration results if they indicate a significant variation from the 
counts. However, these ELISAs indicate that there is no noteworthy recognition of L. 
tropica glycolipids. The lack of binding by L. major sera, which is enriched for anti-
Gal of various specificities (Chapter 4), indicates that if there are αGal epitopes in 
the glycolipids extracted from L. tropica cells, they are at very low levels so as to be 
indistinguishable from background signal.  
 
Sera from healthy individuals from KSA, and those with L. tropica infection show 
very little recognition of either glycolipid extract. This result demonstrates the 
specificity of antibodies produced during L. major infection. However, this glycolipid 
extract contains a variety of glycan epitopes, and the role of anti-Gal in this assay is 
unclear, so confirmation of specificity with coffee bean αGalactosidase (CBAG) 
treatment is necessary. 
 
 
Figure 3.6. Recognition of L. major or L. tropica glycolipids by pooled serum samples from 
individuals with active L. major or L. tropica infection, or from healthy controls from the 
endemic region. Glycolipid extract from L. major (A) or L. tropica (B) promastigotes was 
serially diluted 1:1 (starting from 5 x 106 CE/well). Pooled serum was diluted 1:400 and 
detected with anti-IgG-HRP antibody at 1:5000. RLU = relative luminescence units. 
 
3.2.7 Determining specificity of anti-Gal binding using CBAG enzyme 
To determine the degree of recognition of αGal epitopes by anti-Gal in the different 
pools of sera, plates were coated with purified glycolipids and treated with CBAG to 
cleave terminal αGalactosyl residues of any glycosidic linkages (Figure 3.7) 285,286. 
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Addition of the enzyme should reduce or abolish binding of anti-Gal through 
removal of these residues. In this assay, there was a clear increase in signal when 
enzyme was added to the wells. However, this was true of all wells, including 
controls where glycolipid coating was absent. When RLU was normalised to healthy 
KSA sera (e.g. ௅.  ௠௔௝௢௥ ோ௅௎
௄ௌ஺ ௣௢௢௟ ோ௅௎
) the reduction in binding could be calculated. 
 
Figure 3.7. Reduction in recognition of CBAG-treated Leishmania spp. glycolipid extract by 
pooled sera from patients with active L. major or L. tropica infection. Plates were coated 
with glycolipid extract (5 x 106 CE/well) from L. major promastigotes (A) and L. tropica 
promastigotes (B) before incubation with CBAG (enzyme concentration between 0.025 0.1 
U/well). Negative controls with no enzyme added were treated with buffer only. Relative 
luminescence units (RLU) is plotted normalised to recognition of the extracts by pooled sera 
from healthy KSA controls. 
 
Treatment of L. major glycolipids with CBAG reduces recognition by L. major sera, 
but only marginally by L. tropica sera. This extent of reduction increases with higher 
enzyme concentration (Figure 3.7A, Table 3.2). There is still a degree of recognition 
by antibodies at the highest enzyme concentration for both sera types, which is 
likely a combination of 1) incomplete digestion leaving some glycans intact and 2) 
recognition of non-αGal binding sites by sera.  
 
When comparing these results with the TLC plates (Figure 3.3), the residual binding 
can be explained, at least in part, through the approximately equivalent recognition 
of GIPL-1 (Galfβ-R) and GIPL-2/-3 (Galα-R); removal of the αGal sites leaves a 
significant amount of immunogenic Galfβ-terminating glycolipids that are capable of 
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binding serum antibodies. Additionally, cleavage of the final αGal exposes the next 
glycan in the structure; for GIPL-2, this is a Galfβ, which as discussed is also 
immunogenic in L. major sera. Therefore, when removing binding sites, CBAG 
reveals others. 
 
Treatment of L. tropica glycolipid also showed a reduction in recognition, to a 
similar degree for both sera types. This would indicate that the enzyme is removing 
binding sites for antibodies, an unexpected result based on the TLC immuno- and 
lectin-overlays, where recognition was not detected. The overall level of binding to 
L. tropica glycolipids in the CL-ELISA was considerably lower than when L. major 
glycolipids were the coating antigen, therefore, this is in actuality a very small 
reduction in real terms. If αGal epitopes are present in L. tropica glycolipids, the TLC 
immuno-overlay with HRP conjugated lectin/antibody may not be sensitive enough 
to detect them, if they are at very low levels. Alternatively, the CL-ELISA conditions 
may be optimised to the extent that I am detecting low affinity binding, that is not 
“real” anti-Gal. 
 
Table 3.3. CBAG treatment of Leishmania spp. glycolipids reduces recognition by serum 
pools. Results are expressed as percentages, relative to the untreated control wells (Control 
set at 100%).  
Glycolipid 
Extract Sera pool 
Enzyme (U /well) 
0.025 0.05 0.1 
L. major L. major 97% 68% 65% L. tropica 107% 83% 94% 
L. tropica L. major 83% 67% 71% L. tropica 82% 71% 66% 
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To validate this result, various L. major sera pools were tested against L. major 
glycolipid extract treated with CBAG at 0.1 U/well (Figure 3.8).  
 
Figure 3.8. CBAG enzyme treatment reduced recognition of L. major glycolipids, by pooled 
sera from L. major-infected patients. Plates were coated with glycolipid extract (5 x 106 
CE/well) before incubation with CBAG (enzyme concentration 0.1 U/well). Negative controls 
with no enzyme added were treated with buffer only (Mock Treated). Sera was diluted 1:400. 
Relative luminescence units (RLU) is plotted normalised to recognition of the extracts by 
pooled sera from healthy KSA controls. 
 
As noted in the previous assay, addition of enzyme caused an increase in signal, 
relative to the mock-treated i.e. buffer-only controls. Normalised results indicate a 
clear reduction in binding however, although the extent of the reduction varies 
between pools (Figure 3.8). No reduction in recognition was detected in healthy 
pools, further emphasising the absence of Leishmania-binding anti-Gal in healthy 
sera. 
 
In summary, these experiments show evidence of the potential utility in exploiting 
the anti-Gal recognition of L. major glycolipids as biomarkers of infection. 
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Furthermore, anti-Gal from sera of L. major-infected patients does not appear to 
recognise L. tropica glycolipids at any noteworthy level. 
 
3.3 Discussion 
The main aim of this Chapter was to identify Leishmania glycoconjugates containing 
terminal αGal residues. Until now, the only αGalactosylated glycoconjugates from 
any Leishmania species have been the Type-II GIPL-2 and GIPL-3, both of which are 
recognised by anti-Gal from L. major-infected individuals. However, despite 
reported anti-Gal in serum from patients with L. tropica that recognised a 
trisaccharide Galα(1,3)Galβ(1,4)GlcNAcβ-R, no epitope has been incriminated in L. 
tropica cells 217. Therefore, I have attempted to identify galactosylated glycolipids in 
L. tropica, using TLC and ELISA.  
 
TLC separation of glycolipid extract from L. major sera allowed the confirmation of 
the reported immunogenicity of GIPL-2 and GIPL-3 against serum from patients with 
L. major infection. No binding of healthy serum pools was detected against any 
glycolipid, either in TLC or ELISA formats. Anti-Gal produced during Chagas disease 
is highly specific for T. cruzi glycans, whereas natural anti-Gal from healthy adults 
has much lower reactivity 254,274. This trend is confirmed in L. major infection, with 
antibodies recognising L. major glycolipids not circulating in healthy sera. This is 
essential for the development of a biomarker that is based on native L. major 
glycolipids; the antigen must be specific to Leishmania infection and not also a 
feature of other pathogens that could generate an immune response and cause 
false positives.  
 
CL-ELISAs using whole glycolipid extract contains multiple glycolipid species, and 
likely contamination by membrane phospholipid species and other hydrophobic 
lipid molecules that are not completely removed by the organic solvent extraction 
steps. Therefore, recognition of this extract is not mediated solely by anti-Gal, but 
likely by a combination of several antibody populations. Treatment with CBAG has 
been shown to effectively remove immunogenic epitopes from porcine tissues, and 
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in seroconversion from blood type O to type B through terminal α-gal cleavage 
285,287,288. Treatment of L. major glycolipids with this same enzyme reduced 
recognition by L. major sera but did not completely abolish it. Anti-Gal in sera from 
L. major infected patients was a significant proportion of the binding detected in 
these assays. 
 
L. tropica glycolipids showed surprisingly little reactivity against L. tropica sera, 
despite loading TLC plates with twice the amount required for detection of L. major 
glycolipids with L. major serum. Interestingly, L. major sera did bind a single glycolipid 
species in from L. tropica glycolipid extract. I was unable to identify this band through 
mass spectrometry, but the lesser reactivity against this band as compared to the L. 
major GIPL-2 and GIPL-3, and the absence of recognition by IB4 lectin, suggest it is 
unlikely to be a Galα-terminating structure. However, this is not definite; the epitope 
could be present but at much lower levels than in L. major cells, and as I have only 
tested material from promastigotes, I cannot rule out expression of αGal in L. tropica 
amastigotes. In CL-ELISA assays, L. tropica serum recognition of the L. tropica lipid 
extract was minimal, and indistinguishable from binding by healthy serum. Treatment 
of L. tropica glycolipid extract with CBAG enzyme reduced binding of L. tropica sera 
marginally (~30%), which would be an indication that the enzyme is removing an αGal 
and therefore reducing antibody recognition. However, as the starting levels of 
reactivity were low it’s unclear if this is an artefact of the assay, or truly an indication 
of an αGal epitope. One option for further investigation to quantify the specific 
recognition of anti-Gal would be a CBAG inhibition assay. Sera would first be 
incubated with either enzyme-treated or mock-treated glycolipid extracts 
immobilised on a support/membrane, so that any anti-Gal antibodies would bind to 
available αGal sites. Levels of unbound antibody would be higher in samples exposed 
to enzyme treated glycolipids, due to fewer available binding sites. The unbound 
antibody for all samples could then be incubated with a synthetic αGal-containing 
molecule (i.e. αGal conjugated to BSA) in an CL-ELISA format, and the differences in 
binding detected. Greater inhibition indicates a higher number of αGal-terminating 
glycoconjugates in the glycolipid extract.  
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All of these experiments presented in this chapter have utilised glycolipid extract 
from cultured promastigotes, due to the logistical challenges of generating the large 
cell numbers (>1010) required to obtain sufficient material. L. major GIPLs do not 
change in their galactosylation profile throughout the life cycle, but other 
glycoconjugates of all species do change in abundance, reflecting the different 
environments of each life stage. The L. tropica GIPL profile has not been quantified 
throughout the life cycle, and so it is possible that the galactosylation does change 
between the insect and human stages. Therefore, a true understanding of L. tropica 
glycoconjugates requires further investigation using the full repertoire of 
developmental stages. 
 
To conclude, the reduction in antibody binding of L. tropica sera to L. tropica 
glycolipid extract after CBAG treatment hints at the presence of an αGal epitope 
present at very low levels. However, it looks unlikely that any αGal epitope in such 
diminutive amounts could generate the anti-Gal response reported by Al Salem et 
al. (2014). The lack of similar reactivity in this study indicates that there is no similar 
glycotope in the glycolipid portion of L. tropica cells. Therefore, it is most probable 
that an alternative glycoconjugate is responsible for any anti-Gal recognition. To this 
end, preliminary results have detected low molecular weight glycoproteins 
recognised by IB4 (Liu, YC, and Acosta-Serrano, A, unpublished). In Chapter 5, I have 
explored the localisation of αGal through lectin staining of L. tropica promastigotes 
and amastigotes.  
  
However, native Leishmania glycolipid extracts are not a viable candidate for a 
diagnostic marker. The TLC results here indicate that antibodies against αGal-
containing glycolipids are not the only anti-Leishmania antibodies circulating in L. 
major infected patients, which, in an ELISA, bind to the non-αGalactosylated lipids. 
Synthetic Leishmania-mimetic glycans are likely a better option to investigate the 
specific glycans mediating the immunogenicity of L. major parasites.   
68 
 
 
 
 
 
 
 
 
 
Chapter Four 
Specificity of Leishmania anti-Gal in Old and 
New World leishmaniasis 
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4.1 Introduction 
Anti-Gal profiles during parasitic infection have been described for a number of 
diseases including malaria, cutaneous leishmaniasis, and Chagas 217,265,289,290. 
Antibodies recognising terminal αGal epitopes, in particular the canonical Galili 
glycan sequence (Galα(1,3)Galβ(1,4)GlcNAcα-R), are thought to have a role in 
protection against an array of fungal, microbial and parasitic invaders 291. The 
increased titres of anti-Gal detected during Leishmania infection has potential for 
exploitation as a biomarker of infection, due to the differences in galactosylation of 
surface molecules between Leishmania species 217,275,290. The challenge has always 
been the identification of the correct αGalactosylated antigen(s), to discriminate 
the different populations of anti-Gal antibodies triggered during an infection with 
different Leishmania species. Historically, rabbit gangliosides which contain terminal 
αGalactosyl residues were used to assay levels of anti-Gal antibodies in human 
serum 262. However, they are limited, as most of the oligosaccharidic structures end 
with a Galα(1,3)-R sequence hence preventing the detection of epitopes with other 
Gal linkages (i.e. 1,2/4/6) 292. More recently, neoglycoproteins (NGPs) consisting of 
BSA molecules chemically modified with glycans have become commercially 
available. For example, in this thesis I was used one such NGP, from Dextra 
Laboratories Ltd., that contains glycans made only of the canonical Galili's epitope 
(i.e. Galα1-3)Galβ1-4)GlcNAc-R). 
 
Native αGalactosylated glycolipids extracted from L. major and L. tropica 
promastigotes showed varying levels of success in discriminating between infected 
sera and controls (Chapter Three). However, there are challenges that preclude the 
use of extracted glycolipids as a diagnostic tool, including cost, reproducibility 
between batches of parasite extractions, and the facilities required for large-scale 
cell culture. A panel of synthetic NGP antigens that mimics recognition by the anti-
Gal response during a Leishmania infection has potential application in diagnostic 
test development. Some of these NGPs, synthesised in the lab of Dr Katja Michael at 
the University of Texas, El Paso (UTEP), were effectively used to analyse the 
specificity of Chagasic anti-Gal (Table 4.1) 260,274. The panel encompasses an array of 
70 
 
αGal terminating mono-, di- and trisaccharides chemically conjugated to BSA, with 
various configurations of the bonds between residues. While the αGal terminal 
residue is the immunogenic portion, the presentation of the epitope will depend on 
the whole glycan, and the shape and configuration will determine binding affinity 
and other biophysical properties of the ligand-antibody complex. The rationale 
behind the glycan structures in Panel 1 was twofold; some glycans correspond to 
epitopes described in the literature as of likely importance in mediating 
Trypanosoma cruzi-antibody binding, such as the Galα(1,3)Galβ disaccharide, 
whereas others have similar structures to those described but with slight alterations 
to capture a diversity of antibodies. Panel 3 was synthesised to specifically mimic 
the epitopes identified on L. major GIPL-2 and GIPL-3.  
 
Table 4.1. Non-commercial NGPs used to assess levels of anti-Gal in human serum samples. 
ID refers to the code used to refer to each structure throughout this thesis. The glycan portion 
varies for each structure. R corresponds to the linker-BSA. All NGPs have at least one terminal 
αGal residue, except two controls KM15 (cysteine) and BME (β-mercaptoethanol). The NGPs 
were synthesised in batches; KM1-17 in Panel 1, KM3 and KM24 in Panel 2, and KM27-BME 
in Panel 3. 
Panel ID Structure of Terminal Glycan 
1 
KM1 Galα(1,3)Galβ(1,4)Glcβ-R 
KM3 Galα-R 
KM5 Galα(1,6)Galβ-R 
KM8 Galα(1,2)Galβ-R 
KM9 Galα(1,3)Galβ-R 
KM11 Galα(1,6)[Galα(1,2)]Galβ-R 
KM12 Galα(1,4)Galβ-R 
KM17 Galα(1,3)Galα-R 
KM15 Cysteine-R 
2* KM24 Galα(1,3)Galβ(1,4)GlcNAcα-R 
3 
KM27 Galα(1,3)Galfβ-R 
KM28 Galα(1,6)Galα(1,3)Galfβ-R 
KM30 Galα(1,3)Galfβ(1,3)Manα-R 
BME 2-ME-R 
* Panel 2 also included KM3 
 
In this Chapter, I have used this bespoke panel of synthetic NGPs to study anti-Gal 
profiles during both Old and New World Leishmania-infected sera. I demonstrate a 
comprehensive screening of samples from patients from three geographically 
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distinct regions. These αGal NGPs have most potential in identification of L. major 
sera, although further development may allow application in diagnosis of American 
tegumentary leishmaniasis caused by L. braziliensis. As treatment response varies 
between parasite species, the ability to determine the infecting species will inform 
the correct chemotherapy assignation 100,130. For instance, L. tropica is 
comparatively resistant to SSG injection in Saudi Arabia whereas L. major is typically 
responsive 84. Treatment of L. braziliensis is typically intramuscular pentavalent 
antimonials which has varying success, but is ineffective against L. guyanensis 293. 
Both of these species are co-endemic in Bolivia.  
 
4.2 Results 
4.2.1 Anti-Gal analysis in patients with Old World cutaneous 
leishmaniasis in Saudi Arabia  
For the analysis of anti-Gal antibodies from Old World CL patients, two cohorts of 
sera were collected from the Kingdom of Saudi Arabia, in 2013 and 2017 (Section 
2.6.1). The two species of Leishmania circulating in KSA are L. major (zoonotic) and 
L. tropica (anthroponotic). In 2013, only serum samples from individuals infected 
with L. major were collected, whereas in the 2017 collection, alongside L. major-
positive samples, 15 patients with L. tropica infection were obtained and confirmed 
through molecular identification. 
 
4.2.1.1 Serum levels of anti-Gal antibodies are higher in active L. major 
infected samples, compared to cured and non-CL samples from the 
2013 collection 
The anti-Gal activity against nine NGPs (eight αGal-R-BSA and one control-BSA; 
Table 4.1 - Panel 1) was measured in a panel of serum samples from the 2013 
collection. This cohort had three patient types: 1) active L. major infection, 2) cured 
infection (showing different degrees of lesion healing), and 3) heterologous non-CL 
controls (patients with an alternative skin pathology, but negative for CL).  
 
Of the eight NGPs containing a terminal αGal residue, four (KM3, KM9, KM11 and 
KM17) showed significant difference between patient groups, as determined by 
either ANOVA or Welch ANOVA as appropriate (Supplementary Table 2). Post-hoc 
72 
 
comparisons, however, only showed significant between-group differences for 
three NGPs; KM3, KM17 and KM11 (Figure 4.1; Table 4.2). Although KM15 (negative 
control, cysteine-BSA) was not identified by ANOVA as showing different levels in 
infected vs. control patients, the overall levels of recognition to this control are a 
concern, as they are indistinguishable from the αGalactosylated NGPs (Figure 4.1). 
As a control, KM15 fails to show that recognition of these NGPs is αGal-specific, 
rather than, for example, cross-reactivity against the BSA component, or another 
artefact of the assay. Only one NGP, KM17 (Galα(1,3)Galα-R), had significant 
increased titres in both cured and active infection, when compared to the 
heterologous controls. In comparison to KM9 (Galα(1,3)Galβ-R, significantly 
different within groups by ANOVA p < 0.05), the switch of Galβ to Galα in the 
second position increases its discrimination potential. The two NGPs with 
Galα(1,2)Galβ or Galα(1,4)Galβ linkages had the lowest recognition by sera.  
Figure 4.1. Anti-Gal titres in patient samples with active or cured L. major infection, or 
controls from the endemic region, against αGalactosylated NGPs. Individual sera were 
diluted 1:100 and recognition of 9 NGPs assessed through CL-ELISA. Relative luminescence 
units (RLU) are plotted as Log2 transformed, normalised to the negative control (UK NHS). L. 
major active (n=17), cured (n=31) and Heterologous (n=29). * p < 0.05. Each panel shows data 
for one NGP. A = KM1, B = KM3, C = KM5, D = KM8, E = KM9, F = KM11, G = KM12, H = KM15, 
I = KM17.  
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Table 4.2. Differences in anti-Gal titres against three αGal NGPs (KM3, KM11, KM17) in 
samples from healthy controls, active infection (L. major from the 2013 KSA cohort) and 
cured individuals. Comparison of recognition of NGPs by active L. major patients (Active), 
cured CL patients (Cured) and control patients with non-CL lesions (Heterologous) against 
different NGPs, assessed through CL ELISA. Only significant comparisons are shown, all other 
post hoc tests had p > 0.05. Bonferroni corrected significance is reported for each difference. 
*= p < 0.05, ** = p ≤ 0.01. 
NGP Group 1 Group 2 
Mean 
Difference 
Std. 
Error 
p 
value 
95% CI 
Lower Upper 
KM3 Active Heterologous 0.232 0.074 ** 0.055 0.409 
KM11 Active Heterologous 0.220 0.081 * 0.024 0.416 
KM17  
Active Heterologous 0.181 0.068 * 0.019 0.344 
Cured Heterologous 0.145 0.058 * 0.007 0.282 
 
4.2.1.2 Diagnostic potential of nine NGPs using 2013 L. major cohort 
To ascertain the diagnostic potential of the eight αGal NGPs (Section 4.2.1.1), a 
binomial logistic regression was performed. The logistic regression model was 
statistically significant (χ2(9) = 29.302, p < .001), explaining 64.4% (Nagelkerke R2) of 
the variance in infection status, and correctly classified 82.6% of cases. The ROC 
curve gave an area under the curve (AUC) of 0.909 (95% CI 0.825 to 0.992) (Figure 
4.2). The sensitivity was 70.6%, specificity was 89.7%; in addition, the positive 
predictive value (PPV) was 80% and negative predictive value (NPV) was 83.9%. Of 
the ten predictor variables only one was statistically significant: KM3 
(Supplementary Table 2). An increase in of one Log10-transformed RLU in CL-ELISA 
with KM3 corresponds to a 33 times increased chance of being positive for L. major.  
 
This analysis indicates the potential utility of αGal NGPs in discriminating between 
infected and uninfected patient samples. However, a combination of eight antigens 
has little real-world application, as any diagnostic requiring this many antigens 
would be complex to interpret and expensive to produce. Therefore, further 
refinement of the NGPs was warranted. 
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Figure 4.2. ROC for logistic regression analysis of the recognition of 9 NGPs by L. major and 
control sera (Figure 4.1). Antibody titres in serum samples from L. major positive individuals 
and non-CL heterologous controls were detected in CL-ELISA. Area under the curve (AUC) is 
.909. Curves above the Reference line (solid green) at 0.5 indicates the test is better than 
chance at predicting disease state. 
4.2.1.3 Optimisation to improve detection of anti-Gal levels in pools of 
sera from patients with either active L. major or L. tropica infection, or 
from healthy controls 
For assay optimisation, I used the cohort of serum samples collected from KSA in 
2017 and screened with a new panel of 4 NGPs (Table 4.1, Panel 3). The updated 
panel more closely reflect the naturally occurring glycan structures on the surface of 
L. major, which, as shown in this thesis (Chapter 3) have some discriminating power 
between L. major and L. tropica sera in both CL-ELISA and TLC applications. Three 
NGPs have terminal αGal residues (KM27, KM28 and KM30), while the fourth was 
an updated control, capped with β-mercaptoethanol (BME) (See Table 4.1, and 
Section 2.4.1 for detailed structures). 
 
Initially, anti-Gal levels in pooled serum samples were assessed. Both antigen 
concentration and serum dilution were titrated in each plate, to give a 
checkerboard titration for each combination of NGP and sera type (Figure 4.3). The 
updated control (BME) is an improvement compared to the previous iteration 
(KM15, cysteine-BSA) (Figure 4.3D); there is very little cross-reactivity with the sera 
pools, even at the highest antigen and sera concentrations. All other antigens have 
excellent differentials between L. major and both L. tropica and control sera. On the 
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other hand, the anti-Gal levels in L. tropica pools were indistinguishable from 
healthy controls at all dilutions.  
 
The conditions for subsequent assays were selected based on the concentrations 
that maximised the differential between infected samples and controls and 
minimised the amount of sample required. For KM27, KM30 and BME this was 50 
ng/well, and for KM28 this was 12.5 ng/well. All sera were used at 1:800. 
 
 
Figure 4.3. Titration of antigen (NGP) and pooled sera from control and CL patients, using 
CL-ELISA to assess recognition. CL-ELISA with checkerboard titration of each of four NGPs 
against pooled sera from either L. major (n=3) or L. tropica (n=3) infected patients or healthy 
UK controls (n=1). Quartiles of each panel indicate sera dilution; sera pools were titrated 
from 1:400 to 1:3200. Antigen coating was from 400 ng/well to 3.125 ng/well. A = KM27, B = 
KM28, C = KM30, D = BME. RLU = relative luminescence units.  
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4.2.1.4 Anti-Gal detection in pools of sera samples from the 2017 
collection 
Pools of sera from the 2017 collection were screened using the conditions selected 
through the titration assay (Section 4.2.1.3) in CL-ELISA. Using a small number of 
pooled serum samples (created based on shared patient characteristics, such as 
lesion number, nationality and gender), four NGPs were screened. Pools were from 
L. major (n = 7) or L. tropica (n = 6) infected patients, or healthy controls from KSA 
and UK (n = 10). Due to the small sample size it was difficult to assess normality of 
distributions, so a Kruskal Wallis H test was conducted with post-hoc comparisons, 
to determine if there were significant differences between anti-Gal titres in 
different serum types (Supplementary Table 3 and 4).  
 
L. major sera has significantly highly titres for the three galactosylated NGPs (KM27, 
KM28 and KM30), compared to all other serum types (Figure 4.4). No other 
significant differences were observed, i.e. L. tropica and all healthy controls have 
similar antibody titres (Table 4.3). Anti-Gal titres vary within the groups, but the 
trend is consistent, indicating that anti-Gal levels are increased, independent of 
gender, nationality and lesion number. 
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Figure 4.4. Anti-Gal levels detected by CL-ELISA in pooled sera samples from the 2017 
collection. Pooled sera samples from healthy controls (UK or KSA patients), or active infection 
(L. tropica and L. major) were diluted 1:800. Each panel corresponds to a single antigen. A = 
KM27, B = KM28, C = KM30, D = BME. ** = p ≤ 0.01, *** = p ≤ 0.001, **** = p < 0.0005. 
 
Table 4.3. Differences in anti-Gal titres in pooled sera from healthy controls (UK or KSA 
patients) or active infection (L. tropica and L. major from the 2017 cohort). Differences 
(Diff.) were calculated from CL-ELISA data, subtracting the mean rank score of Group 2 from 
that of Group 1. Mean ranks are listed in Supplementary Table 4. Bonferroni corrected 
significance is reported for each difference. ** = p ≤ 0.01, *** = p ≤ 0.001, **** = p < 0.0005, 
ns = p > 0.05. 
Group One Group Two KM27 KM28 KM30 
Diff. p value Diff. p value Diff. p value 
L. major  L. tropica  21.35 **** 22.9 **** 18.5 **** 
UK 19.25 *** 18.95 ** 20.9 ** 
KSA 22.4 **** 21.15 **** 23.6 **** 
L. tropica UK -2.1 ns -3.95 ns 2.4 ns 
KSA 1.05 ns -1.75 ns 5.1 ns 
UK KSA  3.15 ns 2.2 ns 2.7 ns 
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4.2.1.5 Anti-Gal detection with an updated panel of NGPs is increased 
in active L. major infection, but not L. tropica  
As CL-ELISA using pooled samples indicated that serum anti-Gal titres recognising 
αGal NGPs are significantly increased during active L. major infection, a more in-
depth screen was carried out using individual patient samples from additional 
groups. The samples were from either active infection with L. tropica (n = 15), or L. 
major (n = 56) samples from 2017, or L. major from 2013 (n =24), cured (previous CL 
infection; n = 25), or heterologous control (non-CL dermatological pathologies; n = 
25). For the L. major 2017 group, where some patients visited the clinic on multiple 
occasions, only the first visit was included. A Kruskal-Wallis H test identified that 
there were differences in anti-Gal between the different patient groups, for each of 
the four new NGPs (Supplementary Table 5 and 6). Post-hoc tests identified where 
significant differences lie (Figure 4.5; Table 4.4).  
 
RLU for all samples against BME are very low relative to the galactosylated NGPs 
(<200 RLU), however, one pair-wise comparison was significant; L. major samples 
from 2017 (mean rank = 85.17), and heterologous controls (mean rank = 56.40) (p < 
0.05). Inspection of the data shows that the difference between these groups is 
minor, but this perhaps indicates a trend that could become clearer with an 
increased samples size in the heterologous controls (n = 25).  
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Figure 4.5. Anti-Gal levels detected by CL-ELISA in individual sera samples from the 2013 
and 2017 cohorts, using four NGPs. Antibody titres are plotted as relative luminescence units 
(RLU), for individual patient serum samples from active L. major infection (either 2017 or 
2013 collection cohorts), active L. tropica infection, post-infection (Cured) and heterologous 
(non-CL controls). Each panel corresponds to one NGP - A = KM27, B = KM28, C = KM30, D = 
BME. Lower case letters above data indicate mean ranks that do not differ significantly.  
 
As for the activity against the remaining three αGal NGPs (KM27, KM28 and KM30), 
despite a lower median for the 2013 samples, titres in L. major-positive sera did not 
differ across the cohorts (p > 0.05). All NGPs gave higher mean ranks during L. major 
infection. Most interestingly, both KM27 and KM30, the Galα(1,3) terminating 
structures had significantly higher titres in L. major 2017 patients, than in both 
cured and heterologous control patients. This was not the case for the Galα(1,6) 
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terminating KM28, where the mean ranks for cured patients were not different to 
active L. major patients. L. tropica and heterologous controls show no difference, 
indicating these patients have similarly low levels of circulating anti-Gal.  
 
In summary, of the 11 αGal NGPs screened against these two cohorts of Old World 
CL patients, those with Galα(1,6)Gal and Galα(1,3)Gal detected higher anti-Gal in L. 
major sera than in controls. Galα(1,3)Galβ recognition was improved further when 
the βGal was furanose (as in KM27 and KM30), rather than pyranose (as in KM1 and 
KM9), more closely mimicking the combination of pyranose and furanose glycans in 
L. major GIPLs. 
 
Table 4.4. Comparison of anti-Gal levels for individual patient serum samples from active 
L. major infection (either 2017 or 2013 collection cohorts), active L. tropica infection, post-
infection (Cured) and heterologous (non-CL controls) against four NGPs (KM27, KM28, 
KM30 and BME). Differences (Diff.) are calculated subtracting Group Two mean rank score 
from Group One. Mean ranks are reported in Supplementary Table 6. Bonferroni corrected 
significance is reported for each difference. * = p ≤ 0.05. ** = p ≤ 0.01, *** = p ≤ 0.001, **** 
= p < 0.0005, ns = p > 0.05. 
Group One Group Two KM27 KM28 KM30 BME 
Diff. p Diff. p Diff. p  Diff. p  
L. major 2017 L. major 2013 14.98 ns 4.04 ns 14.10 ns 18.94 ns 
L. tropica  76.90 **** 74.89 **** 82.54 **** 28.77 ns 
Heterologous 79.68 **** 59.13 **** 75.09 **** 30.53 * 
Cured 36.12 ** 21.33 ns 45.37 **** 4.61 ns 
L. major 2013  L. tropica  61.92 **** 70.85 **** 68.44 **** 9.83 ns 
Heterologous 64.70 **** 55.09 **** 60.99 **** 11.59 ns 
Cured 21.14 ns 17.29 ns 31.27 ns -14.33 ns 
Cured L. tropica  40.78 * 53.56 *** 37.17 ns 24.16 ns 
Heterologous 43.56 ** 37.80 ns 29.72 ns 25.92 ns 
Heterologous L. tropica  -2.78 ns 15.76 ns 7.45 ns -1.76 ns 
 
4.2.1.6 Three αGal NGPs have diagnostic potential for L. major but not 
L. tropica infection in KSA 
To assess the discriminatory power of anti-Gal titres in patient sera (comparing 
patients with L. major or L. tropica infection to negative control samples) that bind 
each of the four NGPs (KM27, KM28, KM30 and BME), I first used Frey’s method 
(1998) to calculate a cut off value for end-point ELISA data, below which a reading is 
deemed “negative” and above which, “positive”. Each CL-ELISA plate contained two 
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negative controls (two pools of sera from healthy individuals), so for the equation 
given below, 𝑋ത is the mean of the two control readings, SD is the standard deviation 
of the mean and 𝑓 equals 7.733, giving the confidence interval at the 95% level 
(Equation 4.1). For the data presented in Figure 4.5, I scored each individual sample 
as positive or negative for leishmaniasis (Supplementary Table 7). I performed this 
analysis twice, with different “true negatives”. The first true negative group only 
included patients with no prior history of leishmaniasis (heterologous only) and, the 
second included heterologous controls and those with cured CL infection combined. 
The latter group is likely to be more representative of a true population, as, in an 
endemic region, individuals with past infection may still have specific antibodies at 
detectable levels, which could confound attempts to diagnose only active cases. 
 
Equation 4.1. Equation to calculate the cut-off value between positive and negative scores, 
using ELISA data 294. 
𝑐𝑢𝑡𝑜𝑓𝑓 = 𝑋ത + 𝑆𝐷𝑓  
 
The data for L. major (2013 and 2017 cohorts) and L. tropica patients and the two 
sets of controls were analysed using binomial logistic regression (Supplementary 
Tables 8-13). If the logistic regression model was significant for an individual NGP, a 
secondary analysis was conducted combining the data for all the significant NGPs. 
Finally, ROC curves were generated to compare AUC values for L. major (Figure 4.6, 
Table 4.6) and L. tropica (Figure 4.7, Table 4.7) to assess utility of each NGP as a 
potential diagnostic.  
 
For L. major infection the regression models were significant for all NGPS, whether 
considering the “true negative” group as only heterologous controls, or both 
heterologous and cured combined (Table 4.8). AUC values for αGalactosylated NGPs 
indicate an exceptional level (based on criteria from Scott et al. (2013)) of 
discrimination between positive and negative samples, even when patients with 
cured samples are included in the “true negative” group, with AUC of 0.8-0.9 for 
each individually, >0.9 for all NGPs combined (Table 4.9). AUC values were ≥0.9 for 
each curve, when including only heterologous controls.  
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Sensitivity (the ability to accurately detect a positive test) and specificity (accuracy 
of negative results) for each NGP is summarised in Table 4.5. Reassuringly, BME was 
universally useless as a biomarker, correctly categorising zero samples as positive. 
Sensitivity was generally low for L. tropica infected samples (peaking with KM30 at 
20%), although this is unsurprising given the non-significant difference between L. 
tropica and control groups as shown in Figure 4.5. 
 
Table 4.5. Positive and negative test results calculated for L. major and L. tropica patient 
serum samples screened with four NGPs (KM27, KM28, KM30 and BME). Test Results were 
assigned positive (+) or negative (-) based on the cut-off values, calculated for each CL-ELISA 
plate. Active infection samples are either L. tropica or L. major (collected in 2013 and 2017). 
Negative samples are categorised as Heterologous (only heterologous controls) or Combined 
(cured and heterologous controls). 
NGP Test 
Result 
Disease Present Disease Absent 
L. major L. tropica Heterologous Combined 
KM27 + 118 0 1 12 
- 11 15 27 41 
KM28 + 120 2 3 17 
- 10 13 25 36 
KM30 + 126 3 8 25 
- 3 12 20 28 
BME + 0 0 0 0 
- 129 15 28 53 
 
 
Table 4.6. Sensitivity and specificity for each NGP (KM27, KM28, KM30 and BME) when 
predicting positive or negative status of serum samples. Calculations were performed using 
either heterologous controls only, or combined values for cured patients and heterologous 
controls as the “true negative” group. 
NGP Sensitivity Specificity L. major L. tropica Heterologous only All Negative 
KM27 91% 0% 96% 77% 
KM28 92% 13% 89% 68% 
KM30 98% 20% 71% 53% 
BME 0% 0% 100% 100% 
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Figure 4.6. ROC curve analysis for four NGPs (KM27, KM28, KM30 and BME) for L. major 
infected samples. ROC curves were generated using a “true negative” group of either 
Combined values from cured and heterologous patients (A) or Heterologous control values 
only (B). AUC values for each curve are listed in Table 4.6. Curves above the Reference line 
(solid black) at 0.5 indicates the test is better than chance at predicting disease state. 
 
Table 4.7. Area under curve (AUC) values for L. major ROC curves. ROC curves (Figure 4.6) 
were generated using Combined values from cured and heterologous patients or 
Heterologous control values only.  
NGP 
Combined (Figure 4.6A) Heterologous (Figure 4.6B) 
AUC 
95% CI 
AUC 
95% CI 
Lower Upper Lower Upper 
Combined 0.916 0.872 0.961 0.983 0.966 1.00 
KM27 0.870 0.811 0.930 0.971 0.949 0.994 
KM28 0.798 0.732 0.864 0.898 0.845 0.951 
KM30 0.913 0.867 0.958 0.966 0.932 1.000 
BME 0.597 0.501 0.692 0.683 0.565 0.801 
 
ROC curves for L. tropica patient diagnostics showed a surprising level of 
discrimination, with AUC values of >0.8 when all NGPs were combined, although 
perhaps this was a product of the sample size (negative samples out number 
positives), maximising specificity (Figure 4.7). 
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Figure 4.7. ROC curve analysis for four NGPs (KM27, KM28, KM30 and BME) for L. tropica 
patient samples. ROC curves were generated using either Combined values from cured and 
heterologous patients (A) or heterologous control values only (B). AUC values for each curve 
are listed in Table 4.7. Curves above the Reference line (solid black) at 0.5 indicates the test 
is better than chance at predicting disease state. 
 
Table 4.8. Area under curve (AUC) values for L. tropica (2017 KSA Cohort) ROC curves 
(Figure 4.7). ROC curves (Figure 4.7) were generated using either Heterologous control values 
only (A), or Combined values from cured and heterologous patients (B). 
NGP 
Combined (Figure 4.7A) Heterologous (Figure 4.7B) 
AUC 
95% CI 
AUC 
95% CI 
Lower Upper Lower Upper 
Combined 0.876 0.783 0.969    
KM27 0.663 0.530 0.796    
KM28 0.819 0.696 0.941 0.711 0.536 0.886 
KM30 0.736 0.617 0.856    
 
4.2.1.8 Serum levels of anti-Gal antibodies do not change during 
chemotherapeutic treatment of L. major-infected individuals 
To determine how the serum levels of anti-Gal antibodies change in patients over 
the course of anti-leishmanial drug treatment, I used serum samples taken from 
some of the L. major-positive patients (KSA 2017) and measured their reactivity 
against the updated panel of NGPs (KM27, KM28, KM30, BME). These patients were 
treated with first with azoles and antibiotics, followed by antimonials, as described 
in (Section 2.6.1). To determine significance, a Repeated Measures One-Way 
ANOVA was performed to assess any change in titre over time. As this test cannot 
be used when there are missing values (i.e. when some patients visited the clinic 
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twice, and others three times), only the 15 patients with 3 recorded visits are 
included in the analysis (Figure 4.8). 
 
There was a slight increase in anti-Gal titre against KM28 and KM30 across the time 
points. However, there was no significant change in mean titre for any of the four 
NGPs (Table 4.8). The time between first and last clinic visit is not long enough to 
detect a drop in antibody titre in response to parasite reduction. 
Figure 4.8. Anti-Gal titres in sera from L. major patients (n=15) during a course of drug 
treatment. The activity of individual serum samples from L major-infected patients that 
received 1-3 doses of anti-leishmanial drug treatment was screened against four NGPs 
(panels A-D). Results were plotted as Log10 RLU. Medians for each visit are marked as red 
lines. Repeated measures ANOVA showed no change in titres over time.  
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Table 4.9. Repeated Measures ANOVA results comparing anti-Gal titres in sera from L. 
major patients (n=15) during a course of drug treatment. Titres were detected in CL-ELISA 
analysis of serum samples taken at three separate clinic visits, for the treatment of L. major 
infection. ns = p > 0.05. 
NGP  F Statistic a p value 
KM27 0.295 ns 
KM28 1.324 ns 
KM30 1.730 ns 
BME 0.248 ns 
a DF (2,28) 
 
4.2.1.9 Assessing polyclonality of anti-Gal titres in L. major sera 
samples  
There is a possibility of cross-reactivity among the different anti-Gal populations in 
serum from CL-infected individuals (reflecting the complexity of the parasite glycan 
epitopes). I determined this by assaying the activity of serum from L. major-infected 
patients against NGPs (KM27, KM28 and KM30) under various conditions. First, CL-
ELISA plates were coated with two antigens in the same well, to determine if several 
anti-Gal populations were present. Then I used an enzyme to cleave the terminal 
αGal residue from the NGP, to measure the associated reduction in binding. Finally, 
serum was incubated with various monosaccharides, to investigate if other glycans 
had inhibitory effect on anti-Gal recognition of NGPs. 
 
For the dual antigen assays, a Repeated Measures One-Way ANOVA was conducted 
to determine if there were statistical differences in antibody titres binding antigens 
singly or in combination. L. major serum samples (n = 56; taken at the first clinic visit 
were used) were assayed by ELISA in plates coated with either KM27, KM28 or 
KM30 alone, or KM27+KM28, KM27+KM30 or KM28+KM30 in the same well (Figure 
4.9). Antibody titres were significantly different between the different antigen 
coatings (F (1.798, 95.306) = 70.073, p < 0.0005, partial η2 = 0.569). Planned 
contrasts showed that mean titres increased in all combination wells (Table 4.9). 
This was least pronounced in the comparison of KM30 alone (mean = 3.11) and 
KM27+KM30 (mean = 3.16), however, even this comparison was deemed significant 
after Bonferroni correction for multiple comparisons (p = 0.018).  
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Figure 4.9. Anti-Gal titres in L. major patient samples (n = 56) with single or dual NGP 
antigens. Antibody titres detected in patient sera with active L. major infection, diluted 
1:800. Wells were coated with NGPs alone or in combination, KM27 and KM30 at 50 ng/well, 
and KM28 at 12.5 ng/well. Data are presented as Log10 transformed relative luminescence 
units (RLU). Lines correspond to median. * = p ≤ 0.05, **** = p < 0.0005.  
 
Table 4.10. Comparison of anti-Gal titres detected using single or dual antigens (KM27, 
KM28 and KM30) in serum from L. major-positive samples. Planned contrasts were 
performed after One Way Repeated Measures ANOVA analysis of Log10-transformed CL-
ELISA data with single and dual antigen coatings (Figure 4.9). Difference is calculated between 
the mean of individual NGP (Group Two) and the mean of dual NGPs (Group One). * = p ≤ 
0.05, **** = p < 0.0005. 
 
In order to demonstrate that the terminal αGal residues are essential for 
recognition of the NGP, coffee bean αGalactosidase (CBAG) was used to cleave all 
types of terminal αGal (Galα(1/4/6)) linkages. I immobilised KM30 
(Galα(1,3)Galβ(1,3)Manα-BSA) onto ELISA plates and treated with increasing 
amount of CBAG. Despite titration of the primary antibody (from 1:100 to 1:800 
dilutions), the coating NGP amount (12.5-50 ng/well) and the enzyme amount 
(0.0125-0.1 U/well) I was unable to reduce anti-Gal titres against KM30 by more 
than 18% (Figure 4.10). This is likely due to cross-reactivity against the truncated 
glycan; removal of the terminal αGal leaves Galfβ(1,3)Manα-BSA, which 
Group One Group Two Difference 
CI 
p value Lower Upper 
KM27+KM28 
KM27 0.217 0.174 0.261 **** 
KM28 0.297 0.228 0.75 **** 
KM27+KM30 
KM27 0.333 0.255 0.089 **** 
KM30 0.047 0.006 0.579 * 
KM28+KM30 
KM28 0.466 0.353 0.066 **** 
KM30 0.100 0.579 0.134 **** 
88 
 
demonstrates a high level of binding to patient sera. Due to this complication, I 
decided to use competitive glycan concentrations to confirm specificity. 
 
Figure 4.10. Anti-Gal titres in L. major positive patient samples from KSA (2017 cohort) 
against KM30 are reduced following CBAG treatment. Red arrows and percentages indicate 
reduction of titre between highest enzyme amount (0.1 U/well) and enzyme-negative 
controls (0 U/well). A. L. major positive sera was diluted between 1:100 and 1:800, and 
titrated against increasing amounts of CBAG enzyme. NGP coating was 50 ng/well. B. KM30 
was titrated between 12.5-50 ng/well against increasing amounts of CBAG enzyme. Sera was 
diluted 1:800.  
 
To assess the degree of recognition of NGPs determined by the configuration of the 
terminal galactosyl residue, pooled sera was incubated with monosaccharides at 0.1 
M and 0.5 M concentrations before addition to the CL-ELISA plate (Figure 4.11). 
Glycans used were methyl-α-D-galactopyranose, methyl-β-D-galactopyranose, D-
Galactose and D-Mannose. Inhibition was measured in relation to a glycan-free 
control.  
 
Inhibition of all pools was greatest with αGal and D-Galactose, although β-Gal 
almost completely abolished binding at 0.5 M. Mannose was much less effective at 
inhibiting binding, except at 0.5 M for L. tropica sera, where binding was reduced to 
almost zero.  
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Figure 4.11. Anti-Gal recognition of three NGPs (KM27, KM28 and KM30) in the presence 
of inhibitory glycans, in pooled serum samples from active infection (L. major or L. tropica) 
and healthy controls (UK or KSA). Data are plotted as percentages, relative to a control, 
uninhibited control pools. Pooled serum was pre-incubated with specific glycans at either 
0.1M (blue circle) or 0.5M (red square) concentration. L. major (n = 2), L. tropica (n = 2), UK 
(n =1), KSA (n=1). Top: KM27. Middle: KM28. Bottom: KM30.  
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Taken together, these assays demonstrate the diversity of anti-glycan antibodies 
produced during L. major infection. At least two populations are detected in the 
dual antigen assays (anti-Galα(1,6)-R and anti-Galα(1,3)-R). The inhibition of 
recognition of KM27/28/30 by L. major sera through pre-incubation with galactose 
verifies the importance of the terminal αGal-residue, although as both βGal and D-
Mannose pre-incubation also inhibited recognition of the NGPs, this assay is 
detecting a degree of polyreactivity. Anti-Gal has been shown to be polyreactive 
and low affinity binding to structures other than αGal epitopes has been 
demonstrated 296. 
 
4.2.1.10 Correlation of L. major anti-Gal titre with disease 
characteristics 
Lesion number and parasite load vary widely between CL individuals, and it is 
possible that low parasite numbers could result in low anti-Gal titres, confounding 
diagnosis. C-Reactive Protein (CRP) is a plasma protein that is a well-studied marker 
of inflammation and tissue damage 297. Understanding how host responses to 
infection correlate with anti-Gal levels may flag patient groups for which the test is 
less useful. If patients with low parasite burdens, such as in chronic CL, or very low 
markers of inflammation, have correspondingly low anti-Gal titres, these could 
result in false negatives.  
 
4.2.1.10.1 Serum CRP levels are increased in CL infection 
Kruskal Wallis H test showed the mean rank values for CRP levels in sera were 
significantly different across the three sera types (χ2 (3) p = 0.03, Figure 4.12). Post-
hoc comparisons identified the difference between L. major patients and 
Heterologous controls, but not in any other comparison (Supplementary Table 14, 
Table 4.10). It must be noted that the sample size for these comparisons is very 
small (n= 7 for cured patients, and n = 17 for heterologous).  
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Figure 4.12. CRP levels in individual patient sera from KSA with either active L. major 
infection (2017 cohort), cured patients or healthy controls. CRP was measured, using the 
Eurolyser CRP test kit, in individual patient serum samples from active L. major infection (n = 
37), Cured patients (n=7) and heterologous controls (n = 17). Lines are at the median. * = p ≤ 
0.05. 
 
Table 4.11. Differences in serum CRP levels in patients from KSA with active L. major 
infection (2017 cohort), cured patients and heterologous controls. Kruskal Wallis H results 
comparing differences (Diff) in mean ranks scores, calculated by subtracting the mean rank 
score of Group Two from that of Group One. Bonferroni corrected significance is reported 
for each difference (P). * = p ≤ 0.05.  
Group One Group Two 
CRP 
Diff. p value 
L. major 2017 Heterologous 12.51 * 
Cured -5.18 ns 
Heterologous Cured -17.69 ns 
 
4.2.1.10.2 Anti-Gal titre is not dependent on parasite load or lesion 
number  
Sera was taken at the same time as swabs from CL lesions during the 2017 
collection. This was then used to detect parasite DNA using quantitative PCR 
(molecular tests performed by Yasser Al Raey, LSTM). Detected DNA is proportional 
to parasite load in the sample, allowing an approximate correlation of parasite 
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number to be calculated with other factors. Correlations were not carried out using 
data from L. tropica patients, due to the small sample size in this group (n=15). 
For all NGPs, there is a small, positive correlation of L. major DNA load with anti-Gal 
titres, but this was only significant for CL-ELISA results with KM30 (Table 4.11). 
Detected DNA explains 14% of the variation in log10 antibody titre against KM30. 
Log10 CRP level had a positive moderate correlation with both antibodies 
recognising KM27 and KM28, and with the number of lesions but this was not 
significant (Table 4.11). 
 
Table 4.12. Pearson Correlations for DNA load, lesion number and CRP levels, with antibody 
titres against each of four NGPs (KM27, KM28, KM30 and BME), in KSA patients with active 
L. major infection (2017 cohort).  Correlation coefficients were calculated between anti-Gal 
titres for each NGP, serum CRP levels, the number of lesions and kDNA copy number 
calculated from qPCR analysis of lesion swabs. Positive values indicate a positive correlation, 
negative values indicate a negative correlation. * = p < 0.05 
NGP DNA Lesion Number CRP 
KM27 0.271 0.082 0.313 
KM28 0.259 -0.102 0.183 
KM30 0.373* 0.008 -0.074 
BME 0.114 -0.339* -0.255 
CRP -.237 0.137  
Lesion Number -0.161   
 
4.2.1.12 anti-Gal titres do not differ across blood types 
Cross reactivity between anti-Gal and blood type antigens is widely reported, due to 
similarity in structure between glycans decorating type B blood cells and 
αGalactosylated glycoconjugates found on pathogens. This potential cross-reactivity 
could be detrimental to developing an anti-Gal diagnostic. A Kruskal-Wallis H test 
was used to determine if there were differences in antibody titre between patients 
with different blood type: A, B, O or AB. Mean rank titres were not statistically 
significantly different between blood types for all NGPs, indicating that blood type 
has no impact on levels of antibody recognising the three NGPs assessed (Table 
4.12). This is potentially due to the inclusion of the galactofuranose in this panel, 
which closely reflects the natural glycochemistry of L. major GIPLs. 
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Table 4.13. Anti-Gal titres against three NGPs (KM27, KM38 and KM30) in serum samples 
from individuals with either A, B, AB, or O type blood. Kruskal Wallis H Test results 
comparing antibody titres between blood types. ns = p > 0.05.  
NGP χ2 DF p value 
KM27 3.295 3 ns 
KM28 4.436 3 ns 
KM30 1.193 3 ns 
 
4.2.2 Analysis of the anti-gal response in patients from other 
geographical locations.  
Structural studies performed on surface glycoconjugates from Leishmania spp. 
isolated from different parts of the world have demonstrated that there is a degree 
of overlap in some of these molecules 230. The similarity is not only restricted to the 
type of molecule (e.g. LPG and GIPLs) expressed by a given Leishmania species, but 
also on the type of sugar residues and how they may be displayed. This means that 
there is a potential for developing an antibody-based diagnostic to have a universal 
deployment, if a generic Leishmania antigen of oligosaccharidic nature could be 
found. On the other hand, travel between areas of endemicity could confound 
accurate diagnostics, if antigens are not included in the detection panel that are 
species specific. To this end, in addition to the Middle Eastern samples described 
above, I have screened a patient cohort with American leishmaniasis infection 
collected from Bolivia, and another cohort from Spain infected with L. infantum.  
 
4.2.2.1 Anti-Gal titres in individual Bolivian sera are highest in 
ML/MCL patients 
The Bolivian cohort were categorised by lesion location; either cutaneous lesions 
(CL; n = 32) or mucosal lesions (ML/MCL; n = 20). Control patients (n = 36) with a 
non-CL lesions were also sampled. PCR was not performed to identify the species, 
but based on epidemiological data, we can assume the majority (85%) are L. 
braziliensis. L. braziliensis has a similar GIPL profile to L. major, with predominantly 
Type-II, αGalactosylated GIPLs.  
 
This cohort was screened initially with three NGPs (Figure 4.13). KM3 (Galα-BSA) 
was selected based on the results from the 2013 L. major cohort screen, which 
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indicated that KM3 was the most important of the nine NGPs screened, in L. major 
detection. A commercial NGP termed Dextra-BSA (Galα(1,3)Galβ(1,4)GlcNAcβ-BSA) 
which had been used to great effect by Al-Salem et al. (2014) to detect anti-Gal in 
Old World CL, was also used, alongside a “complimentary” structure, KM24 
(Galα(1,3)Galβ(1,4)GlcNAcα-BSA). KM24 differed from Dextra-BSA only in that it 
contains an αGlcNAc configuration (instead of βGlcNAc). Anti-Gal titres against 
these glycans were measured in CL-ELISA for the three sera types (CL, ML/CL and 
Controls) alongside L. major positive controls and Chagas positive controls for 
reference. Kruskal Wallis H test followed by post-hoc comparisons was used to 
determine if anti-Gal titres differ between sera types (Supplementary Tables 15 and 
16). 
Figure 4.13. Anti-Gal activity in individual Bolivian patient sera with active tegumentary 
leishmaniasis (CL or ML/MCL lesions) or healthy controls against three αGalactosylated 
NGPs (Dextra-BSA, KM24, KM3). In the ML/MCL group, closed circles (n = 4) indicate patients 
with both mucosal and cutaneous lesions (MCL). Open circles indicate patients with only 
mucosal lesions (ML). Lines correspond to median. Comparisons were only performed 
between CL, ML/MCL and Controls, and not for Chagasic or L. major positive sera. Only 
significant differences are identified. A = Dextra-BSA, B = KM24, C = KM3. * = p ≤ 0.05. 
 
The levels of anti-Gal recognising each of the three NGPs was significantly increased 
in patients with mucosal lesions (ML/MCL) versus the negative controls (Figure 4.13, 
Table 4.13). Antibody titres did not differ between patients with mucosal tissue 
involvement (MCL/ML), compared to patients with only cutaneous lesions (CL), 
although it is interesting to note that the four patients with both mucosal and 
cutaneous lesions (MCL) showed titres above the median in all cases. A limitation of 
this cohort is that without parasite identification, there is likely a mix of species 
present within each of the two groups. L. braziliensis is known for its relatively high 
percentage of ML/MCL progression, but other species present in the region also 
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have this potential. Control patients show a large amount of variation in anti-Gal 
titres (Figure 4.13). 
 
Seven patients had very low titres against both Dextra-BSA and KM24. There is no 
universal aspect of their patient history i.e. they are mix of primary and recurring 
infection, Chagas infection state and various lesion numbers. These seven patients 
do not demonstrate similarly low titres against KM3, indicating that different 
antibody populations are recognising the Galα monosaccharide.  
 
Table 4.14. Anti-Gal titres against three NGPS (Dextra-BSA, KM24 and KM3) in Bolivian 
patient serum samples with either active Leishmania infection (CL or ML/MCL lesions), or 
from healthy Bolivian controls. Kruskal Wallis H results comparing differences in mean ranks 
scores. Differences (Diff.) were calculated subtracting the mean rank score of Group 2 from 
that of Group 1. Bonferroni corrected significance is reported for each difference (P). * = p ≤ 
0.05, ns = p > 0.05. 
Group One Group Two 
Dextra-BSA KM24 KM3 
Diff. p value Diff. p value Diff. p value 
CL 
ML/MCL -3.91 ns -6.48 ns -11 ns 
Control 13.4 ns 12.45 ns 9.17 ns 
ML/MCL Control 17.31 * 18.93 * 20.17 * 
 
4.2.2.2 No cross-reactivity of anti-Gal titres in Bolivian patients with 
both leishmaniasis and Chagas disease is detected 
In sera from chagasic patients, the anti-Gal antibody titres are reportedly 4- to 5-
fold higher than in sera from healthy or bacteria-infected individuals 220,298. Chagas 
seroconversion takes up to 5 years, indicating that patients deemed negative for 
Chagas through parasitological methods may still have detectable chagasic anti-Gal, 
which may cross react with leishmaniasis anti-Gal. There is little in the literature 
about specific antigen/antibody complexes that are responsible for cross-reactivity 
between these two parasite infections, however shared surface antigen families 
have been reported. 
Despite previous reported cross-reactivity of leishmaniasis anti-Gal and chagasic 
anti-Gal, there was no difference in overall recognition of αGal epitopes (at least 
when using Dextra-BSA, KM24 and KM3) between patients positive for Chagas 
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infection and those who were negative (Table 4.14), independent of Leishmania 
infection status.  
 
Table 4.15. Differences in anti-Gal titres serum samples from Bolivian individuals with and 
without Chagas disease. Mann Whitney U tests comparing anti-Gal titres in patients with 
(Ch+) or without (Ch-) Chagas infection, for either control patients or those where Leishmania 
was diagnosed. Mann Whitney U statistic for each test, with corrected test statistic (z). ns = 
p > 0.05.  
NGP 
Controls CL/ML/MCL 
U z p value Diff  (Ch+-Ch-) U z p value 
Diff  
(Ch+-Ch-) 
Dextra-BSA 183 1.10 ns 4.04 209 0.10 ns 0.5 
KM24 160 0.35 ns 1.27 187 -0.43 ns -2.24 
KM3 155 0.18 ns 0.66 190 -0.36 ns -1.87 
  
4.2.2.3 Anti-Gal titres in Bolivian serum using updated NGP panel are 
increased in active disease compared to healthy controls 
KM27, KM28 and KM30 proved most successful in discriminating infected from 
control sera in the Middle Eastern samples. Therefore, I applied the same 
conditions used in (Section 4.2.1.5) to measure anti-Gal titres in the remaining 
Bolivian sera. This equated to 18 CL samples, 3 ML samples and 21 control samples. 
Due to the small sample number for ML patients, all infected sera results were 
grouped together for analysis (combined infected patients, n = 21). 
 
Only anti-Gal titres against KM27 and KM30 were significantly increased in infected 
sera as compared to controls (Figure 4.14, Table 4.15). As before, the BME control 
showed minimal recognition by all sera types, with RLU <200 in all samples. 
97 
 
 
Figure 4.14. Anti-Gal activity in individual Bolivian patient sera with active tegumentary 
leishmaniasis (all lesion types) or healthy controls against three αGalactosylated NGP 
(KM27, KM28, KM30 and BME). In the CL/ML group, shaded circles indicate ML patients and 
open circles indicate CL patients. Only significant comparisons shown. L. major and Healthy 
pools shown for reference RLU values. * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001.  
 
Table 4.16. Anti-Gal titres against four NGPS (KM27, KM28, KM30 and BME) in Bolivian 
patient serum samples with active tegumentary Leishmania infection, or from healthy 
Bolivian controls. Mann Whitney U comparison (U) results for comparison of anti-Gal titres 
in Bolivian serum samples, between healthy controls and patients with tegumentary 
leishmaniasis (all lesion types). z - corrected test statistic. Diff. * = p ≤ 0.05, *** = p ≤ 0.001, 
ns = p > 0.05. 
NGP U z p value Diff. 
KM27 309.5 2.239 * 8.48 
KM28 270.5 1.258 ns 4.76 
KM30 347 3.183 *** 12.04 
BME 224.5 0.101 ns 0.38 
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4.2.2.4 Two panels of αGal NGPs have moderate diagnostic potential 
for Bolivian leishmaniasis 
As before, the usefulness of anti-Gal titres to discriminate between infected and 
control patients was assessed through binomial logistic regression followed by ROC 
curve generation for each NGP individually (Supplementary Table 17 - 19). 
Significant NGPs were then combined for a secondary analysis.  
 
The results indicate that none of the 7 NGPs in this small screen are useful at 
discriminating between disease (CL and ML/MCL patients combined, n = 52) or 
control samples (n =36) (Figure 4.15). The initial screen with Dextra-BSA, KM24 and 
KM3 had moderate discriminatory power (AUC = 0.6-0.7) (Figure 4.15, Table 4.16). 
KM3 was the least effective, but the reduction in AUC was very small. The combined 
model was still poorly discriminative. The second panel demonstrated some 
improvement, with the combined model having an AUC of 0.79. KM30 was most 
effective, with an AUC at almost identical levels to the combination model. The 
second panel screened a smaller number of samples, due to limited volume of 
serum remaining for many of the patients. 
 
 
Figure 4.15. ROC curve analysis for Bolivian patient samples with tegumentary 
leishmaniasis. ROC curves were generated using all CL and ML patient samples combined. 
Panel A = initial NGP panel. Infected patients (n= 42), control patients (n = 36). Panel B = 
second NGP panel. Infected patients (n = 21), control patients (n = 21). AUC values for each 
curve are listed in Table 4.16. Curves above the Reference line (solid black) at 0.5 indicates 
the test is better than chance at predicting disease state.  
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Table 4.17. Area under curve (AUC) values for Bolivian patient ROC curves (Figure 4.15). A 
= initial NGP panel (Dextra-BSA, KM24 and KM3). B = second NGP panel (KM27, KM28 and 
KM30). 
 NGP AUC 95% CI Lower Upper 
A Combined 0.735 0.630 0.840 
Dextra-BSA 0.669 0.557 0.781 
KM24 0.670 0.559 0.781 
KM3 0.652 0.537 0.768 
B Combined 0.791 0.655 0.928 
KM27 0.702 0.545 0.859 
KM28 0.613 0.439 0.788 
KM30 0.787 0.649 0.925 
 
4.2.2.5 Anti-Gal levels are increased in serum samples from patients 
with active VL caused by L. infantum (Spanish cohort) 
The Spanish cohort (L. infantum infections) was categorised by disease 
presentation; either visceral (VL) or cutaneous (CL) disease. Samples were collected 
from some patients following treatment (paired samples), with an additional set of 
samples without matched pairs (i.e. only active infection, or only cured samples). 
Control samples were also collected from both healthy individuals from the 
endemic region (endemic controls) and patients with positive Leishmania test, but 
no symptom of disease (asymptomatic). 
 
Detection of anti-Gal titres in L. infantum sera was performed using the most 
successful panel from the KSA cohorts: KM27, KM28, KM30 and BME as control 
(Figure 4.16). Due to the paired nature of some of these samples, comparisons were 
only made between L. infantum samples (active or cured infection) and control 
groups. Mann Whitney U test demonstrated that anti-Gal titres in patients with L. 
infantum infection were significantly increased, compared to both endemic controls 
and asymptomatic cases, only when the disease was active and visceral 
(Supplementary Table 20 and Table 4.17). CL cases were indistinguishable from 
controls, except for active CL titres against KM30. Titres against both KM27 and 
KM30 were significantly higher in Cured VL cases, compared to healthy controls (but 
not asymptomatic cases). Of significant concern in this cohort, however, is the 
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apparent cross reactivity against the BME control in all L. infantum positive sera 
types, including to a limited extent the asymptomatic individuals. BME was in fact 
the most impressive antigen, performing better than the three galactosylated 
structures.  
 
Figure 4.16. Anti-Gal titres in serum samples from infected with L. infantum, using a panel 
of four NGPs (KM27, KM28, KM30 and BME). Antibody titres are plotted as relative 
luminescence units (RLU), for individual patient serum samples from Asymptomatic (n = 30) 
or Endemic Controls (n = 30), or patients with L. infantum infection. Infected patients are 
grouped as cutaneous leishmaniasis, either active (Active CL; n = 25) or cured (Cured CL; n = 
30), or visceral leishmaniasis, either active (VL Active; n = 20) or cured (VL Cured; n = 37). 
Each panel corresponds to one NGP - A = KM27, B = KM28, C = KM30, D = BME.  
 
101 
 
 
Ta
bl
e 
4.
17
. C
om
pa
ris
on
 o
f a
nt
i-G
al
 ti
tr
es
 a
ga
in
st
 fo
ur
 N
G
Ps
 (K
M
27
, K
M
28
, K
M
30
, B
M
E)
 b
et
w
ee
n 
co
nt
ro
ls
 g
ro
up
s (
En
de
m
ic
 C
on
tr
ol
s o
r A
sy
m
pt
om
at
ic
s)
 
an
d 
pa
tie
nt
s w
ith
 a
ct
iv
e 
of
 c
ur
ed
 L
. i
nf
an
tu
m
. M
an
n 
W
hi
tn
ey
 U
 st
at
ist
ic
 fo
r e
ac
h 
te
st
, w
ith
 c
or
re
ct
ed
 te
st
 st
at
ist
ic
 (z
). 
* 
= 
p 
≤ 
0.
05
, *
**
* 
= 
p 
< 
0.
00
05
, n
s =
 
p 
> 
0.
05
. 
 
102 
 
4.2.2.6 Anti-Gal titres in decrease following cure of active VL 
15 patients each with VL infection and 19 patients with CL infection had an 
additional sample taken after clinical cure. A Paired Sample T Test compared means 
before and after cure in these patients, to determine if anti-Gal titres changed 
during the test window (Table 18). 
 
There was a significant reduction in antibody titre against all antigens, including the 
control BME antigen, in VL patients after cure (Figure 4.17). No difference was 
detected in CL patients. Again, a high level of cross-reactivity was observed against 
the BME control.  
 
Figure 4.17. Anti-Gal levels detected in paired sera samples of L. infantum patients, using a 
panel of NGPs (KM27, KM28, KM30 and BME). Antibody titres are plotted as relative 
luminescence units (RLU), for matched pairs of patient serum samples patients with L. 
infantum infection. Pairs are plotted at active and cured infection states, for VL (n = 15) and 
CL (n = 19). Each panel corresponds to one NGP - A = KM27, B = KM28, C = KM30, D = BME. * 
= p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, ns = p > 0.05. 
103 
 
Table 4.19. Differences in anti-Gal titre before and after treatment in patients with L. 
infantum infection, against four NGPs (KM27, KM28, KM30 and BME). Paired Sample T-Test 
analysis of change in anti-Gal titre (Diff.), calculated from Active (A) RLU subtracted from 
Cured (C). One sample is excluded from CL BME analysis, due to its being an extreme outlier. 
Significance (P) of the test statistic (t) is reported as * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 
0.001, ns = p > 0.05.  
Disease 
Type NGP 
Diff. 
(C-A) 
95% CI of Diff. 
t DF p value 
Lower Upper 
CL  
KM27 -24 -58 9 -1.5 18 ns 
KM28 17 -20 54 1.0 18 ns 
KM30 7 -20 35 0.6 18 ns 
BME ‼ -7 -28 13 -0.8 17 ns 
VL 
KM27 -400 -684 -117 -3.0 14 ** 
KM28 -349 -646 -51 -2.5 14 * 
KM30 -458 -721 -196 -3.8 14 ** 
BME -449 -663 -234 -4.5 14 *** 
‼ n = 18 
 
4.2.2.7 Glycan inhibition of anti-Gal in L. infantum infection 
A glycan inhibition assay was performed to determine anti-Gal specificity. Pools of 
sera were preincubated with a range of inhibitory sugars, before assayed against 
immobilised NGPs on an ELISA plate. For active VL sera, inhibition was fairly uniform 
across all glycan treatments, indicating the binding to the NGPs may not be due to 
recognition of αGal residues only, unlike that seen in L. major infection (Section 
4.1.2.5). BME binding was inhibited to same degree as the αGal-NGPs. No glycan 
reduced binding by more than 50%, even at 0.5 M concentration (Figure 4.18). 
Cured VL sera binding to the NGPs was slightly more inhibited, especially against 
KM28 (Galα(1,6)-R) by the three galactose monosaccharides tested.  
 
The inhibition of VL antibody recognition by this broad range of glycans shows that 
the NGPs are not binding specific anti-Gal, and further work is required to 
understand the affinity of the antibodies produced during L. infantum infection.  
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Figure 4.18. Glycan inhibition of anti-Gal recognition of KM30 in pooled L. infantum sera. 
Pooled serum from active (Top) or cured (bottom) VL patients was preincubated with one of 
eight glycans at either 0.1 M (open circles) or 0.5 M (filled squares). Left to Right: Methyl-D-
α-galactopyranose (αGal), Methyl-D-β-galactopyranose (βGal), D-galactose, D-α-mannose 
(αMan), D-Mannose (Man), L-Rhamnose (L-Rham), D-Glucose (D-Glu) and α-Glucose (αGlu). 
Reduction was measured relative to an uninhibited control pool.  
 
4.3 Discussion 
Previous work has validated the use of synthetic, αGalactosylated NGPs in the 
detection of Leishmania anti-Gal in human sera 103,275,290. Using a cohort of patients 
from KSA, Al-Salem and colleagues (2014) detected a significant increase in anti-Gal 
in patients with either active or cured Leishmania infection compared to uninfected 
patients. However, the synthetic epitope used was not suited to use in diagnostics 
when differentiating between Leishmania infection types, as L. major and L. tropica 
samples had similar titres. Any successful diagnostic test would need to accurately 
distinguish between parasite species. This is a pressing concern for the control of 
leishmaniasis in the Middle East. A rapid diagnostic test, capable of detecting 
species-specific antibodies would fill a gap in the current diagnostic tool kit, which 
relies heavily on dermatologist expertise and microscopy. Furthermore, a diagnostic 
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tool that detects antibodies in sera could have utility in monitoring response to 
treatment, as Al Salem et al. (2014) data indicates that, despite lesion healing, 
parasites could persist and continue to generate an antibody response.  
 
The surface glycocalyx of the different Leishmania species is rich in immunogenic 
sugars. Since the specificity and titres of anti-Gal antibodies is likely to vary among 
Leishmania infections, in this Chapter I show the results from the screening and 
epitope characterisation of these antibodies from infected individuals from three 
geographically distinct regions, using a panel of non-commercial αGalactosylated 
NGPs (summarised in Table 4.19). 
 
4.3.1.1 Anti-Gal antibodies as potential biomarkers of Leishmania 
infection? 
Screening of the Old World CL samples from KSA have three patient types; active 
leishmaniasis infection (L. major or L. tropica), cured CL infection and heterologous 
non-CL individuals. This latter group is an important control, as these were 
individuals who presented at a clinic with a skin infection that was suspected to be 
CL, but subsequently determined to be an alternative skin pathology, such as 
eczema. Accurate diagnosis of CL is hampered by the overlap of symptoms between 
many dermatological conditions, and so this is the patient group at most risk of a 
false-positive diagnostic. Thirteen NGPs were used to screen these samples (Table 
4.19). While comparison between the first and second set of assays is complicated 
by a number of changes to the method, the variation in the glycan component gives 
insight into the specificity of anti-Gal produced during Leishmania spp. infection.  
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Table 4.20. Summary of anti-Gal titres against fifteen NGPs used to screen sera from three 
geographically distinct cohorts of patients with leishmaniasis. +/++ = titres are increased in 
leishmaniasis patients compared to controls. - = no difference between infected and 
uninfected samples detected. nd = the NGP was not used to detect anti-Gal in these samples. 
NGPs are grouped based on the terminal glycan/glycosidic linkage. ID refers to the assigned 
code for each glycan. Dextra is the only commercially sourced NGP in this study, all others 
are synthesised by Dr Michaels, UTEP. Structure of Glycan is the glycan component of each 
NGP, where R is the linker-BSA component. 
Terminal 
Glycan ID Structure of Glycan 
Species 
L. major L. tropica Bolivian* L. infantum 
Galα(1,6) 
KM28 Galα(1,6)Galα(1,3)Galfβ ++ - + +◊ 
KM11 Galα(1,6)[Galα(1,2)]Galβ + nd nd nd 
KM5 Galα(1,6)Galβ - nd nd nd 
Galα(1,3) 
KM17 Galα(1,3)Galα + nd nd nd 
KM27 Galα(1,3)Galfβ ++ - + +◊ 
KM1 Galα(1,3)Galβ(1,4)Glcβ - nd nd nd 
KM30 Galα(1,3)Galfβ(1,3)Manα ++ - + +● 
KM9 Galα(1,3)Galβ + nd nd nd 
KM24 Galα(1,3)Galβ(1,4)GlcNAcα nd nd +¥ nd 
Dextra Galα(1,3)Galβ(1,4)GlcNAcβ nd nd +¥ nd 
Galα KM3 Galα   + nd +¥ nd 
Other 
KM8 Galα(1,2)Galβ - nd nd nd 
KM12 Galα(1,4)Galβ - nd nd nd 
BME 2-ME - - - +◊ 
KM15 Cysteine - - nd nd 
* Species unconfirmed, majority likely L. braziliensis  
¥ Mucosal leishmaniasis only  
◊ VL only 
● CL and VL infection 
 
KM3 (the simplest structure tested, Galα-BSA) was surprisingly useful as a 
biomarker for L. major CL; I had expected the more complex structures to have 
more discriminatory power. It is possible that monosaccharide αGal is picking up an 
array of polyclonal anti-Gal antibodies, which are at greater abundance in L. major 
infection than in control sera, and could bind at low affinity to this glycan. Of the 
three NGPs with terminal Galα(1,6), the trisaccharide KM28 had excellent 
discrimination between active L. major infection and heterologous controls. Anti-
Gal titres against this NGP were also increased in cured patients, which may indicate 
that this NGP would have utility as a biomarker for cure; it is likely that despite 
107 
 
healed lesions, there are very low levels of parasite persistence which can result in 
reactivation or recurrence after apparent cure 299. A glycovaccine based on a 
Galα(1,6) glycotope gave partial protection against an experimental L. major 
infection, and with the results presented in this Chapter, it appears that antibodies 
against this epitope likely have a role in natural infection 122. 
Galα(1,6)Galα(1,3)Galfβ-R is based on the structure of L. major GIPL-3, which 
actually has additional Manα at the reducing end. Further development of this NGP 
type to extend the glycan to include the mannose residues could improve 
recognition even further.  
 
Changing the second glycan in KM9‘s Galα(1,3)Galβ from β-galactopyranose to β-
galactofuranose, as in KM27, gave much improved recognition by anti-Gal in L. 
major infection. The glycans of L. major GIPL-2 have the terminal structure of 
Galα(1,3)Galfβ(1,3)Manα, and the furanose in the second position appears 
important for recognition. There is not much difference in the discriminatory power 
between the disaccharide KM27 and the trisaccharide KM30, despite higher anti-Gal 
titres binding to the latter. The third glycan in the sequence may not be contributing 
much in terms of specificity of the antibody, and in fact, reduces the sensitivity of 
assay due to an increase in titres detected in controls. Interestingly, the significant 
increase of titres in both active L. major and cured sera that was detected by KM17 
(Galα(1,3)Galα-BSA), indicates that having a Galα in the second position is at least 
immunogenic as Galβ, despite this structure not reported in L. major GIPLs 
(although it could of course be present on an alternative glycoconjugate).  
 
Based on these results, the combination of galactopyranose and galactofuranose 
improves detection of anti-Gal more than the extension of the glycan structure 
from di- to trisaccharide. A combined diagnostic with KM27 (Galα(1,3)Galfβ-BSA) 
and KM28 (Galα(1,6)Galα(1,3)Galfβ-BSA) has excellent potential to detect anti-Gal 
during L. major infection, with minimal false positives. The dual antigen assays in 
Section 4.2.1.9 indicate that the anti-Gal binding to each of these NGPs are distinct 
populations, and the combination will maximise antibody capture. 
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Unfortunately, no NGP used in this thesis allowed identification of L. tropica 
patients; anti-Gal titres in the 15 L. tropica patients available for this study were 
indistinguishable from healthy controls using three αGal NGPs. In Chapter 3 and 5, I 
present evidence that αGal may be expressed by L. tropica cells, but at very low 
levels. This may explain the lack of reactivity of L. tropica sera to these NGPs, 
particularly as only three structures were available to test with these patients (and 
two of them are very similar to each other). It is likely the NGPs based on L. major 
GIPLs will be failing to detect anti-Gal in L. tropica samples, due to low affinity of L. 
tropica sera for L. major antigens. Of course, the small sample size here does not 
allow for definitive conclusions to be drawn, and a much larger cohort is required 
for investigation. 
 
Some points to consider relating to this dataset remain. The data here somewhat 
differ to that shown by Al Salem et al. (2014), although the overall trend was similar 
(one NGP detected significantly higher titres in cured patients). This is likely 
explained by the variation in reagents used as both antigen and antibodies were 
different, due to discontinuation of the originals from suppliers. Additionally, Al 
Salem assayed the samples shortly after collection, whereas I accessed them years 
later. Degradation through long term storage could explain the dampened response 
seen here, and the lack of distinction between the control (KM15, cysteine-BSA) 
antigen and the galactosylated NGPs. An important consideration for the results in 
Figure 4.1 is the demographic differences between the groups. L. major infection 
was fairly evenly distributed across several nationalities, but the cured group was 
dominated by patients from India (14/31) and the heterologous group dominated 
by Saudi patients (21/29). As prior exposure to L. major will differ due to regional 
endemicities, antibody titres will also likely differ depending on nationality 81. It is 
possible that the differences detected here are at least partly a result of selection 
bias. 
 
Two NGP panels were utilised in screening Bolivian patient samples, with limited 
success. Parasite species in this cohort was not confirmed, but likely can be 
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attributed to L. braziliensis, based on epidemiological data for the region. L. 
braziliensis parasites have Type-II GIPLs, like L. major, and therefore a 
predominance of αGalactosylated surface glycolipids. NGPs that are useful in L. 
major diagnosis may therefore also have utility in L. braziliensis detection. The first 
panel, however, gave a combined AUC of 0.74 which indicates potential, but CL 
patients could not be accurately discriminated from controls. The follow up panel 
using NGPs based on L. major GIPLs (KM27, KM28 and KM30) was more successful 
but had very low specificity, likely due to the presence of non-L. braziliensis infected 
samples in this cohort. Further investigation should focus on the KM27/KM30 NGPs, 
as the Galα(1,3)Galfβ glycans detected higher titres in active tegumentary 
leishmaniasis, whereas the Galα(1,6) KM28 did not. However, the small sample size 
and high variation within each group could be masking true differences, so a larger 
cohort may improve discrimination.  
 
L. infantum surface GIPLs do not have a predominance of αGal, unlike L. major or L. 
braziliensis, and are more similar to L. tropica GIPLs in glycosylation. However, 
patients with VL L. infantum infection did demonstrate higher titres against the 
KM27/KM28/KM30 panel, which were designed based on L. major GIPLs. An 
important caveat remains however; reactivity of sera in L. infantum patients (CL or 
VL, active or cured) was also significantly higher against the BME control. This 
cannot be attributed to a batch effect (the same stock was used for all assays with 
all cohorts and stored in aliquots at -80 °C until use) or a technical issue (all 
reagents, plates and equipment was identical). Furthermore, pooled serum positive 
and negative controls on each plate did not reflect this unusual pattern; L. major 
and L. tropica positive sera always showed minimal reactivity to BME, as did the 
healthy control pools. Finally, samples of all types were included on each plate so 
that they would all be subject to identical conditions, and the high titres are 
consistently detected only in L. infantum positive samples. In case this was due to 
excessive concentrations of reagents, I performed a separate assay with much 
lower antibody and NGP concentrations, and the trend was identical (data not 
shown). Therefore, I must conclude that there is an unusual, and unexplained cross 
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reactivity of L. infantum sera against some part of the NGP, potentially the BSA 
component. Therefore, based on the results shown in this Chapter, it is not possible 
draw conclusions on specificity of anti-Gal titres in L. infantum infection. 
 
Reassuringly, the reported cross-reactivity between antibodies that bind blood type 
B antigens and pathogen αGalactosylated surface molecules was not detected in 
this analysis 204. It should be noted that there are very few individuals with AB type 
blood in the 2017 KSA cohort, but this is reflective of the population; 3.8% of the 
Saudi population are Type AB 300. Patients with Chagas infection reportedly 
demonstrate significant increases in anti-Gal titres, compared to healthy controls 
301. This potential cross-reactivity would confound the use of an antibody diagnostic 
in certain regions, if the biomarker is not sufficiently specific for Leishmania. 
Differential anti-Gal titres against the NGPs used in this chapter was not detected 
between patients with Chagas co-infection, vs patients without Chagas. These two 
important barriers to an anti-Gal RDT are not an issue with this antigen set, for the 
patients tested.  
 
4.3.1.3 Specificity of the repertoire of anti-Gal antibodies in Old World 
cutaneous leishmaniasis 
 The results of inhibition experiments showed an interesting relationship between 
the glycan used and the sera type. While galactose (both αGal and βGal) showed 
similar levels of inhibition across all sera types, αMan was particularly effective at 
reducing L. tropica sera binding to all NGPs. L. major sera was relatively unaffected, 
even at 0.5 M αMan. These results, taken together with the known mannosylation 
of L. tropica surface glycoconjugates, indicates that L. tropica mannose-containing 
antigens may be generating an immune response that is otherwise undetected by 
TLC or other methods. Alternatively, immunogenic mannose residues may be part 
of another type of glycoconjugates yet to be characterised. It must be noted that 
the conditions used in these CL-ELISAs resulted in very low levels of L. tropica 
binding even in the controls, with RLU <100 in almost all cases, and therefore these 
results may be exaggerating what is, in reality, a small effect. Healthy Saudi sera 
was also more susceptible to mannose interference in binding, when compared to 
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UK healthy controls. The degree of cross-reactivity hinted at through this 
experiment is surprising. The literature indicates that anti-Gal antibodies are highly 
specific to galactose in the alpha-configuration, but as binding to these NGPs can be 
inhibited by 0.1 M βGal, it is unclear how much of the binding detected in these 
assays can be attributed to these antibodies alone. 
 
Taken together with the detection of polyclonal antibodies in the dual antigen 
assays, it is likely that the NGPs are binding a population of both specific and 
polyclonal antibodies. A second assay should be conducted, using antigen at a high 
enough concentration to allow detection of binding in controls, and therefore 
calculation of any change in binding levels in experimental wells. 
 
However, questions of specificity and polyclonality remain. The degree of inhibition 
by βGal was unexpected, and indicates, at the very least, that the NGPs based on 
αGal-terminating structures may face issues of cross-reactivity with βGal and α-
mannose containing structures. It is unfortunate as these glycans are frequently 
found in nature and are a common feature of microbial pathogens faced by the 
human immune system. However, the controls used in this cohort are 
representative of a number of other dermatological infections, and false positives 
were minimal using the KM27-KM30 set.  
 
4.3.1.2 Anti-Gal titres during chemotherapeutic treatment of L. major 
infection 
The 2017 collection had a large advantage over the earlier KSA cohort in that 
several patients had multiple samples allowing a longitudinal assessment of anti-Gal 
throughout treatment. However, as visits were not at consistent set time points (i.e. 
one month post-diagnosis, six months post-diagnosis) or strictly categorised into 
treatment types, it’s unsurprising that there were no consistent differences across 
the time points. Another complication of this dataset is missing information 
regarding treatment; it’s unclear where some patients were in their treatment 
cycle, i.e. were they still under antibiotic treatment when the sample was taken, or 
had they completed the course. Considering these caveats, I decided to categorise 
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the patients based on visit number, assuming that, as cured patients do not return 
to the clinic for further treatment, and treatment assignation follows a specific 
sequence, the 15 patients with three visits are similar enough to warrant 
investigation. 
 
Anti-Gal titres have been noted to persist for months in CL infection, and years in VL 
infection, following successful treatment, the short duration between first and final 
visit is unlikely to be long enough to detect reduction in circulating antibodies. A 
more useful study would follow up patients beyond treatment conclusion, to 
understand further how anti-Gal titres correlate with active vs past infection. 
Similar analysis in L. infantum infection did detect a reduction in antibody titre 
following cure in visceral infections, however, the specificity of these antibodies is in 
doubt, and this requires more investigation. 
 
4.3.1.4 Correlation with CRP, DNA, lesion number and antibody titres 
Antibody-based tests suffer from issues of sensitivity and could fail to detect low 
titres 302. Antibody level variation between patients is a result of several complex 
factors, and in this Chapter, I investigated three; parasite burden, lesion number 
and disease severity. Antibody titre has been shown to positively correlate with 
lesion number, in both Old and New World CL 302,303. Conversely, Sousa-Atta (2002) 
detected an inverse relationship between IgE antibody levels and lesion number, in 
a cohort of patients from Brazil. CRP levels and lesion number can be considered 
measures of disease severity 304–307. Cases where multiple lesions occur may reflect 
an inability of the immune response to control infection, or a more advanced state 
of disease progression. Multiple lesions would cause more tissue damage, and 
therefore immune stimulation, including circulating antibodies against Leishmania. I 
have used CRP detection as a proxy for inflammation as it is a general marker of 
tissue damage, and increased levels are detected in several infectious diseases 
including VL, although less well studied in CL 307,308. CRP levels can also be a useful 
marker of treatment efficacy in VL; elevated CRP levels remain high for up to three 
months in VL infection, and higher levels indicate slower parasite clearance 308–310.  
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Parasite number (estimated from qPCR analysis by Yasser Al Raey, for L. major 
infected patients in the 2017 cohort) had weak positive correlation with anti-Gal 
titres, and this was only significant for KM30. Conventional diagnosis of CL relies on 
heavily microscopy, which has limited sensitivity particularly when parasite 
numbers are low. These results indicate that detection of anti-Gal is sensitive to 
even the lowest parasite burdens, a substantial improvement on existing diagnostic 
methods. Lesion number has no linear relationship with anti-Gal titre. This is 
potentially due to the tendency of L. major infection to result in single lesions. This 
is reflected in this cohort with the majority of cases showing 1 or 2 lesions (24 out of 
the 44 patients included in this analysis). While CRP levels are higher in L. major 
infected patients than controls, there was no correlation with any other disease 
characteristic. In the Bolivian cohort, I was also unable to detect any difference in 
anti-Gal titre between patients with cutaneous lesions, and those with the more 
advanced pathology of mucosal lesions, despite reported increases in antibody 
titres associated with disease progression in NWCL 303. This relationship requires 
further investigation (the sample size was small), but, as with parasite number, anti-
Gal titres are independent of general inflammatory responses.  
 
Ridley & Ridley (1984) reported that antibody infiltration into lesions is increased 
when parasite numbers are low, and a localised, lesion immune response differing 
to systemic levels is common for many immune complexes/effectors in Leishmania 
infection. Systemic CRP levels were unaffected in BALB/c mice infected with L. 
major parasites 311, and similarly the assays used here, may be failing to detect a 
localised response as described by Ridley and Ridley (1984).  
 
4.3.1.5 Concluding Remarks 
I found that while tegumentary leishmaniasis patients from Bolivia, or with L. major 
infection from KSA recognised terminal Galα(1,3)Galβ(1,4) NGPs, CL patients with L. 
tropica infection did not. Furthermore, sera from L. major infected individuals 
showed reactivity with terminal Galα(1,6)Galβ. Patients with L. infantum only had 
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higher anti-Gal titres with visceral disease, although cross-reactivity to the control in 
these assays requires additional investigation. 
 
In summary, I have shown that three αGal-terminating NGPs are excellent 
discriminators of L. major from L. tropica infection, but also of L. major infection 
from healthy individuals. With further development, there is potential for their use 
in New World settings, due to lack of cross-reactivity with anti-Chagas antibodies. 
Detection of seropositive patients is robust, despite low parasite and lesion 
numbers.  
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Chapter Five 
Detection and partial characterisation of 
surface αGalactosylated antigens from 
Leishmania spp. 
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5.1 Introduction  
The detection of αGal epitopes on the surface of L. major cells and other 
kinetoplastid parasites, has been widely reported in the literature and discussed in 
the introduction of this thesis (Section 1.11). However, as previously mentioned, no 
such epitope has been detected on the surface of L. tropica cells. This in itself is not 
especially noteworthy, except when considered alongside the reportedly high levels 
of anti-Gal detected in L. tropica patients 217. 
 
In the context of the evolutionary role of serum anti-Gal antibodies as a major 
protector of humans and higher primates against infectious disease, it is 
unsurprising that a successful, human kinetoplastid pathogen would not express 
surface αGal residues 312,313. It would be highly advantageous in terms of immune 
system evasion to have lost (or to otherwise lack) the expression of this well-
recognised epitope. A recent study has shown that a αGal-based glycovaccines 
offers a degree of protection against L. major infection in αGal-KO mice, supporting 
previous hypotheses about the evolutionary advantage of anti-Gal acquisition 
122,201,314. There is a key difference in the life cycles of L. major and L. tropica; L. 
tropica infections are largely anthroponotic, that is, human-to-human transmission 
via the vector, whereas L. major is found in many animal species, as well as humans 
49. With this in mind, it is perhaps more likely that L. tropica will lack (or produce 
fewer of) the antigenic glycoconjugates that can lead to a robust protective immune 
response, whereas L. major, faced with less evolutionary pressure against αGal 
expression will continue to benefit from the (assumed) non-immune related 
functions of these glycans when infecting non-human mammals. 
 
However, if this is the case, what is responsible for generating the anti-Gal in L. 
tropica patients? Antibody binding to αGal in L. tropica infection requires that the 
epitope be accessible to the immune system, although this does not necessarily 
mean it must be an external, surface structure, as cryptic epitopes can be exposed 
to the immune system on cell death and lysis. To understand the antibody 
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specificity of anti-Gal for L. tropica, it is necessary to localise and characterise the 
epitope that is recognised by anti-Gal. 
 
In this chapter, I detail the methods used to attempt purification of anti-Gal 
antibodies from patient sera using a commercially available NGP. In addition, results 
are shown on the labelling of in vitro cultured Leishmania cells using Griffonia 
simplicifolia Lectin I isolectin B4 (IB4 lectin), which is specific for αGal residues 
283,315.  
 
5.2 Results 
Localising the binding of anti-Gal to cultured Leishmania cell required purification of 
antibodies from infected sera. Affinity chromatography exploits the strength of 
binding between antibody-antigen pairs, excluding non-binding antibodies from the 
final eluate. However, as no resin for the purification of anti-Gal is commercially 
available, I attempted to make my own.  
 
5.2.1 Anti-Gal purification from L. major infected sera 
Historically, researchers purifying anti-Gal from sera have used Synsorb 115 resin, 
manufactured by Chembiomed, (Alberta, Canada), which has subsequently ceased 
trading. To address this lack of specific resin, I used a Protein G column to enrich for 
IgG antibodies, followed by either a bespoke column of αGal-BSA conjugated to 
resin, or nitrocellulose membrane coated in αGal-BSA.  
 
5.2.1.1 Anti-Gal purification using Dextra-BSA column resulted in low 
yield 
Initially, I trialled antibody purification from sera using a series of columns. The first 
was a Protein G column, selected for its high affinity to all human IgG subtypes, in 
order to acquire a sample of IgG at a known concentration. This IgG sample was 
then applied to a column made through conjugation of a commercial NGP to NHS-
activated agarose, exploiting the primary amines on the BSA component of the 
NGP. The acquisition of synthetic glycan with an easily conjugatable linker was 
challenging. Whilst I had an array of structures to hand (Methods Section 2.4.1, 
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Table 2.1), I opted to use Dextra-BSA (Galα(1,3)Galβ(1,4)GlcNAc-BSA) in order to 
represent the classic "Galili" epitope, in hopes of capturing this important 
population of antibodies. Additionally, this glycan being commercially available 
through Dextra Labs would be more easily acquired than the bespoke NGPs 
synthesised by UTEP collaborators. However, on elution from the second column 
there was no detectable protein in the final, concentrated sample. Repeated 
attempts using longer incubation (i.e. 4 °C overnight) or repeated application of the 
sera flow through back on to the column, increased the yield marginally. This low 
yield is potentially due to the use of Dextra-BSA, rather than the unconjugated 
glycan originally intended. It was clear that some of the NGP had bound to the 
column (measured through a reduction in the before and after protein 
concentration), however possibly the column was too small (0.5 mL) to bind a large 
enough quantity of antibody. Additionally, I investigated whether the method of 
elution from the column could be optimised, using a 0.5 M D-galactose solution for 
competition elution as compared to low pH elution buffer. Neither option offered a 
significant improvement in yield. Due to the high costs associated with scaling up 
this method, I decided at this point to attempt an alternative as the yield was too 
low to be useful. 
 
5.2.1.2 Purification of anti-Gal from L. major infected sera using 
glycan-coated nitrocellulose  
Nitrocellulose strips were incubated with Dextra-BSA in solution, before incubation 
of the coated strips in diluted L. major infected sera. Antibody bound to the Dextra-
BSA was eluted with low pH buffer (termed anti-Dextra antibody). All fractions of 
the final elution from the nitrocellulose strip were pooled and dialysed into PBS, 
reducing the total volume to around 50 µL. Protein concentration was assessed 
through BCA quantification. The fractions collected were the FT (unbound IgG) and 
the final elution. A sample of the whole sera was kept as a comparison, as was a 
sample of the diluted sera that was applied to the column. This method resulted in 
successful purification of anti-Dextra antibody, as confirmed through a number of 
SDS-PAGE, western blot and dot blot experiments (Figures 5.1-5.6). 
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Samples were loaded onto a 12.5% gel at 1.5 µg/lane, or for whole sera, at 1:1000 
dilution. The expected banding pattern was clearly seen in the eluted sample, with 
bands with an apparent molecular mass on SDS-PAGE of 50 kDa and 25 kDa, which 
correspond to the heavy and light chains of human IgG, respectively 316 (Figure 5.1).  
 
Figure 5.1. SDS-PAGE analysis of purified anti-Gal antibodies. A. Coomassie blue stained 
12.5% protein gel showing IgG band pattern after elution. B, nigrosine nitrocellulose staining 
control after transfer and development. Flow through (unbound sera), anti-Dextra and Pre-
Column IgG samples loaded at 1.5 µg/lane. Whole sera pooled from L. major positive patients 
was diluted 1:1000 before mixing with sample buffer.  
 
This was confirmed through transfer to nitrocellulose and probing with Goat anti-
Human IgG-HRP antibody. Signal was again clearly detected in the expected 50 kDa 
and 25 kDa pattern. (Figure 5.2). 
 
Figure 5.2. Recognition of purified anti-Gal from L. major positive sera by anti-IgG antibody. 
Nitrocellulose membrane with transferred proteins was incubated with HRP conjugated anti-
Human IgG and processed for ECL development. Flow through (unbound sera), anti-Dextra 
and Pre-Column IgG samples loaded at 1.5 µg/lane. Whole sera pooled from L. major positive 
patients diluted 1:1000. 
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5.2.1.3 Galactosidase treatment of glycan, and glycan inhibition of 
purified antibody abolishes recognition by anti-Dextra  
The next step was to confirm that the eluted antibody was specific for the αGal 
glycan structure, and not non-specific IgG contaminating the FT, or antibodies 
recognising the BSA component of the NGP.  
 
Treatment with CBAG removes non-reducing terminal α(1,3/4/6)galactosyl residues 
285. Incubation of Dextra-BSA with CBAG removes the final glycan in the 
trisaccharide, leaving a Galβ terminating disaccharide, and rendering the glycan 
unrecognisable to anti-Gal antibodies (Figure 5.3A). To confirm that the eluted IgG 
recognised the Dextra-BSA glycan structure, a simple dot blot assay was performed 
(Figure 5.3B). 0.1 μg Dextra-BSA was incubated overnight with either CBAG or 
buffer, and spotted onto nitrocellulose, alongside BSA negative control. The 
membrane was incubated with 1 μg/mL anti-Dextra. Signal was detected in the 
untreated sample only, indicating that cleavage of the terminal Galα(1,3)-R 
abolished recognition by the purified antibody. 
 
Figure 5.3. Dot blot shows treatment with CBAG blocks recognition of purified anti-Dextra 
antibody. A. Representation of cleavage site for CBAG on Dextra-BSA. B. Dot blot of enzyme 
treated and untreated Dextra-BSA spotted onto nitrocellulose (BSA was used as negative 
control). The membrane was probed with anti-Dextra antibody eluted from Dextra-column. 
121 
 
 
Figure 5.4. SDS-PAGE analysis of CBAG-treated Dextra-BSA. Coomassie blue staining of 
12.5% agarose gel. The Dextra-BSA band (red arrow, ~88 kDa) migrates with a reduced 
apparent molecular mass after treatment with CBAG (blue arrow, ~83 kDa). The BSA carrier 
protein for the enzyme is visible in both CBAG lanes.  
 
Following detection in a dot blot format, western blotting was used to confirm 
specificity more robustly, using both IB4-HRP lectin and the purified anti-Dextra 
antibody. Dextra-BSA was either mock-treated or incubated overnight with CBAG, 
and loaded on to a 12.5% polyacrylamide gel, alongside controls (BSA, CBAG alone 
and buffer alone). After the proteins were separated through electrophoresis, the 
gel was stained with Coomassie blue to confirm reduction in apparent molecular 
weight of the enzyme-treated glycan (Figure 5.4). The Mw shift is clear (comparing 
lane 1 and 2), where the band of untreated Dextra-BSA shifts from ~88 kDa to a 
band closer to 83 kDa. After Coomassie staining, the BSA carrier protein for the 
enzyme is distinctly visible in both enzyme-containing lanes.  
 
A 12.5% polyacrylamide gel was loaded with CBAG-treated Dextra-BSA (0.1 µg/lane 
Dextra-BSA, 0.1 U/lane CBAG), untreated Dextra-BSA (0.1 µg/lane Dextra-BSA), 
CBAG only and Buffer only controls. The separated proteins were transferred to 
nitrocellulose and probed with either anti-Dextra (Figure 5.5A) or IB4-HRP (Figure 
5.5B). Signal was detected only in lanes with untreated glycan, and not in lanes with 
treated glycan, or enzyme alone. Some recognition of BSA in the lanes with enzyme 
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was seen when incubated with anti-Dextra antibody, but this is most likely non-
specific recognition due to the large amount of the BSA carrier in the enzyme 
sample (compare to Figure 5.4) 
 
Figure 5.5. Recognition of Dextra-BSA by purified antibody and IB4-HRP lectin, following 
treatment with CBAG. A. Western blot showing specificity of anti-Dextra for αGal- 
terminating glycan. B. Lectin blot showing specificity of IB4-HRP for αGal-terminating glycan. 
Untreated Dextra-BSA band at ~88 kDa. C. Nitrocellulose membrane stained with Nigrosin. 
The Dextra-BSA band (red arrow, ~88 kDa) shows a reduced molecular mass after treatment 
with CBAG (blue arrow, ~83 kDa). The BSA carrier protein of the enzyme is also recognised 
by the purified antibody.  
An experiment was performed to confirm the specificity of anti-Dextra through 
glycan inhibition. A 12.5% polyacrylamide gel was loaded with Dextra-BSA in four 
lanes. The proteins were then transferred to nitrocellulose and cut into four strips. 
IB4 lectin and anti-Dextra were each incubated with 0.5 M galactose for one hour, 
prior to incubation with the nitrocellulose strips. When the 0.5 M galactose was 
present, recognition of Dextra-BSA was inhibited completely for IB4 (Figure 5.6A) 
and reduced for anti-Dextra (Figure 5.6B), although the resolution for these films is 
poor due to high background signal for anti-Dextra. 
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Figure 5.6. Inhibition of anti-Dextra and IB4-HRP recognition of Dextra-BSA, with 0.5 M D-
galactose. SDS-PAGE of Dextra BSA loaded at 0.1 µg/lane and transferred to nitrocellulose 
membrane. Strips incubated with purified anti-Dextra antibody (Antibody) or IB4-HRP (IB4), 
preincubated with either 0.5 M D-Galactose (+) or buffer without D-galactose (-). Dextra-BSA 
migrates band at ~88 kDa.  
Taken together, these results confirm the specificity of the purified anti-Dextra 
antibody for the trisaccharide (Galα(1,3)Galβ(1,4)GlcNAc-BSA). 
  
5.2.2 Lectin fluorescence analysis of Leishmania promastigotes 
An attempt to localise αGalactosylated epitopes on the surface of Leishmania 
parasites was made using anti-Gal antibodies. Methods were first validated using 
IB4 lectin, which is specific for αGal-terminating glycans, using L. major (as this 
species has known αGalactosylated surface lipids), before progression to L. tropica 
cells. 
 
 5.2.2.1 IB4-labelling of L. major promastigotes 
L. major promastigotes were labelled with IB4-AF488, to localise the αGal-
terminating residues during this life stage. The specificity of labelling was then 
confirmed through incubation with inhibitory glycan.  
 
Initial difficulties in establishing this protocol required lengthy troubleshooting 
(summarised in Table 5.1). It was not clear if the problem lay in 1) high 
background/non-specific staining of the lectin masking true signal, 2) degradation or 
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other problem with the inhibitory glycan, or 3) technical error. When cells were 
fixed with PFA (either 1% or 4%) only, no stain was observed. This is possibly due to 
the epitopes (likely localised on the relatively short GIPLs) being inaccessible 
without a stronger method of fixation/permeabilisation. The addition of Triton-X 
was also unsuccessful, due to changes in cell morphology. However, when cells 
were fixed with 100% methanol (alone or following PFA fixation at 4%) bright 
fluorescence was visible throughout the parasite cytosol. Titration experiments 
allowed the selection of 5 µg/mL IB4-AF488 lectin as an acceptable level of signal, 
with minimal background green staining. While it was expected that the brightest 
stain would be localised to the cell surface, in promastigotes this was not the case, 
for reasons discussed below. Specificity was confirmed through the incubation of 
the lectin with 0.5 M of an inhibitory glycan, for one hour at 27°C (Figure 5.7, Table 
5.2). 
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Table 5.1. Summary of conditions optimised during method development for the IB4-lectin 
stain of L. major promastigotes 
 
 
Table 5.2. Summary of results testing inhibition of IB4 binding to L. major promastigotes by 
various glycans. 
 
 
Glycan  Range Tested Result 
methyl-α-D-galactopyranoside 0.1 up to 1.5M Some inhibition at 1M, but not complete.
galactose 0.1 up to 0.5M  Inhibition at 0.5M 
methyl-β-D-galactose 0.1 up to 0.5M  No inhibition 
melibiose 0.1 up to 0.5M  No inhibition 
methyl-α-D-glucopyranoside 0.5M  No inhibition 
methyl-α-D-mannopyranoside 0.5M  No inhibition 
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Figure 5.7. IB4 staining of L. major promastigotes is inhibited by 0.5 M D-galactose. Top 
Panel: IB4-AF488 lectin was pre-incubated with 0.5 M D-galactose. Bottom: IB4-488 without 
preincubation. Left to right: DIC, IB4, DAPI, merged fluorescence. Scale is 5 µM. 
 
5.2.2.2 IB4-labelling of L. tropica promastigotes 
L. tropica promastigotes cells showed a similar pattern of stain compared to L. 
major promastigotes. The level of fluorescence is considerably reduced in L. tropica, 
reflecting perhaps a lower amount of glycan on the parasite surface, or a low 
affinity/non-specific recognition. As this binding is inhibited by the presence of 0.5 
M galactose, and to a lesser extent 0.5 M D-mannose, it may be a combination of 
these factors accounting for the reduced signal (Figure 5.8).  
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Figure 5.8. Pre-incubation with either galactose or mannose inhibits binding of IB4 lectin 
to L. tropica promastigotes. Top to bottom: uninhibited IB4-AF488, IB4-488 pre-incubated 
with 0.5M αgalactose or IB4-AF488 pre-incubated with 0.5M D-mannose. Left to right: DIC, 
IB4-AF488, DAPI, Merged fluorescence. Scale is 5 µM. 
 
5.2.2.3 IB4-labelling of L. major amastigotes 
While the GIPLs profile of L. major is reportedly invariant throughout the life cycle, 
other surface glycoconjugates are up or down regulated, reflecting their various, life 
stage-specific functions 235. This may change availability of surface glycans for 
binding by antibodies at promastigote stages compared to amastigotes. Therefore, I 
extracted amastigotes from THP-1 cells, and labelled with IB4-AF488 to search for 
the location of αGalactosylated epitopes. Anti-paraflagellar rod (PFR) was used to 
confirm the cells were amastigotes (truncated flagellum as compared to 
promastigotes). 
 
This protocol proved difficult due to the delicate touch required for extraction from 
infected macrophages. Increased addition of SDS gave a higher yield of extracted 
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parasites but resulted in degradation, malformation and death of the amastigotes. 
One experiment resulted in extraction and staining, and successful inhibition of IB4-
AF488 through incubation with 0.5 M galactose (Figure 5.9). 
 
Figure 5.9. IB4-AF488 labelling of L. major amastigotes extracted from THP-1 cells. 
Top Panel: IB4-AF488 preincubated with 0.5M galactose. Bottom Panel: IB4-AF488 
without preincubation. Left to right: DIC, anti-PFR. IB4-AF488, DAPI, merged 
fluorescence. Scale is 5 µM. 
 
5.2.2.4 IB4-labelling of L. major-infected THP-1 cells  
Due to difficulties extracting viable amastigotes for labelling, I subsequently focused 
on staining amastigotes in situ, without prior extraction from the THP-1 host cell. 
IB4 labelling of L. major amastigotes within human THP-1 cells showed bright 
surface stain of the intracellular parasites (Figure 5.10). There was also diffuse green 
staining with the cytoplasm of the THP-1 cells. It has been reported that N-
glycosylated proteins from THP-1 cells could contain terminal galactosyl residues, 
but these are highly unlikely to be in the α-configuration, based on the structural 
analysis of these glycans and the lack of a human αGalactosyl-transferase that 
would be capable of producing such structures 317. IB4 lectin is reportedly specific 
for terminal αGal residues, so is unlikely to be recognising other structures 315. 
Inhibition experiments with promastigotes and various glycans show inhibition only 
through αGal. The high concentration required to stain the amastigotes may be 
resulting in non-specific stain and/or it may be that unbound lectin takes a long 
time to diffuse back out of the cell after incubation. However, neither the inclusion 
of Tween20 in the wash buffer, increasing the number and duration of washes had 
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any impact on the level of background staining. Therefore, it is possible that the 
diffuse green stain is a result of shed material from the parasites. Incubation of the 
IB4-AF488 lectin with 0.5 M galactose prior to application to the cells reduced the 
bright foci of fluorescence, but did not completely abolish all the diffuse, 
background stain. 
Figure 5.10. IB4 staining of THP-1 cells infected with L. major amastigotes. Top Panel: IB4-
AF488 preincubated with 0.5M galactose. Bottom Panel: IB4-AF488 without preincubation. 
Left to right: DIC, IB4-AF488, DAPI, Merged fluorescence. Scale is 5 µM. 
 
5.2.2.5 IB4-labelling of L. tropica-infected THP-1 cells with  
Interestingly, IB4 did not seem to stain the amastigote surface of L. tropica parasites 
within THP-1 cells, despite apparent labelling in promastigote cells (Figure 5.11). All 
fluorescence in the green channel is not associated with the parasite surface 
(counterstained with anti-tubulin hybridoma). Label is the same regardless of the 
presence of 0.5 M galactose, which inhibits binding effectively in L. major infection.  
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Figure 5.11. IB4 staining of THP-1 cells infected with L. tropica amastigotes. Top 
Panel: IB4-AF488 preincubated with 0.5M galactose. Bottom Panel: IB4-AF488 
without preincubation. Left to right: DIC, anti-Tubulin, IB4-AF488, DAPI, Merged 
fluorescence. Scale is 5 µM 
 
5.3 Discussion 
Investigation of the immunogenicity of L. tropica glycolipids in Chapter 3 indicated 
that any αGal epitope must be located on an alternative glycoconjugate. While anti-
Gal specificities for L. major have been studied Chapter 4, L. tropica sera did not 
show differential recognition of any of the three αGalactosylated NGPs used in the 
screen. Therefore, a different approach was required; the localisation and 
characterisation of the epitope in L. tropica cells. 
 
In an attempt to identify the location of antigen expression in both Leishmania 
species, I have taken two main approaches. The first, to use a lectin to stain αGal at 
various parasite life stages, and the second, to use antibody purified directly from 
patient sera to localise αGal epitopes directly on the parasite surface. To study the 
localisation of αGal-structures, I have exploited a lectin derived from the seeds of 
the Bandeira simplicifolia (Griffonia simplicifolia), GSL I. GSL I is a family of 
glycoproteins of which there are two types of subunit, each with different glycan 
preferences 315. GSL IB4 contains only the B type subunit, which is specific for 
terminal αGal residues. 
 
L. major promastigotes are known to have a number of αGalactosylated GIPLs 
decorating the surface of the cell, and this was validated by staining of the 
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promastigotes with the lectin IB4. The fluorescence is clearly seen throughout the 
cytosol, although excluded from the nucleus and kinetoplast. All non-
permeabilisation methods of fixation resulted in negative staining, as did live 
staining of cells with no fixation (not shown). The labelling by IB4 was inhibited by 
0.5 M D-galactose and α-methyl-D-galactopyranoside, but not by β-methyl-D-
galactopyranoside, D-mannose or D-glucose, emphasising the specificity of the 
lectin-glycan binding. Low level IB4 staining of L. tropica promastigotes was 
consistently observed. This was inhibited by prior incubation of the lectin with 0.5 
M D-galactose and, to a lesser degree, 0.5 M D-mannose. L. tropica cells may be 
expressing αGal at low levels at this point in the life cycle, although the partial 
inhibition by incubation with mannose indicates that IB4 recognition of this epitope 
is perhaps lower affinity than would be expected. 
 
It is unfortunate that non-permeabilisation methods of fixation did not allow IB4 
labelling, as these images do not give a clear answer about the localisation of the 
αGal molecules. From this experiment, it looks likely that ɑGal residues are 
expressed on the amastigote surface, but it seems also detectable within the 
parasite cytosol, and shed within THP-1 cells. The percentage of L. major GIPLs that 
are expressed on the surface ranges from 15-84%, depending on the GIPL type 280. 
Furthermore only 30% of L. major GIPLs quantified from whole cell lysate could be 
labelled at the cell surface 280. A similar trend may be followed in L. tropica cells.  
 
The most biologically relevant results in relation to anti-Gal production during a 
Leishmania infection, are in αGal localisation in amastigotes. After one successful 
extraction/labelling experiment using L. major infected THP-1, I was unable to 
replicate the amastigote extraction in order to further optimise the protocol, and so 
any images must be interpreted with caution. However, this experiment conforms 
with reported GIPL expression throughout L. major lifecycle, as the bright IB4 stain 
was completely inhibited on incubation of the lectin with 0.5 M D-galactose. I was 
unable to replicate this result using L. tropica amastigotes, and so I proceeded with 
labelling of amastigotes in situ. 
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Final experiments focussed on the labelling of Leishmania within the THP-1 host 
cell. Surprisingly, despite the additional complication of the intact human cell, this 
yielded the clearest IB4-AF488 labelling of the three life stages for L. major. In the 
presence of 0.5 M galactose, IB4-AF488 signal was almost completed inhibited, 
except in some case diffuse fluorescence remained at very low levels in some 
infected cells. It is likely that the diffuse staining material is shed from amastigotes, 
due to the noted exchange of parasite and host material, and it is reported that 
amastigote debris can result in stronger label signals by human sera than live 
amastigotes 31. L. tropica infected THP-1 cells had very small amounts of IB4 stain, 
however it was not associated with amastigotes, and was uninhibited by glycan pre-
incubation of the lectin. It is possible that this stain is the result of unbound lectin 
that is not removed by washes. The low level of recognition in the promastigote 
stage indicates that the method needs further optimisation for L. tropica cells due 
to the reduced level of αGal available for detection in this species. 
 
The use of resin conjugated to an epitope of interest is an established method to 
obtain antibodies of a desired specificity. In this chapter I use Protein G resin to first 
purify IgG from sera, but the subsequent step required a different approach. The 
first approach was to attempt to make a column by conjugating an NGP to agarose 
beads. The commercially available NGP, Dextra-BSA), was the obvious first 
candidate for this protocol, as it was more easily sourced than the bespoke NGPs 
used elsewhere in this thesis (Chapter 4). The structure follows the classical Galili 
trisaccharide structure (Galα(1,3)Galβ(1,4)GlcNAc-R) where the R is linker-BSA.  
 
I am confident, based on the work presented here, that I have successfully purified 
the anti-Dextra antibody of interest, due to its proven specificity for Dextra-BSA 
through both enzyme cleavage of the binding site and inhibition by galactose. 
Unfortunately, this came too late for use in immunofluorescent assays. 
 
Aside from the localisation of the L. tropica αGal epitope, I hoped to use the 
purified antibody in a number of assays. Data showing the lytic potential of anti-Gal 
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antibodies from Chagasic serum hint at the protective role these antibodies may 
play in parasitic infection 318. I had planned to incubate the parasites (both species) 
with anti-Dextra antibody, and monitor survival and agglutination. I am particularly 
interested in the in vitro binding of anti-Dextra to L. tropica parasites, to further 
understand the relationship between L. tropica infection and anti-Gal titres. Anti-
Gal produced on immunisation of mice with Galα(1,6)Galβ has the ability to lyse L. 
major metacyclics 122. No such investigation has been conducted with L. tropica 
cells, and would be an exciting prospect for further work.  
 
Data shown in Chapter 4 indicates that there are multiple anti-Gal antibodies 
circulating in L. major infected sera. This presents the possibility that by using 
alternative glycans to purify antibodies from sera, I could obtain information about 
the relative abundance of the varying specificities. Furthermore, with the potential 
use of anti-Gal as a marker for treatment efficacy (as with Chagasic anti-Gal), the 
changing profile of anti-Gal during chemotherapy could inform the development of 
a robust method for monitoring treatment outcome.  
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Natural anti-Gal, antibodies that recognise terminal αGalactosyl residues, are the 
most abundant IgG antibodies in healthy adult humans 191. Unique to humans and 
Old World apes, anti-Gal has been proposed as the major protective antibody 
following a catastrophic event during primate evolution around 30 million years 
ago, allowing the proliferation of individuals who had a mutated and therefore non-
functional galactosyl transferase gene (α1,3GT) 203. This gene is essential for the 
formation of saccharides terminating in αGal residues, and its silencing means no 
such epitopes are formed in human cells. As a result, antibodies against αGal are 
not selected out as self-reactive clones, and therefore can proliferate in response to 
xenoantigens from multiple pathogens 319.  
 
In parasitic infection, anti-Gal has been implicated in protection from clinical 
malaria caused by P. falciparum 262. High titres are detected in response to P. vivax 
infection, suggesting an additional role in disease caused by this species 263. T. cruzi, 
the causative agent of Chagas disease, has heavily galactosylated surface mucins 
which elicit a strong immune response during human infection, and a glycan vaccine 
exploiting this response shows promising results in mice 271. Levels of Chagasic anti-
Gal can be exploited in monitoring response to treatment, as a sensitive marker of 
the presence of parasites 320.  
 
Antibodies against αGalactosyl present an intriguing possibility for a Leishmania 
diagnostic that exploits their natural specificity. Diagnostic protocols vary, but 
typically require human expertise to identify parasites, or laboratory infrastructure 
and considerable resources for molecular approaches (elegantly reviewed by 3). As 
global patterns of disease are changing through increased migration and human 
displacement throughout the Middle East and Europe, tools for rapid screening are 
sorely needed. Furthermore, in endemic settings where cases of CL are typically 
sporadic, active surveillance in rural clinics will be improved through the advent of 
rapid, easy-to-read tests that do not require the prohibitive costs of travel to 
specialist clinics. Early case detection has myriad benefits, including minimising the 
spread of the disease through rapid control, and the correct assignation of 
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treatment, avoiding complications and distress through inaccurate diagnoses 152. An 
antibody-based diagnostic, with a simple interface and a short time to generate a 
result, has the potential to revolutionise the current state of CL diagnostics, much as 
RDTs have transformed malaria diagnosis. 
 
The αGalactosylation of surface glycolipids (GIPLs) in L. major is described in the 
literature, as is the apparent lack of similar galactosylation in L. tropica. Anti-Gal 
antibodies have been detected in sera from patients infected with either L. major or 
L. tropica species; however the presence of αGalactosyl residues have only been 
identified for L. major GIPLs, whereas for L. tropica αGalactosylated surface 
glycoconjugates have not yet been detected 217. In this thesis, I was able to 
corroborate previous work done Schneider et al. (1995), which showed that L. 
tropica promastigotes only express Type-I GIPLs, despite recognition of IB4 lectin 
(specific for terminal αGalactose) on the whole parasite surface in 
immunofluorescent assays (Chapter 5). L. major immunofluorescent labelling by IB4 
was consistent throughout all stages, from promastigote to amastigote, fitting the 
reported pattern of GIPL expression. This suggests that αGalactosylation of another 
surface glycoconjugates may be taking place in L. tropica, most likely linked to 
glycoproteins. In fact, preliminary IB4 blotting on L. tropica protein fractions 
showed recognition of low molecular weight components after fractionation on 
SDS-PAGE (Yuk-Chien L., and Acosta-Serrano A, unpublished). Interestingly, TLC-
immunostainings (Chapter 3) showed that unlike the excellent recognition of L. 
major GIPLs by sera from infected patients, L. tropica glycolipid extracts were poorly 
recognised by the same sera, suggesting a lack for diagnostic potential. 
Furthermore, L. major sera was shown to bind a single glycolipid species in L. 
tropica extract but, unfortunately, I was unable to confidently identify this band 
using LC-MS due to insufficient material. On the other hand, L. tropica sera was 
universally unreactive against glycolipid extract from either parasite species; a 
surprising result that points to an alternative source of any anti-Gal detected in 
previous studies. More biochemical work is needed to identify and structurally 
characterise αGalactosylated glycoconjugates expressed by L. tropica parasites. This 
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is necessary for to better design NGPs that will specifically discriminate L. tropica 
from L. major infections. This glycolipid analysis confirms the immunogenicity of L. 
major GIPL-2 and GIPL-3 in sera from L. major-infected patients only; no recognition 
of these molecules is detected in healthy sera. The specificity of the anti-Gal 
produced during L. major infection is key to designing a diagnostic based on this 
antibody; natural anti-Gal is ubiquitous in healthy adults, but Chapter 3 confirms 
that it has low affinity for Leishmania glycotopes. 
 
The unexpected pattern of anti-Gal titres in L. tropica serum samples demonstrated 
by Al-Salem et al. (2014) was the inspiration for this thesis, but I was unable to 
replicate those results in Chapter 4.Both the antigen (Galα(1,3)Gal1,4)GlcNAc-R, 
Vector Labs) and secondary antibody used in that study are no longer available, 
which could explain some of the discrepancy. Nevertheless, I was able to screen a 
panel of NGPs that have excellent potential as biomarkers of L. major infection, 
which could be used in conjunction with microscopy to rapidly determine which 
infections are L. major (and therefore more likely to resolve without treatment).  
 
L. major anti-Gal constitutes at least two separate populations, although there are 
likely more still undetected. In Chapter 4, two glycotopes have the most potential as 
biomarkers for L. major infection; Galα(1,6)Galα(1,3)Galfβ-R and Galα(1,3)Galfβ-R. 
Based on the L. major GIPLs, demonstrated in Chapter 3 to have excellent reactivity 
with L. major sera, a combination of these two structures has the potential to 
capture two distinct antibody populations. Confirming the pattern demonstrated 
with native GIPLs, antibodies binding these glycans are not found in sera from L. 
tropica patients, or in healthy adults.  
 
Antibodies against Galα(1,6)Galα(1,3)Galfβ, (GIPL-3) were detected at significantly 
higher levels in patients with apparently healed lesions. Reactivation of CL is 
reported decades after clinical cure, indicating that parasites can persist at 
asymptomatic levels 299,321. Antibody biomarkers of infection have potential utility in 
detecting such occult infections, as demonstrated in Chagas disease 320. With 
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further investigation, KM28 may be another such marker. Unfortunately, the time 
scale for the longitudinal samples from patients with L. major infection collected for 
this study did not allow detection of antibody titre reduction in response to 
treatment, but a longer-term collection would allow such monitoring, and validation 
of this proposal.  
 
With hindsight, I could have implemented a target product profile (TPP) prior to the 
design and synthesis of the update panel of biomarkers. A TPP is a critical 
evaluation of the optimal and minimal parameters for the eventual diagnostic, and 
is often used in diagnostic development 322–324. This process would have focused my 
interpretation of the results and given a framework for assessment of a successful 
biomarker. The TPP for a point-of-care diagnostic for cutaneous leishmaniasis would 
give parameters for sensitivity and specificity, as well as target population (for 
example active surveillance of at-risk populations, or passive surveillance of 
individuals presenting at a clinic), required sample type and volume (such as serum 
or whole blood) and the expertise or training required for staff performing such 
tests. Such a report would be an asset in the further development of these NGPs 
into a viable and useful diagnostic test. 
 
Looking ahead 
With more time, I would investigate the mystery glycolipid band extracted from L. 
tropica cells and recognised by sera from L. major infected sera. The limitation so 
far has been extracting enough material for LC-MS or NMR analysis. With more time 
and resources, I would focus on characterising this band, with larger scale 
extraction. The antibody purified in Chapter 5 could also be used in TLC immuno-
overlays, as could an additional panel of lectins with specificity for different glycans 
(e.g. Concavalin A which bind α-D-Mannose). These methods could indirectly 
characterise the antigenic glycans in this band.  
 
The lack of immunogenic glycolipids detected in TLC overlays points to an 
alternative source of anti-Gal other than GIPLs. Preliminary work in this area 
detected low molecular weight proteins using IB4, although further experiments are 
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needed to confirm this. Treatment of protein lysate with coffee bean 
αGalactosidase (to remove terminal αGal residues) and PNGaseF (to remove N-
linked saccharides from protein) followed by SDS-PAGE/Western blots, alongside 
incubation with sera/lectins using inhibitory glycans would be my immediate 
priorities. If L. tropica glycoproteins have a novel αGal-terminating oligosaccharide, 
this could be exploited alongside the NGPs used in this thesis, for the development 
of a L. major/L. tropica RDT with utility in areas of overlapping endemicity.  
 
One unfortunately truncated aspect of this thesis is in the purification of anti-Gal 
from sera. The lack of a commercially available resin for affinity chromatography 
presented a challenge, although I am confident that I managed to acquire a small 
volume of anti-Gal through my second approach, using NGP-coated nitrocellulose. 
It’s possible that more anti-Gal could be purified using a different glycotope, such as 
KM28 Galα(1,6)- or KM27 Galα(1,3)-, titres against which were excellent at 
discriminating L. major sera from healthy controls. The expense of synthesising 
these non-commercial NGPs meant I opted first to use the NGP available from 
Dextra Laboratories. Anti-Gal recognising this glycan was detected in high levels by 
Al-Salem et al. (2014), although as discussed above, the suppliers differed and 
therefore the linkage between the glycan and BSA component likely does too. One 
final method I did not try, was to biotinylate the BSA portion of the NGP, and use a 
streptavidin-sepharose column to capture it. This may have been successful, 
although more expensive, and time limitations meant I did not attempt it.  
 
Lytic anti-Gal against T. cruzi is likely an important component of protection from, 
and control of, the infection, and I would have liked to investigate any similar 
properties of L. major anti-Gal. The preliminary success of the anti-L. major vaccine 
demonstrated by Iniguez et al. (2017), and their demonstration of complement-
independent lysis of metacyclics by sera of immunised mice, indicates there may be 
similar potential in human anti-Gal. While the protocol for amastigote extraction 
was variable, with further fine-tuning, enough cells could be produced to 
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understand the protective potential throughout the life cycle of L. major within the 
mammalian host. 
 
An unexplored aspect of αGal expression by Leishmania is the identification of the 
genes responsible for galactopyranose incorporation into glycoconjugates. No 
galactopyranosyl transferases have been incriminated in Leishmania as essential for 
GIPL synthesis. Galactofuranosyl transferases have been identified in the L. major 
genome, although all are linked to the biosynthesis of LPG and not GIPLs 325. One 
approach would be to follow a methodology similar to that used to study galactosyl 
transferases in ticks 326. Cabezas-Cruz et al. (2018) transfected human cells with 
candidate tick genes and used immunofluorescence to detect αGal expression. With 
the advent of efficient CRISPR cas9 genome editing in Leishmania spp., there is new 
potential for investigation of likely candidates coupled with the immunofluorescent 
methods optimised in this thesis; the knock down of genes responsible for GIPL 
αGalactosylation would abolish the IB4 labelling demonstrated in Chapter 5 327,328. 
 
In Chapter 4, I discuss the perplexing cross-reactivity of L. infantum sera with the 
control NGP. Further investigation was clearly warranted, but due to the limited 
amount of sera available I was forced to end this section unanswered. I would very 
much like to have solved this mystery. Natural antibodies against dietary proteins 
(such as BSA) is common, and could explain some of the cross-reactivity, although 
why this would be so elevated in L. infantum positive sera only is unclear 329. One 
approach would be to pre-absorb sera with BSA, to remove any cross-reacting 
antibodies against this component of the NGP. A wider screen of this cohort with 
NGPs with different carrier protein would also help understand the relative 
importance of the protein and glycan portions, however, the costs associated with 
this are prohibitive. Deeper investigation of anti-Gal specificities in all sera pools 
could have come through the use of glycan microarrays, such as those available 
through the Imperial College Carbohydrate Microarray Facility. Additionally, for L. 
tropica, where the epitope is completely unknown, this approach could help to 
narrow the focus into a smaller subset of likely structures.  
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In summary, this thesis identifies excellent candidates for further development into 
a diagnostic capable of discriminating between two important causative species of 
Old World CL. With additional investigation, these NGPs may have utility in certain 
New World CL diagnoses, although L. infantum diagnosis is unsuited to this 
approach due to an unusual, and unexplained, cross-reactivity to the carrier.  
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Chapter Seven 
Supplementary Tables 
  
143 
 
4.2.1.1 Serum levels of anti-Gal antibodies are higher in active L. major infected 
samples, compared to cured and non-CL samples from the 2013 collection  
  
Supplementary Table 1. One-Way ANOVA results for nine NGPs, used to screen three 
groups of patient sera from the 2013 KSA collection. Active L. major (n = 17), cured 
leishmania (n = 31) and heterologous controls (n = 29). Degrees of freedom for the ANOVA 
results are marked a. A Welch adjustment is denoted by w for two NGPs, with associated 
degrees for freedom b and c. P-values of < 0.05 indicate a significant difference between 
patient groups and were followed with post-hoc tests. 
NGP F  p value 
KM1 2.954 a 0.058 
KM3 5.070 a 0.009* 
KM5 0.004 a 0.996 
KM8 2.451 a 0.093 
KM9 3.681 a 0.030* 
KM15 0.005 a 0.995 
KM17 4.688 a 0.012* 
KM11 3.690 w,b  0.032* 
KM12 0.684 w,c  0.510 
w Welch adjusted ANOVA  
Degrees of freedom a 2,74; b 2,47.7; c 2,46.0 
* Significance p < 0.05  
 
Supplementary Table 2. Logistic regression predicting likelihood of being L. major 
positive (2013 cohort) based on antibody titres against 9 NGPs. ROC curves 
presented in Figure 2. * = p ≤ 0.05. ** = p ≤ 0.01, *** = p ≤ 0.001, **** = p < 0.0005, 
ns = p > 0.05. 
NGP B S.E. Wald df p value Odds Ratio 
95% C.I. for Odds 
Ratio 
Lower Upper 
KM1 0.751 0.424 3.132 1 ns 2.119 0.922 4.867 
KM3 3.497 1.521 5.283 1 * 33.013 1.674 651.203 
KM5 -1.310 1.092 1.438 1 ns 0.270 0.032 2.295 
KM8 -1.595 0.822 3.764 1 ns 0.203 0.040 1.016 
KM9 -0.379 0.656 0.334 1 ns 0.685 0.189 2.476 
KM11 0.162 0.567 0.081 1 ns 1.175 0.387 3.569 
KM12 -0.407 0.574 0.504 1 ns 0.665 0.216 2.049 
KM15 -0.913 0.918 0.990 1 ns 0.401 0.066 2.425 
KM17 0.736 1.041 0.500 1 ns 2.088 0.272 16.056 
Constant -2.075 1.314 2.495 1 ns 0.126   
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4.2.1.4 Anti-Gal detection in pools of sera samples from the 2017 collection 
 
Supplementary Table 3. Independent Samples Kruskal Wallis results for comparison of 
pooled sera from healthy controls (UK or KSA patients), or active infection (L. tropica and 
L. major from KSA 2017 cohort), using KM27, KM28, KM30 and BME. Mean ranks for each 
serum type listed in Supplementary Table 4. Post-hoc pairwise comparisons listed in Table 3. 
**** = p < 0.0005, ns = p > 0.05. 
NGP χ2 DF p value 
KM27 25.464 3 **** 
KM28 25.643 3 **** 
KM30 25.994 3 **** 
BME 0.408 3 ns 
 
Supplementary Table 4. Kruskal Wallis calculated mean rank scores for pooled sera from 
healthy controls (UK or KSA patients), or active infection (L. tropica and L. major, from the 
2017 cohort), using KM27, KM28 and KM30. Mean ranks are only calculated for NGPs with 
a p-value of < 0.05 for the Kruskal Wallis test (see Supplementary Table 3). Post-hoc pairwise 
comparisons of mean rank scores listed in Table 3. 
Sera Type KM27 KM28 KM30 
L. tropica  15.2 13.6 18.0 
L. major 36.5 36.5 36.5 
UK 17.3 17.6 15.6 
KSA 14.1 15.4 12.9 
 
 
4.2.1.5 Anti-Gal detection with an updated panel of NGPs is increased in active L. 
major infection, but not L. tropica  
 
Supplementary Table 5. Kruskal Wallis H test results for serum anti-Gal titres in individual 
patient serum samples from active L. major infection (either 2017 or 2013 collection 
cohorts), active L. tropica infection, post-infection (Cured) and heterologous (non-CL 
controls) against four NGPs (KM27, KM28, KM30 and BME). Mean rank scores reported in 
Supplementary Table 6. ** = p ≤ 0.01, **** = p < 0.0005. 
NGP χ2 DF p value 
KM27 85.838 4 **** 
KM28 63.068 4 **** 
KM30 87.124 4 **** 
BME 13.259 4 ** 
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Supplementary Table 6. Mean Ranks scores for patient serum samples from active L. major 
infection (either 2017 or 2013 collection cohorts), active L. tropica infection, post-infection 
(Cured) and heterologous (non-CL controls) against four NGPs (KM27, KM28, KM30 and 
BME). Antibody titres were measured in individual patient serum samples from active L. 
major infection (either 2017 or 2013 collection cohorts), active L. tropica infection, post-
infection (Cured) and heterologous (non-CL controls). Post-hoc pairwise comparisons of 
mean rank scores listed in Table 4. 
Sera Type KM27 KM28 KM30 BME 
L. tropica  26.5 20.4 21.25 56.4 
L. major 2017 103.4 95.29 103.79 85.17 
L. major 2013 88.42 91.25 89.69 66.23 
Cured 67.28 73.96 58.42 80.56 
Heterologous 23.72 36.16 28.7 54.64 
 
4.2.1.6 Three αGal NGPs have diagnostic potential for L. major but not L. tropica 
infection in KSA  
 
Supplementary Table 7. Binomial logistic regression models for L. major infection 
prediction using either Combined (heterologous and cured) controls or Heterologous only 
controls, using KM27, KM28, KM30 and BME. Each row is a separate model. All NGPs is the 
model when data for all four NGPs is combined into a single analysis (Row 1). The model for 
each NGP is also presented individually in Rows 2-5. Details of each model are presented in 
Supplementary Tables 8 and 9. * = p ≤ 0.05, ** = p ≤ 0.01, **** = p < 0.0005. 
NGP Combined Controls Heterologous only 
Χ2 DF p value Χ2 DF p value 
All NGPs 90.998 4 **** 99.498 4 **** 
KM27 62.004 1 **** 84.769 1 **** 
KM28 45.903 1 **** 52.438 1 **** 
KM30 88.097 1 **** 81.542 1 **** 
BME 4.303 1 * 9.163 1 ** 
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Supplementary Table 8. Detailed Binomial logistic regression models (Supplementary Table 
7) for L. major infection predication using Heterologous only controls, using KM27, KM28, 
KM30 and BME. Each row is a separate model. The model for each NGP is presented 
individually in Rows 1-4. All NGPs is the model when data for all four NGPs ((KM27, KM28, 
KM30 and BME) is combined into a single analysis (Row 5).  
NGP Variable B S.E. Wald df p value 
Odds 
Ratio 
95% CI for Odds Ratio 
Lower Upper 
KM27 KM27 0.017 0.004 21.035 1 0.000 1.017 1.010 1.025 
Constant -2.313 0.636 13.230 1 0.000 0.099   
KM28 KM28 0.009 0.002 15.107 1 0.000 1.009 1.004 1.013 
Constant -0.944 0.477 3.922 1 0.048 0.389   
KM30 KM30 0.007 0.002 21.941 1 0.000 1.007 1.004 1.010 
Constant -1.924 0.569 11.415 1 0.001 0.146   
BME BME 0.028 0.011 6.911 1 0.009 1.028 1.007 1.050 
Constant 0.608 0.386 2.483 1 0.115 1.837   
Combined KM27 0.012 0.005 6.094 1 0.014 1.012 1.002 1.022 
KM28 0.002 0.003 0.517 1 0.472 1.002 0.996 1.009 
KM30 0.004 0.002 4.964 1 0.026 1.004 1.001 1.008 
BME -0.021 0.019 1.143 1 0.285 0.980 0.944 1.017 
Constant -3.231 1.013 10.165 1 0.001 0.040   
 
Supplementary Table 9. Detailed Binomial logistic regression models (Supplementary Table 
7) for L. major infection predication using all controls (Heterologous and cured) combined, 
using KM27, KM28, KM30 and BME. Each row is a separate model. The model for each NGP 
is presented individually in Rows 1-4. All NGPs is the model when data for all four NGPs 
(KM27, KM28, KM30 and BME) is combined into a single analysis (Row 5). 
NGP Variable B S.E. Wald df p value 
Odds 
Ratio 
95% CI for Odds Ratio 
Lower Upper 
KM27 KM27 0.005 0.001 27.166 1 0.000 1.005 1.003 1.007 
Constant -1.111 0.348 10.172 1 0.001 0.329   
KM28 KM28 0.003 0.001 23.010 1 0.000 1.003 1.002 1.005 
Constant -0.644 0.303 4.528 1 0.033 0.525   
KM30 KM30 0.004 0.001 33.910 1 0.000 1.004 1.002 1.005 
Constant -1.599 0.378 17.898 1 0.000 0.202   
BME BME 0.012 0.006 3.860 1 0.049 1.012 1.000 1.025 
Constant 0.401 0.293 1.880 1 0.170 1.494   
Combined KM27 0.001 0.001 0.311 1 0.577 1.001 0.998 1.004 
KM28 0.001 0.001 0.537 1 0.464 1.001 0.999 1.003 
KM30 0.003 0.001 15.177 1 0.000 1.003 1.002 1.005 
BME -0.008 0.008 1.085 1 0.297 0.992 0.976 1.007 
Constant -1.622 0.472 11.810 1 0.001 0.198   
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Supplementary Table 10. Binomial logistic regression models for L. tropica infection 
predication using either Combined (heterologous and cured) controls or Heterologous only 
controls, using KM27, KM28, KM30 and BME. Each row is a separate model. All NGPs is the 
model when data for significant, individual NGPs is combined into a single analysis [BME is 
not included] (Row 1). The model for each NGP is also presented individually in Rows 2-5. nd 
= not done. * = p ≤ 0.05, *** = p ≤ 0.001, **** = p < 0.0005, ns = p > 0.05. 
NGP Combined Controls Heterologous only 
Χ2 DF p value Χ2 DF p value 
All NGPs 22.986 3 **** nd   
KM27 6.77 1 *** 0.03 1 ns 
KM28 15.466 1 **** 4.127 1 * 
KM30 12.163 1 **** 3.433 1 ns 
BME 1.147 1 ns 0.002 1 ns 
 
Supplementary Table 111. Detailed Binomial logistic regression models (Supplementary 
Table 10) for L. tropica infection predication using all controls (Heterologous and cured) 
combined, using KM27, KM28, KM30 and BME. Each row is a separate model. The model for 
each NGP is also presented individually in Rows 1-4. Combined NGPs is the model when data 
for three NGPS (KM27, KM28 and KM30) is combined into a single analysis (Row 5). 
NGP Variable B S.E. Wald df p value 
Odds 
Ratio 
95% CI for Odds 
Ratio 
Lower Upper 
KM27 KM27 -0.007 0.003 3.985 1.000 0.046 0.993 0.987 1.000 
Constant -0.327 0.455 0.517 1.000 0.472 0.721 
  KM28 KM28 -0.010 0.004 7.533 1.000 0.006 0.990 0.982 0.997 
Constant 0.207 0.472 0.192 1.000 0.661 1.230   
KM30 KM30 -0.010 0.005 4.066 1.000 0.044 0.990 0.981 1.000 
Constant -0.101 0.485 0.043 1.000 0.835 0.904   
BME BME -0.013 0.013 1.057 1.000 0.304 0.987 0.962 1.012 
Constant -0.786 0.480 2.684 1.000 0.101 0.455 
  Combined KM27 0.016 0.008 3.972 1.000 0.046 1.017 1.000 1.033 
KM28 -0.014 0.006 6.250 1.000 0.012 0.986 0.975 0.997 
KM30 -0.015 0.008 3.836 1.000 0.050 0.985 0.971 1.000 
Constant 0.419 0.612 0.468 1.000 0.494 1.520   
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Supplementary Table 122. Detailed Binomial logistic regression models (Supplementary 
Table 10) for L. tropica infection predication using Heterologous controls only using KM27, 
KM28, KM30 and BME. Each row is a separate model. The model for each NGP is presented 
individually in Rows 1-4. No combined analysis was performed, as only one NGP was 
significant alone. 
NGP Variable B S.E. Wald df p value 
Odds 
Ratio 
95% CI for Odds 
Ratio 
Lower Upper 
KM27 KM27 0.001 0.005 0.030 1.000 0.863 1.001 0.991 1.011 
Constant -0.546 0.553 0.975 1.000 0.323 0.579   
KM28 KM28 -0.007 0.004 3.321 1.000 0.068 0.993 0.986 1.001 
Constant 0.249 0.487 0.261 1.000 0.609 1.282   
KM30 KM30 -0.006 0.004 1.693 1.000 0.193 0.994 0.986 1.003 
Constant 0.003 0.474 0.000 1.000 0.995 1.003   
BME BME -0.001 0.015 0.002 1.000 0.968 0.999 0.970 1.030 
Constant -0.453 0.542 0.697 1.000 0.404 0.636   
 
4.2.1.10.1 Serum CRP levels are increased in CL infection 
 
Supplementary Table 133. Kruskal Wallis calculated mean rank scores for CRP levels in 
individual serum samples. CRP was measured in individual patient serum samples from 
active L. major infection (n = 37), Cured patients (n=7) and heterologous controls (n = 17). 
Sera Type Mean Rank 
L. major 2017 33.89 
Cured 39.07 
Heterologous  21.38 
 
4.2.2.1 Anti-Gal titres in individual Bolivian sera are highest in ML/MCL patients 
 
Supplementary Table 14. Kruskal Wallis H Test statistics for comparison of anti-Gal titres in 
Bolivian Patient Samples for three NGPs (KM3, KM24 and Dextra-BSA). Mean rank scores 
reported in Supplementary Table 16. * = p ≤ 0.05. 
NGP χ2 DF p value 
KM3 8.132 2 * 
KM24 8.074 2 * 
Dextra-BSA 7.525 2 * 
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Supplementary Table 154. Mean Rank scores for comparison of anti-Gal titres in Bolivian 
Patient Samples for three NGPs (KM3, KM24 and Dextra-BSA). Post-hoc pairwise 
comparisons of mean rank scores listed in Table 13. 
Sera Type Dextra-BSA KM24 KM3 
CL 49.09 48.12 45.75 
ML/MCL 53.00 54.60 56.75 
Control 35.69 35.67 36.58 
 
4.2.2.4 Two panels of αGal NGPs have moderate diagnostic potential for Bolivian 
leishmaniasis 
 
Supplementary Table 165. Logistic regression analysis of anti-Gal titres in Bolivian patient 
sera, against two panels of NGPs. Panel A = initial NGP panel (KM3, KM24, Dextra-BSA). 
Infected patients (n= 42), control patients (n = 36). Combined analysis includes all three NGPs. 
Panel B = second NGP panel (KM27, KM28, KM30 and BME). Infected patients (n = 21), 
control patients (n = 21). Combined analysis includes only the NGPs with significant individual 
models (KM27, KM28, KM30). 
 NGP χ2 DF p value 
A Dextra-BSA 9.23 1 0.002 
KM24 8.256 1 0.004 
KM3 11.532 1 0.001 
Combined 16.331 3 0.001 
B KM27 6.532 1 0.011 
KM28 4.501 1 0.034 
KM30 14.235 1 0.000 
BME 0.771 1 0.380 
Combined 14.28 3 0.003 
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Supplementary Table 17. Detailed Binomial logistic regression models (Supplementary 
Table 16A) for Bolivian patient serum samples combined, using Dextra-BSA, KM24 and 
KM3. Each row is a separate model. The model for each NGP is presented individually in Rows 
1-3. Combined is the model when data for the three NGPS (Dextra-BSA, KM24 and KM3) is 
combined into a single analysis (Row 4). 
NGP Variable B S.E. Wald df p value 
Odds 
Ratio 
95% CI of 
Odds Ratio 
Lower Upper 
Dextra-BSA  Dextra 0.000 0.000 8.118 1 0.004 1.000 1.000 1.000 
Constant -0.522 0.370 1.992 1 0.158 0.593 
  
KM24  KM24 0.000 0.000 7.464 1 0.006 1.000 1.000 1.000 
Constant -0.956 0.521 3.361 1 0.067 0.385 
  
KM3  KM3 0.000 0.000 8.013 1 0.005 1.000 1.000 1.000 
Constant -0.474 0.344 1.907 1 0.167 0.622 
  
Combined  Dextra-BSA 0.000 0.000 1.219 1 0.270 1.000 1.000 1.000 
KM24 0.000 0.000 0.040 1 0.841 1.000 1.000 1.000 
KM3 0.000 0.000 5.440 1 0.020 1.000 1.000 1.000 
Constant -0.944 0.630 2.245 1 0.134 0.389 
  
 
 
Supplementary Table 186. Detailed Binomial logistic regression models (Supplementary 
Table 16B) for Bolivian patient serum samples combined, using KM27, KM28, KM30 and 
BME. Each row is a separate model. The model for each NGP is presented individually in Rows 
1-4. Combined is the model when data for the three NGPS (KM27, KM28, KM30) is combined 
into a single analysis (Row 4). 
NGP Variable B S.E. Wald df p value 
Odds 
Ratio 
95% CI of 
Odds Ratio 
Lower Upper 
KM27  KM27 0.007 0.003 4.305 1 0.038 1.007 1.000 1.013 
Constant -0.772 0.456 2.871 1 0.090 0.462 
  
KM28  KM28 0.002 0.001 2.822 1 0.093 1.002 1.000 1.004 
Constant -0.486 0.399 1.479 1 0.224 0.615 
  
KM30  KM30 0.013 0.005 7.132 1 0.008 1.013 1.003 1.022 
Constant -1.719 0.665 6.677 1 0.010 0.179 
  
BME BME -0.007 0.008 0.728 1 0.393 0.993 0.978 1.009 
Constant 0.280 0.448 0.392 1 0.531 1.324   
Combined KM27 -0.001 0.005 0.025 1 0.875 0.999 0.990 1.009 
KM28 0.000 0.001 0.027 1 0.871 1.000 0.998 1.002 
KM30 0.013 0.007 3.911 1 0.048 1.013 1.000 1.026 
Constant -1.717 0.664 6.690 1 0.010 0.180 
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4.2.2.5 Anti-Gal levels are increased in serum samples from patients with active 
VL caused by L. infantum (Spanish cohort) 
 
Supplementary Table 197. Independent Samples Kruskal Wallis results for comparison of 
individual Spanish sera from healthy controls (Endemic Control), active infection (VL or CL), 
cured infection (VL or CL) and asymptomatically infected patients. * = p ≤ 0.05, ** = p ≤ 
0.01, *** = p ≤ 0.001, **** = p < 0.0005, ns = p > 0.05. 
NGP χ2 DF p value 
KM27 44.519 5 **** 
KM28 28.636 5 **** 
KM30 50.531 5 **** 
BME 98.203 5 **** 
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